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Abstract 
Toxoplasma gondii is an intracellular parasite, infecting almost all warm-blood 
animals� I t is the most prevalent chronic parasite infection in human. Based on 
serological studies, prevalence of this infection ranged from 20-80% in different 
populations. Toxoplasmosis is typically benign in healthy individuals but it can cause 
severe life-threatening infection in neonates and immunocompromised patients. 
Eradication of T. gondii with anti-microbial agents is not possible as it only against 
the multiplying and metabolically active form (tachyzoite) but not against the non-
multiplying or the metabolically inactive form (bradyzoite) of the parasite. A vaccine 
against T. gondii will be extremely valuable for preventing both fetal infection and 
reactivation in immunocompromised individuals. It may also reduce economic losses due 
to abortion in farm animals. A live-attenuated tachyzoite vaccine is commercially 
available and has successfully prevents abortion in sheep and pigs. However, these 
vaccines do not completely prevent tachyzoite stage from being established, therefore it 
is not suitable for human. Previous works with inactivated vaccines using whole T. 
gondii and subunit vaccines found only moderate protective efficacy against infection. 
Besides, vaccination with stage-specific antigens leads to stage-limited protection, i.e. 
not capable to induce immunity to the cyst stage. 
As an intracellular parasite, T. gondii evades direct attack by the humoral immune 
response. It is now generally accepted that the induction of a Th-1 polarized cellular 
immune response confers resistance against T. gondii. In this study, a synthetic gene 
encoding three distinct Toxoplasma T-cell epitopes of the antigens: P30, GRA2 and 
R0P2, together with a T-helper epitope (TTP30) of the tetanus toxin was expressed in 
both E. coli and Arabidopsis thaliana for making a peptide vaccine. These antigens were 
chosen as they have been demonstrated to induce antigenic activation of T-cells and to 
elicit protective responses in the immunized host while T-cell epitope from tetanus toxin 
can be recognized by T-helper cells that in turn promote the engagement of antigen-
vii 
specific B-cells, which is important for the generation of an optimal antibody response. 
Moreover, the inclusion of different life-stage antigens hopefully can elicit a full-
protection against T. gondii. 
His-tag multi-epitopic antigen of 21KDa (MEA) was expressed in E. coli and was 
purified into high homogeneity by TALON resin-affinity column from the soluble fraction 
of the induced bacterial lysate. Antigenicity of this protein was demonstrated as it could be 
recognized by the seropositive serum of human and mice, but not the seronegative serum. 
Mice immunized with his-tag MEA developed IgG antibodies against the corresponding 
Toxoplasma antigens — P30 (30.5kDa), GRA2 (37.2kDa) and R0P2 (54.9kDa) in the total T. 
gondii lysate and was demonstrated by western blot. The cross-reactivity of anti-serum 
against MEA to the other three Toxoplasma antigens was further confirmed by its ability to 
recognize the E. co/z-expressed P30, GRA2 and R0P2 which the antigenic and 
immunogenic properties were proved. The immunological properties and the protective 
efficacy of the MEA antigen were further compared to the well-documented predominant 
subunit vaccine candidate, P30, in term of T-cell responses, cytokine expression profile in 
in vitro stimulated spleenocytes and the percentage of survival after lethal challenge. 
Altogether, supporting that the multi-epitopic antigen would be an ideal vaccine candidate 
against toxoplasmosis, even better than the well-established vaccine candidate of single 
antigen, P30. 
Besides expressing in the prokaryotic system, the possibility of using plant as bio-
reactor for large scale production of this recombinant antigen was also investigated. By 
the help of the stabilizing effect of the fusion partner-lysine-rich protein (LRP), MEA 
antigen could be expressed and stably accumulated in mature seeds of transgenic A. 
thaliana. But more investigation is need before it can be used as a source of vaccine or 
directly used as an edible vaccine. 
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Chapter 1 General Introduction 
1.1 Toxoplasma gondii and Toxoplasmosis 
Toxoplasmosis, a ubiquitous protozoan infection, is caused by an intracellular 
parasite, Toxoplasma gondii (Dubey 1977; Dubey and Beattie 1988). It was discovered 
since 1908 and was named because of its form and in which it was discovered (Toxo - arc; 
plasma - form and Ctenodactylus gondii [rodent]). Toxoplasmosis is the most prevalent 
chronic parasite infection in human and this infection is usually asymptomatic in healthy 
person. Serological studies indicate that the prevalence of infection by this infection ranges 
from 20-80% in different populations and there are increased cases of toxoplasmosis in 
immuno-compromised patients. 
Toxoplasmosis is of major clinical and verterinary importance, being a cause of 
congenital disease and abortion in human and their domestic animals (Dubey and Beattie 
1988). Acquired toxoplasmosis may lead to fatal outcome, including retinochoroiditis, 
myocarditis and pericarditis while congenital toxoplasmosis may lead to still bom of the 
fetus, or live bom with severe brain or eye damage or other kinds of handicaps. It is also 
an important opportunistic pathogen in immuno- compromised patients including organ 
transplant, cancer chemotherapy and AIDS patients (Luft and Remington 1992; Luft and 
Remington 1993) due to reactivation of chronic infection. It has been estimated that 1.4 
million cases of toxoplasmosis occur annually with associated 310 deaths. Besides, 
toxoplamosis has leaded to great economical loss around the world, including medical 
costs, loss in personal productivity, special education and residential care due to T. gondii 
infection and the economical loss in agriculture. 
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1.1.1 Biology and life cycle of T, gondii 
What made the successfulness of T. gondii infection? Understanding its life cycle 
may give us some hints. T. gondii is an intracellular coccidian. Cat and other felids were 
infected by ingestion of oocysts or bradyzoites. They are the only host (definitive host) in 
which that parasite can complete its entire life cycle, both the asexual schizogonic cycle 
and sexual gametogonic cycle, and the only animals that excrete the environmentally 
resistant and infectious oocyst in the feces. Human, mouse and other agricultural animals, 
are usually the intermediate host. In the intermediate host, T. gondii undergo asexual 
multiplication with 2 parasite forms — tachyzoite, which is the rapidly dividing form and it 
is responsible for acute infection and the bradyzoite, the slowly dividing form which is 
characteristic to chronic phase of toxoplasmosis. 
Three methods of transmission are possible. It may be by congenital transmission, 
or acquired transmission by ingestion of oocysts from the cat feces, or by ingestion of 
bradyzoite cyst from infected meat. During acute infection, initiated by accidentally 
ingestion of oocysts or cysts, the ingested oocysts or tissue cysts enter the intestine and 
release sporozoites or bradyzoite, respectively. They penetrate intestinal epithelial cells 
and transform into rapidly dividing tachyzoites which invade and proliferate with virtually 
any nucleated cells, resulting in host cell lysis and re-infection of more cells. Concurrent 
with the development of immunity, tachyzoites transform into slow-growing bradyzoites 
which residue with cysts in tissue of muscles and central nervous system (CNS). The stage 
conversion of the parasite leads to the transition between acute and chronic infection and 
this chronic infection can persist for the life of the host, but re-initiation will lead to acute 
infection. Life cycle of T. gondii and its transmission are illustrated in Figure 1.1. 
Bradyzoites are the essentially dormant and harmless forms of the parasite. They 
can survive with cysts which are composed of mainly of host-derived products, so, the 
differentiation from tachyzoite to bradyzoite stage makes the parasite being isolated from 
host's immune system. Although bradyzoites are apparently harmless, a persistent 
immunity to T. gondii is required to avoid re-emergence to the tachyzoite stage, thus in 
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immuno-compromised patients, there is always a reactivation of the parasite leading to 
acute toxoplasmosis. 
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Figure 1.1. Life cycle of Toxoplasma gondii. 
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1.2 Treatment of Toxoplasmosis 
1.2.1 Chemotherapy 
Chemotherapy is the use of anti-toxoplasma drugs which specifically inhibit the 
metabolism of parasites such as nucleic acid and protein synthesis�Only a few drugs are 
available for treatment of human toxoplasmosis. 
(a) Pyrimethamine and sulfadiazine 
Pyrimethamine (Derouin and Chastang, 1989) and sulfadiazine are regularly used 
in combination and are the first choice for most clinical conditions. Pyrimethamine can 
inhibit the key enzyme, dihydrofolate reductase, in the folic acid metabolism of the 
parasite by converting dihydrofolate to tetrafolate. Sulfadiazine is an analogue of 
para-aminobenzoic acid and it can competitively inhibit de novo synthesis of folic acid. 
Both of them can inhibit the nucleic acid synthesis of T. gondii. Pyrimethamine is 
parasiticidal whereas sulfadiazine is though to inhibit replication rather than killing the 
parasite (Derouin and Chastang 1989). They can act synergisterically against the 
tachyzoite stage of T, gondii (Joss 1992). However, they are potentially teratogenic and 
thus not suitable for pregnant woman and may cause hypersensitivity in long term 
treatment (Joss 1992). 
(b) Clindamycin and Spiramycin 
As Clindamycin would cause less adverse effects than sulfadiazine and spiramycin 
are not as tetreogenic as pyrimethamine, they have successfully been used as an 
alternative treatment. These chemotherapeutic agents inhibit the metabolism of the 
parasite at protein level but have no effect on RNA synthesis (Blais et ah, 1993). 
Clindamycin inhibits protein synthesis by binding to the ribosome, thus reducing the 
level of the replication of the parasite and also impairing the ability of tachyzoites to 
infect host cells (Blais et al, 1993). Spiramycin is a macrolide antibiotic, although its 
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antiparasitic effect is rather low, its exceptional persistence in tissues (especially the 
placenta) made it to be a good drug for preventing spread of infection to fetus by 
inhibiting the proliferation of parasites released from cysts which residue in the placenta 
(Schoondermark-van de ven et al, 1994). 
(c) Hydroxynaphthoquinones and new Macrolides 
Since persistent infection with cysts is the source of reactivated toxoplasmosis, 
drugs that are effective to both the tachyzoite and the cyst stage, such as hydroxyl-
naphthoquinones (Araujo et al, 1992) and macrolides, might even be the more effective 
drugs against toxoplasmosis. Hydroxy Inaphthoquinones target the parasite's 
mitochondrial bci complex and disrupt the transfer of electrons from ubiquinone to 
cytochrome C (Hudson 1993) and its parasiticidal effect was shown in both the 
tachyzoites and bradyzoites. However, these drugs cannot totally eliminate the parasites 
from the infected host (Ferguson et al, 1994), probably due to that the drug is more 
active against the metabolically active-immature bradyzoites that the mature organism. 
1.2.2 Toxoplasma vaccine 
Besides the potential problems of applying different therapeutic agents, drug 
resistance is becoming a problem in the chemotherapy with the emergence of resistant 
organism in clinical settings. Moreover, most of the anti-microbial therapy is not 
effective against the metabolically inactive form of parasite that means the bradyzoite 
stage. The emergence of T. gondii as a major opportunistic organism in immuno-
compromised individuals and the steady increase in economic losses due to animal 
toxoplasmosis has fuelled the interest in vaccine development. It is believed that 
toxoplasmosis could be prevented by immunoprophylaxis as nature infection of T. 
gondii gives the host a long-lasting and almost complete protection against re-infection. 
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(a) Vaccine using mutant strain of J. gondii 
Mutant strains of T. gondii for use as vaccine include, temperature sensitive mutant 
(ts-4) (Waldeland and Frenkel, 1983), S48 (Wastling et al., 1995) and T-263 mutant 
(Dubey, 1996). Ts-4 is a temperature-sensitive mutant tachyzoite isolated from the 
pathogenic M-7741 strains, although two subcutaneous (s.c.) or intra-intestinal 
immunizations did not completely protect against development of T. gondii in the brains 
of mice, it could reduce cysts formation in immunized mice and partially protect the 
mice against congenital infection (McLeod et al, 1988). S48 is an incomplete tachyzoite 
isolated from the strain, 56/48 and is deployed to control toxoplasma abortion in sheep. 
It could induce local and systemic antibody responses and afford protection against 
subsequent challenge with the parasite, and the mechanisms of immunity had also been 
studied (Buxton and Irnies, 1995). A live vaccine using a mutant stain of T. gondii, 
T-263，could reduce oocyst shedding by cats, but unfortunately, it did not elicit 
protection immunity against T. gondii in experimental animals (Dubey, 1996). 
The use of mutant strains of T. gondii as vaccine got a promising result in farm 
animals as these vaccines can reduce economical loss in farming industry and the risk of 
human exposure to T. gondii through the ingestion of infected meat. However, as the 
genetic lesions responsible for the attenuation are mostly undefined, they may lead to 
greater risk of revision and vaccine-induced diseases. Furthermore, as the use of whole T. 
gondii with undefined composition as vaccine may result in complicated and 
inconsistent results, they are not suitable for human. In human, vaccines comprising 
subunit or recombinant antigens or synthetic peptides are more likely to be approved for 
use. 
(b) Subunit vaccine 
Subunit vaccines are able to overcome many of above problems by having defined 
modifications, giving the vaccine specific properties. With the advanced in the 
molecular biology, many of the T. gondii antigens had been isolated, prepared or 
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synthesized and were used for vaccination with auspicious results, such as GRAl, 
GRA2, GRA4, GRA5, R0P2, SAGl and SAG2. 
The recombinant strain of Mycobacterium bovis (BCG) which produced and 
secreted GRA 1 which is one of the major excreted/ secreted T, gondii antigens, induced 
GRAl-specific cell-mediated responses and partial protection in sheep (Supply et al, 
1999). GRA2 and GRA5 were shown to be the potential vaccine candidates against 
congenital toxoplasmosis as immunization with these two purified excretory-secretory 
antigens (ESA) conferred a significant protection in rat model (Zenner et al, 1999). The 
R0P2 protein of T. gondii possesses immunological and biological properties and the 
identification of its T-cell epitopes which recognized by a high percentage of the 
immune population further strengthen its potential as a vaccine candidate (Saavedra et 
al,’ 1996). Immunization with a purified membrane antigen, P30, with liposomes as 
adjuvant, gave protective efficacy in mice and these results indicated that P30 is an 
appropriate antigen for development into a subunit vaccine for immunization of humans 
and/ or domestic livestock (Bulow and Boothroyd, 1991). Immunization of mice with 
recombinant SAG2 protein with glutathione-S-transferase (GST) as the fusion partner 
resulted in the production of specific antibodies although no protective effect could be 
observed after oral challenge infection (Lunden et la” 1997). 
Although these subunit vaccines could induce specific T-cell or B-cell responses 
against T. gondii, they conferred only a partial protection against T. gondii infection. 
These could be explained with the accumulating evidences that vaccination with 
stage-specific antigens leads to stage-limited protection (Alexandre et al, 1996) and 
there is another speculation that immunogenicity of the vaccine in a population with 
divergent class II haplotypes will be limited by MHC-restricted T cell immunity (Roy et 
al., 1989; Alexander et al, 1994). 
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1.3 The immune response 
T. gondii is an opportunistic parasite of humans and animals and it will 
establish itself within the host and this infection will persist for the life-long. Initiating 
and sustaining strong T-cell-mediated immunity is crucial in preventing the emergence 
of T. gondii as a serious pathogen. Several populations of immune cells are involved in 
this protective immunity, including nature killer (NK) cells, CD8+ T cells and CD4+ T 
cells of the helper subtypes. Each of these cells types is able to produce 
interferon-gamma (IFN-y) which is the prerequisite mediator for protective immunity of 
T. gondii and IFN-y can trigger anti-parasitic activity in macrophage and other cells. 
And now, it is generally accepted that the induction of a Th-1 polarized cellular immune 
response confers resistance against T. gondii (Mordue et al., 2001). 
1.3.1 Protective immune responses 
Generation of T lymphocytes possessing parasite-specific cytolytic activity is a 
characteristic of both human and murine toxoplasmosis. Cytotoxic T cells (CTLs) are 
best known for their ability to kill infected and transformed target cells. Like other 
intracellular protozoans, T. gondii can effectively stimulate CD8+ CTL function against 
infected target cells, by their ability to traffic antigenic peptides into the MHC class I 
presentation pathway (Brown and McLeod, 1990; Gazzinelli et al., 1992). The 
stimulation of CTL function by these parasites may be related to their capacity to evade 
the lysomal pathway during cell invasion and to residue in either in the cytoplasm or 
within a parasitophorous vacuole. 
In acute toxoplasmosis, strong and persistent cell-mediated immunity elicited by T. 
gondii would result in host protection against rapid tachyzoite growth and consequent 
pathological changes (Ganinelli et al., 1991; Garrinelli et al., 1997). The importance of 
T-cell immunity against toxoplasmosis was illustrated by the extreme susceptibility of 
the athymic nude mice to both virulent and avirulent strains of the parasite (Lindberg 
and Frenkel, 1977). Evidence for the participation of both CD4+ and CD8+ T cell in T. 
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gc>«(izz-induced immunity was also obtained for depletion experiments in mouse and 
adoptive transfer of parasite-specific T cells in which the animals were protected from 
lethal challenge (Frenkel 1967; Suzuki et al., 1988; Suzuki and Remington, 1990; Parker 
et al., 1991). Furthermore, the influence of the MHC class I and II to the susceptibility to 
the parasite gave additional evidences on the importance of the T lymphocytes in 
determining the outcome of infection (McLeod et al., 1989; Brown and McLeod 1990; 
McLeod etal., 1993). 
Cytokines are important effector molecules responding to T. gondii infection. IFN-y 
and tumor necrosis factor- alpha (TNF-a) are essential for both the acute and chronic 
phase of infection (Suzuki et al” 1989; Johnson 1992; Gazzinelli et al., 1993; 
Scharton-Kersten et al., 1997) while interleukin 10 (IL-10) and IL-12 are more 
important in the initial phase but not in the chronic phase of infection (Gazzinelli et al., 
1994; Gazzinelli et al., 1996). IFN-y and TNF-a controls the replication of tachyzoites 
and IL-12 has the promoting effect on the elicitation of an effective cell-mediated 
immunity (CMI) against tachyzoite. On the other hand, IL-10 can modulate this 
immunity for avoiding an excessive immune response that would cause extensive 
inflammation and the damage of host tissue by regulating the synthesis of IL-12 and 
IFN-y (Neyer et al” 1997). At the early stage of infection, NK cells, CD4+ and CD8+ 
T-cells are the dominant sources of IFN-y while during chronic phase, IFN-y was 
synthesized by aP T lymphocytes (Subausta et al,, 1995; Gajewski and Fitch, 1988; 
Ksaper et al., 1996). 
These cytokines would in turn activate macrophages to kill T. gondii by a 
combination of oxygen dependent, reactive nitrogen intermediate (RNI)-dependnet and 
tryptophan starvation mechanisms (Suzuki et al., 1988; Adams et al., 1990; Langermans 
et aL, 1992; Gazzinelli et al., 1992; Pfefferkom 1984) and in certain immunodeficiency 
states, this is critical to host survival. Besides, this T-cell independent immunity plays an 
important role in influencing the development of parasite-specific T-cells. 
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(a) Cytokines involved in the immunity against J. gondii 
IFN-y: Role in resistance to infection 
IFN-y is the most extensively studied cytokine in the field of toxoplasmosis. It was 
produced in significant amount in the acute stage of acquired toxoplasmosis and also in 
the course of congenital infection. IFN-y is an important mediator for cellular immunity 
as its capacity to activate macrophages for enhanced cytotoxicity and it is known to play 
a major role in the differentiation of Thl cells (Gajewski and Fitch 1988). During early 
stages of infection just before the T-cell mediated immunity can be established, IFN-y is 
synthesized by NK cells and it acts as a major barrier for the proliferation of tachyzoites. 
In vitro studies indicated that CD4+, CD8+ and mono-nucleated cells isolated from 
T. gondii seropositive patients could be stimulated to produce IFN-y by T. gondii 
antigens (either crude extract or purified antigen, e.g. P30) or weaken tachyzoites 
(Sklenar et al., 1986; Canessa et al,, 1988; Khan et al； 1988) and IFN-y production was 
also dependent on other cytokines such as IL-1, IL-2, and the human leukocyte antigen 
(HLA) system (Kelly et al., 1989). 
In immuno-compromised patients such as AIDS patients，the secretion of IFN-y 
was impaired, probably as a result of CD4+ cells reduction (Canessa et al., 1992). 
Furthermore, in vitro studies demonstrated that lymphocytes derived from AIDS patients 
were unable to produce IFN-y upon antigenic stimulation (Murray et al., 1984). These 
findings suggested that reactivation of T. gondii in immuno-compromised patents may 
be due to the impairment of IFN-y production and it was believed to be the cytokine of 
major importance for eliciting immune responses against toxoplasmosis in human. 
TNF-a: Synergetic Role with IFN-y 
TNF-a is one of the most important cytokine involved in the acute phase of 
inflammation. It acts synergistically with IFN-y to mediate killing of tachyzoites 
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(Gazzinelli et al, 1996) and it performs an important regulatory role in the control of 
anti-microbial activity by IFN-y-primed macrophages (Esparza et al, 1987; Heidenreich 
et al, 1988; Liew et al, 1990; Green et al” 1990). Involvement of TNF-a in the 
induction of toxoplasmastatic activity was confirmed by neutralizing effect of 
anti-TNF-a antibodies to the IFN-y induced toxoplasmastatic activity (Langermans et al, 
1992). TNF-a, although unable to confer antitoxoplasmal activity when used alone to 
treat macrophages, was capable of triggering IFN-y-primed macrophages to kill or 
inhibit intracellular T. gondii (Sibely et al., 1993). Although T cells are important in 
protective immunity against T. gondii, the combination of IFN-y and TNF-a would 
enhance the production of reactive radicals and nitric oxide (NO), leading to killing of 
parasite by a T cell-independent mechanism (details will be discussed in 1.3.l.c). 
IL-12: Role in T cell differentiation 
IL-12 is the key cytokine produced by tachyzoite-activated macrophages, 
responsible for the induction of IFN-y synthesis by NK cells and T cells (Gazzinelli et 
al., 1993; Khan et al., 1994) and IL-12 has synergetic effect with TNF-a on the 
induction of IFN-y synthesis (Hunter and Remington 1994; Hunter et al., 1994). 
Treatment of anti-IL12 antibodies increased the susceptibility and accelerated the 
mortality of the experimental animals upon T. gondii infection (Gazzinelli et al., 1993; 
Hunter et al.’ 1995), suggesting that IL-12 also play an important role in resistance to T. 
gondii infection through the initiation of IFN-y synthesis by lymphocytes (Gazzinelli et 
al,, 1994). 
Development of the appropriate T helper (Th) subset during an immune 
response is important for disease resolution and Th-1 polarized cellular immune 
response is believed to be the major resistance mechanism against T. gondii. Although 
cytotoxic T-cells are the major effector cells in this resistance mechanism, this killing is 
also directed by Th cells, because the proliferation of most of the CTLs depends on IL-2 
which is mainly synthesized by Thl cells. The differentiation of Th precursor cells 
towards the Thl phenotype was proved to be driven by IL-12, together with IFN-y 
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(Hsieh et al., 1993; Seder et al., 1993) and IFN-y, induced by IL-12, inhibited the 
expansion of TH2 cells, favouring the differentiation and expansion of T-cells 
possessing the Thl phenotype. 
IL-10: Role in immuno-regulation 
IL-10 is an anti-inflammatory cytokine which can be produced by a large variety of 
cells, for example, B cells and macrophages. It was demonstrated to have inhibitory 
effect on cytokine production (such as IFN-y) by Thl cells (Fiorentino et al,, 1991) and 
was shown to be produced by Th2 lymphocytes (Fiorentino et al., 1989). It can modulate 
cytokine synthesis by macrophages upon stimulation through the inhibition of 
monokines synthesis, especially IL-12 (Fiorentino et al, 1991; Dandrea et aL, 1993; 
Hsieh et al, 1993). 
During acute phase of T. gondii infection, the production of IL-10 by macrophages 
and/ or dentritic cells is induced. It was believed to be involved in the regulatory 
mechanism of IL-12 and Th-1 type cytokines and for establishing the parasite-host 
equilibrium during toxoplasmosis (Gate et al., 1994; Gazzinelli et al” 1996). 
Experimental evidences could be obtained from the studies in IL-10 knockout (IL-IOKO) 
mice, in which upon infection, with higher mortality (Gazzinelli et al” 1996). The 
abnormal immune response to infection, of uncontrollable high level of IL-12 which 
could be harmful or even lethal to the animals, was proved to be responsible for the 
increase in mortality in IL-10 KO mice; indicating that IL-10 has an important 
physiological and regulatory role in controlling cytokines synthesis during the initiation 
ofCML 
Other cytokines 
Many cytokines are demonstrated to be involved in toxoplasmosis in in vitro 
studies although their in vivo roles cannot be identified, including IL-1 (Kelly et al, 
1989; Bala et al., 1994; Pelloux et al., 1994), IL-2 (Canessa et al, 1988; Prigione et al, 
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1995), IL-4 and IL-5 (Pringione et al, 1995), IL-6 (Bala et al, 1994) and gramilocyte/ 
macrophage colony - stimulating factor (GM-CSF) (Bala et al, 1994). These cytokines 
were induced to be secreted by different cell models upon stimulation by T. gondii 
antigens. 
(b) Immuno-modulatory role of Nitric oxide (NO) 
The generation of nitric oxide (NO) is the second most important mechanism by 
which macrophages regulate the immune response during experimental acute 
toxoplasmosis. IFN-y and TNF-a, besides acting synergistically for direct killing to 
tachyzoite, they can enhanced the production of free radicals and NO which mediate 
parasite killing (Langermans et al., 1992; Sher et al,, 1993). NO is an end-product of the 
IFN-y dependent pathway and was produced by the action of the inducible nitric oxide 
synthase (iNOS). This inducible nitric oxide is essential for host control of persistent but 
not acute infection with T. gondii and its protective role is rather tissue-specific than 
systematic (Scharton-kersten et al., 1997). Besides, based on in vitro and in vivo studies, 
the immuno-modulatory role of NO, in particular during the early phase of T. gondii 
infection, were demonstrated (Candolfi et al,, 1994). The NO effects are targeted 
primarily at CD4+ T cells and at least in part due to the induction of apoptosis (Lopes et 
al., 1995; Martin et al, 1995). It is believed that this immuno-regulatory mechanism is 
essential for the control of immune response induced by T. gondii for preventing an 
exacerbated CMI leading to tissue damage — 
(c) Humoral immunity against T. gondii 
B-cell immunity seems not to be the major arm of immunity and does not play a 
crucial protective role against toxoplasmosis as T. gondii does not have an extra-cellular 
stage as other parasite such as Trypanosoma brucei and the passive transfer of T. 
gondii-spQcific antibodies did not protect the host from lethal challenge (Freakel 1967). 
However, some studies indicate that, IgA is an important element in avoiding 
re-infection with T. gondii, as it is a critical component of mucosal immunity to oral 
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infection with toxoplasma cysts (Chardes et al” 1990; Chardes and Bout. 1993). 
Induction of IgA is an alternative approach for vaccine development. 
Furthermore, the role of B cells in resistance against T. gondii was 
demonstrated by using B cell-deficient (muMT) mice with decreased resistance to T. 
gondii infection with despite unimpaired expression of IFN-y, TNF-a, and inducible 
nitric oxide synthase (Kang et al, 2000). These results indicate that B cells also play an 
important role in the immunity against toxoplasmosis, most likely through the 
production of specific antibodies which may block the infection of the host cells by 
tachyzoites (Kang et al, 2000). 
1.3.2 Toxoplasma proteins known to elicit T cell-dependent immunity 
Antigenic T-cell activation is based on the cell surface interaction between an 
antigen-presenting cell (APC) and a T-lymphocyte whose receptor matches the APC. This 
highly selective response is known as the Major Histo-compatibility Complex (MHC) 
restricted T-cell response. MHC molecule bears the processed antigenic peptide within its 
binding groove and is classified into 2 classes -MHC class I and MHC class II. MHC class 
II molecules can be recognized by CD4+ T cells while the MHC class I molecules can be 
recognized by CD8+ T cells. 
Several T, gondii proteins of both membranous and cytoplasmic ongin were reported 
to be recognized by T cells and also they were able to mediated protective effects in vitro 
and in vivo (as summarized in table 1). They are the surface antigens, rhoptry proteins and 
dense granules proteins. 
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Table 1.1. Toxoplasma proteins that can induce antigenic activation of T cells 
Antigen Experimental model(s) Protective immunity References 
P30 Mouse Reduced mortality and brain Khan et al, 1991 
cyst number 
Rat Prolonged survival and Darcy 1992 
induction of specific 
antibodies in nude rats follow-
ing adoptive transfer 
Mouse Cytolytic activity for infected Kasper et al, 1992 
macrophages 
Mouse Reduced mortality and brain Khan et al, 1994 
cyst number 
Mouse and rat Induction of specific Goddxd et al, 1994 
antibodies responses after 
vaccination 
GRA2 Mouse Prolonged survival and Brinkmann et al, 
induction of specific 1993 
antibodies after vaccination 
R 0 P 2 Human Release of IFN-y and IL-2 Saavedra and 
Herion，1991 
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(a) Surface antigen 1 (SAGl/ P30) 
P30, also called SAGl, is a highly conserved and abundant surface antigen of 
both extra- and intra-cellular tachyzoite (Sibley and Boothroyd, 1992), representing 5% 
of the total amount of tachyzoite proteins, of molecular weight of 30kDa (Kasper et al, 
1983). It is also a component of the vesicular network within the parasitophorous 
vacuole (PV). P30 is a stage-specific T. gondii antigen and can only be detected in 
rapidly dividing and invasive tachyzoites but not in the bradyzoites of tissue cysts or 
sporozoites from oocyts (Kasper 1989). 
P30 can induce both humoral and cell-mediated immune responses in 
immunized animals (Gross et al, 1992). It can induce IFN-y production in cultured human 
lymphocytes from sero-positive individuals but not form sero-negative individuals (Khan 
et al, 1988) and immunization with purified and recombinant antigens or DNA 
vaccination with SAGl can elicit the production of IgA, IgM and IgG specific antibodies 
(Chardes et al, 1990; Khan et al.’ 1991; Gross et al, 1992; Peterse, et al, 1998; Nielsen et 
al, 2000; Couper et al, 2003). It is probably the most immunogenic Toxoplasma antigen 
as it is the principal antigen recognized by infected serum (Potasman et al” 1986; Pinon et 
al., 1995). Moreover, because of the direct accessibility to the immune system, P30 
probably represented the candidate targets for the killing of the extracellular parasite and 
was considered to be an ideal candidate for immuno-protection. Passive transfer of 
immune cells or antibodies against P30 could give partial protection in experimental 
models (Darcy et al” 1992; Johnson et al., 1983). Furthermore, vaccination with purified 
P30 protein could reduce the number of brain cyst and prolonge survival of the immunized 
animals, compared to the non-immunized group (Bullow and Boothroyd, 1991; Khan et al., 
1991;Debrad et al, 1996). 
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(b) Dense granules protein 2 (GRA2/ P28) 
Toxoplasma cell contains three distinct secretory organelles: the rhoptry, the 
micronemes and the dense granules. Release of the dense granule proteins appear 
continuously during intracellular development of the parasite (Leriche and Dubremetz, 
1990) and contribute to majority of T. gondii circulating antigen in serum. The family of 
dense granule molecules is highly conversed in both the tachyzoite and bradyzoite of the 
parasite. Based on deduction from the amino acid sequences, all dense granule proteins 
bear a NHi-terminal hydrophobic domain (Cesbron-Delauw 1994) that fits the 
characteristic of a signal peptide which probably to be the sorting signal that target the 
proteins into the dense granules. Dense granule proteins were suggested to play a major 
role in the intracellular survival and/ or multiplication of the parasite. 
Eight distinct dense granule proteins have been characterized so far. Several of 
them were demonstrated to exhibit T cell stimulatory properties (Saavedra and Herion, 
1991; Saavedra et al, 1991; Duquesne et al, 1991). Vaccination of mice with purified 
GRA2 induced protection against lethal T. gondii infection (Sharma et al, 1984). This 
protein is one of the antigens specifically recognized by anti-sera of the patients infected 
by T. gondii and its immunogenicity was further confirmed by the detection of primed 
antigen-specific T cells in infected animals, so it is a potential candidate for an effective 
vaccine against toxoplasmosis which is of special value for immuno-compromised 
patients such as those with AIDS or neoplastic disease. 
GRA2 is the major component involved in excreted-secreted antigen (ESA) 
immunity and possibly acts in conjunction with GRAL Upon infection, it is secreted in a 
Ca2+-dependent manner, into the parasitophorous vacuole (PV) and targeted to the 
microvillus membranous network. Both the soluble form and membrane-bound form of 
GRA2 had been identified (Sibley et al, 1995). Although the predicted amino acid 
sequence for GRA2 does not contain any typical transmembrane domain, there is a large 
amphipathic a-helical region, which might adopt to a transmembrane configuration 
(Mercier et al, 1993). 
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(c) Rhoptry protein 2 (R0P2/ P54) 
Rlioptries are secretory organelles of the parasite near the site of attachment to the 
host cell that discharge their contents during host cell invasion. Rhoptries secrete 
molecules might cause degeneration of the host cell membrane. More recently, a 54kDa 
protein component of the rhopteries expressed in 3 stages of T. gondii life cycle, the 
R0P2 protein (Sadak et al, 1988) which has been observed to be associated with the PV 
membrane (PVM) formation, was proposed to be the target for mucosal immune 
mechanism. 
Since the main mode of transmission of Toxoplasma infection is by ingestion of 
oocysts or cysts, IgA antibodies against this parasite should be strongly displayed by 
hosts (Chardes et al, 1990). In addition, the cellular sub-localization of IgA epitopes on 
tachyzoite has been analyzed in the course of human acute, chronic and congenital 
toxoplasmosis, showing high rhoptry immuno-labelling in all cases (Kumolosasi et al, 
1996). During human toxoplasmosis, R0P2 induces strong humoral immune response 
involving the production of acute phase markers IgG and IgA and acute- and chronic-
phase marker IgM (Martin et al, 1998). Besides eliciting antibody responses, R0P2 
protein was shown to have the capacity to induce IFN-y production and the proliferation 
of T. gondii-XQdicXiyQ T-cell clone (TCC) derived from an infected/ immune individual 
(Saavedra et al, 1991). The use of this antigen as vaccine component was thus 
proposed. 
1,3.3 Appropriate vaccine design 
Both the cell-mediated and humoral immune responses are required in conferring 
immunity against T. gondii infection (Dubey et al” 1993). Based on previous studies, the 
protective immunity against this parasite mainly rests on CD8+ T cells and is mediated 
by IFN-y (Denkers and Gazzinelli” 1998). On the other hand, B cells are also required 
for vaccination-induced resistance as they produce antibodies which may block the 
infection of the host cells by tachyzoites (Kang et al” 2000). There are accumulating 
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evidences showing that vaccination with stage-specific antigens will lead to 
stage-limited protection (Alexandre et al, 1996). Besides, there is another speculation 
that the immunogenicity of the vaccine in a population with divergent class II haplotype 
will be limited by MHC-restricted T cell immunity. Therefore, a vaccine, which makes 
use of a combination of different life stage antigens of the parasite, with the ability to 
elicit a Th-1 polarized immunity and to overcome MHC-restricted T-cell immunity will 
be a good vaccine candidate and is likely to elicit protective immunity against 
toxoplasmosis. 
A multi-epitopic vaccine carrying epitopes from antigens of the parasite of different 
life stages and a promiscuous helper T-cell epitope may fulfil the above requirements. 
This vaccine allows the use of defined epitopes to stimulate an appropriate immune 
response that leads to resistance and to eliminate other epitopes potentially responsible 
for pathological effects due to non-specific and undesirable stimulation. Besides, 
combine with the knowledge of the cellular and molecular basis of antigen processing 
and antigen recognition by both T and B cells, it is able to activate the relevant arm of 
the immune system (Nardin et al, 1995). Examples for multi-epitopic vaccine constructs 
were summarized in Table 1.2.. Moreover, the inclusion of the promiscuous helper 
T-cell epitope in the vaccine construct can help the recognition of the antigenic peptide 
fragment by T-helper cells that in turn promoter the engagement of antigen-specific B 
cells, so this is important for generation of an optimal antibody immune response 
(Herrington et al., 1987; Herrington et al., 1992; Lairmore ef al” 1995; Dei Guercio et 
al” 1997; Franke et al, 1999). As demonstrated by previous studies, this epitope is 
universally immunogenic, thus the chimeric vaccine construct with helper T-cell epitope 
ensure the immunogenicity of the peptide in a genetically diverse population by-passing 
certain haplotypes- restricted immune response and provide broader immunogenicity in 
a larger population (Lairmore et al,, 1995; Del Guercio et al, 1997; Franke et al, 
1999). 
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Table 1.2. Examples for multi-epitope/ antigen vaccine constructs 
Year Multi- epitope/ antigen vaccine Defined T- Promiscuous References 
/B-cell epitope T-cell epitope 
(V/x) (V/x)  
2003 Chimeric multi-human epidermal � V Dakappagari et 
growth factor receptor-2 B cell al, 2003 
epitope peptide vaccine 
2003 Leishmania infantum X X Molano et al., 
multi-component antigenic protein 2003 
2002 Synthetic multi-antigen peptide X X Edelman et al., 
vaccine (PfCS-MAPINYU) 2002 
against Plasmodium falciparum 
sporozoites 
2002 Multi-antigen DNA vaccines X X Nascimento et 
against schistosomiasis al., 2002 
2002 Multi-epitope vaccine containing V X Li et al, 2002 
repeats of neutralizing epitopes 
against HIV-1 
2002 Multi-subunit recombinant X X Skeiky et al, 
leishmanial vaccine (Leish-11 If) 2002 
2002 Multi-epitope M protein-based V X Dunn et al, 2002 
group A streptococcal vaccine 
2002 Synthetic multi-antigen peptide X X Kublin et al., 
vaccine (PfCS-MAP INYU) 2002 
against Plasmodium falciparum 
sporozoites 
2001 Triple antigen recombinant vaccine X X Young et al, 
for adult hepatitis B - 2001a 
Young et al., 
2001b 
Zuckerman et al, 
2001 
2001 Multi-epitope-vaccines against V X Lu et al., 2001 
HIV-1 Tian et al, 2001 
2001 Multi-epitope polypeptide TAB9 V X Toledo et al., 
against HIV-1 2001 
2001 V3 loop multi-epitope polypeptide V X Gomez et al., 
(TAB13) of HIV-1 Env 2001 
2001 Multi-epitope live vaccine V V Dong et al., 2001 
candidate for Plasmodium 
falciparum 
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Year Multi- epitope/ antigen vaccine Defined T- Promiscuous References 
/B-cell epitope T-cell epitope 
pZ/x) (V/x)  
2000 DNA immunization with � Zhong et al, 
recombinant plasmids of 2000 
polyvalent epitopes of Plasmodium 
falciparum 
2000 Multi-epitope synthetic peptide V X Houghton et aL, 
against Trypanosoma cruzi 2000 
2000 Plasmodium falciparum merozoite X Wu et al., 2000 
surface protein fused to tetanus 
toxin fragment C 
2000 Multi-epitope vaccine against V X Ding et al, 2000 
HIV-1 
2000 Multi-epitope schistosome vaccine X Yang et al, 2000 
2000 Multi-envelope HIV vaccine X X Lockey et al, 
2000 ‘ 
1999 Multi-epitope antigen gene of V X Huang et al, 
hepatitis C vims (HCV) 1999 
1999 Multi-epitope, multi-stage malaria V V Li et al, 1999 
vaccine 
1999 Multi-epitope chimeric malaria � V Jiang a/., 1999 
DNA vaccine 
1999 Multi-CTL epitope-based DNA V X Hanke and 
prime MVA boost vaccine for McMichael 
AIDS 1999 
1999 Multi-epitope synthetic peptide X Houghton et al, 
against Trypanosoma cruzi 1999 
1999 Multi-epitope DNA against HIV V X Hanke et al, 
1999 
1998 DNA vaccine encoding four X X Hedstrom et al, 
pre-erythrocytic antigens from 1998 
Plasmodium falciparum 
1998 Lipidated HTL-CTL constructs V V Oseroffer al, 
prime for multiple HBV and HCV 1998 
CTL epitope responses 
1998 DNA multi-CTL epitope vaccines V X Hanke et al, 
for HIV and Plasmodium 1998 
falciparum 
1997 Multiple T cell epitope vaccine � X Schluesener 1997 




Year Multi- epitope/ antigen vaccine Defined T- Promiscuous References 
/B-cell epitope T-cell epitope 
(V/X) pZ/x)  
1997 Multi-epitopic recombinant X Cao et aL, 1997 
allergen for the prevention of , 
allergies and asthma 
1996 Multiple antigen peptide of X X Wang et al, 1996 
Plasmodium yoelii ‘ 
circumsporozoite protein (PyCSP) 
* 叫” means "with" while "X" means "without" 
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1.4 Aim of the study 
Infection with the intracellular parasite T. gondii is responsible for toxoplasmosis in 
humans and other warm-blooded animals. It may lead to severe damage to 
immuno-compromised patients such as those with AIDS，transplanted organs or 
chemotherapy and it also lead to great economical loss in agriculture. Thus, a vaccine 
that can prevent foetal damage and abortion would be of extremely importance for 
medical and veterinary uses. On the other hand, vaccines that are capable of limiting the 
number of cysts in meat products or reducing oocysts shedding by cats would also have 
significant beneficial implications for public and veterinary health. 
Both humoral and cell-mediated immunity are important in conferring resistance to T. 
gondii infection. Several Toxoplasma antigens have been demonstrated to induce 
antigenic activation of T cells or to be strongly recognized by serum from infected 
animals, including P30, GRA2 and R0P2. A synthetic gene encoding a multi-epitopic 
antigen for T. gondii was made. Based on previous studies, four linear T-cell epitopes 
were selected from these three linear T-cell target Toxoplasma antigens, including two 
epitopes from P30, P30I (amino acid [aa] 138-154 [Velge-Roussel et aL, 1994]) and 
P30II (aa 191-209 [Gordard et aL, 1994]), one epitope for R0P2 (aa 197-216 [Saavedra 
et al, 1996] ), and the last one from GRA2 (aa 171-185 [Duquesne et al” 1991]) which 
is also a B-cell epitope (Cesbron-Delauw et aL, 1992; Murray et al, 1993] ). A 
promiscuous T-helper epitope from tetanus toxin (aa 951-968 [Demotz et al, 1989a; 
Demotz et al, 1989b; Panina-Bordignon, et al, 1989; Diethelm-Okita et al., 2000]) was 
also included in this synthetic gene. 
P30 is a tachizyote stage-specific antigen whereas R0P2 and GRA2 are conserved in 
both the tachyzoite and brachyzoite stage. The use of mixture of different life-stage 
antigens in a single vaccine may help to overcome the problem of stage-specific 
protection as in subunit vaccine using a single antigen. Furthermore, the T-helper 
epitopes can enhance immunogenicity of the vaccine and also help to overcome 
MHC-restricted immune responses to the vaccine due to MHC polymorphism, making it 
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to be universally immunogenic (Kaumaya et al, 1993; Buus et al, 1987; Chicz et al, 
1993; Lairmore et al, 1995; Alexander et al, 1998; Van der Burg et al, 1999; 
Kobayashi et al” 2000). We speculated that this peptide vaccine might induce protective 
immunity against toxoplasmosis, furthermore, it may also have a potential usage for 
diagnostic purposes. This synthetic gene will be expressed in E. coli and purified, later 
on; immunological assays will be performed to demonstrate its protective efficacy 
against toxoplasmosis in mice models. Lastly, the possibility of using plant as 
bio-reactor for large scale production of this recombinant antigen was in vestigated� 
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Chapter 2 Expression of the Synthetic Gene Encoding the 
Multi-epitopic Antigen (MEA) for Toxoplasma 
gondii in Escherichia coli 
2.1 INTRODUCTION 
Toxoplamosis, caused by T. gondii which is an intracellular parasite, is the most 
prevalent chronic parasitic infection in human. In health adults, this infection is typically 
begnin, however, it is one of the most common opportunistic infection in immuno-
compromised patients and will cause severe life-threathening diseases. Besides causing 
health problems, it would also cause economical problems in the world. Till now 
although many different vaccines have been developed against T. gondii, none of them 
shows a satisfactory result. Thus, a vaccine that can give full protection against T. gondii 
would be extremely valuable. 
2.1.1 Multi-epitopic antigen for T, gondii as vaccine 
The major challenge in vaccine development against T. gondii is to use defined 
antigen to stimulate appropriate immune responses that leads to resistance. The use of 
peptide-based vaccine is gaining greater attention as its flexibility in the incorporation of 
multiple defined and different epitopes into a single construct for eliciting desirable arms 
of the immune system (Nardin et al, 1995). Besides, the incorporation of a universal 
helper T-cell epitope can help to overcome haplotype-restricted immune responses and 
to elicit adequate and appropriate T-cell and B-cell responses (Herrington et al., 1987; 
Herrington et al,, 1992; Lairmore et al., 1995; Del Guercio et al, 1997; Franke et al” 
1999). 
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a) Epitopes from Toxoplasma antigens, P30, GRA2 and ROP2 
Based on previous studies, several B- and T-cell epitopes were identified from the 
three T. gondii antigens - P30, GRA2 and R0P2. For the construction of MEA, two 
epitopes were selected from P30 and one epitope was selected from each of the GRA2 and 
R0P2 antigen and they were briefly summarized as follow. 
T- and B-cell epitopes from P30 (aa 138-154, aa 191-209) 
Based on previous studies, the importance of SAGl (P30) antigen in toxoplasmosis 
had been demonstrated (Decoster et al, 1992; Kasper et al., 1992). T and B cell epitopes 
of this major T. gondii antigen and its antigenic and immunogenic properties were studied 
and these epitopes are of extremely important for both diagnosis and immunoprophylaxis 
of toxoplasmosis (Velge-Roussel et al., 1994; Godard et aL, 1994). The P30I epitope (aa 
138-154) included in the multi-epitopic antigen, was proved to be a T-cell epitope in mice 
model and it could stimulate anti-P30 T lymphocytes proliferation although this 
recognition seems to be haplotype-restricted (Velge-Roussel et aL, 1994). The other P30 
T-cell epitope in the vaccine construct, P30II epitope (aa 191-209)，could induce B-cell 
response with the induction of multiple antibody isotypes and also T-cell immunity 
independent of the route of immunization (Gordard et al,, 1994). Besides, this epitope 
displayed major antigenic and immunogenic properties among different P30-derivd 
peptide within the same study (Gordard et al., 1994). 
T-cell epitope from ROP2 (aa 197-216) 
Because of the immunological and biological properties, R0P2 protein was 
proposed to be a vaccine candidate. By submitting the amino acid sequence to different 
reported T-cell epitope prediction algorithm, several T-cell epitopes were predicted from 
the R0P2 protein (Saavedra et al., 1996). Each of these epitopes was tested with T-cell 
proliferation assay for their antigenic and immunogenic properties. Among several 
epitopes tested, an epitope from aa 197-216 showed the highest ability to stimulate the 
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proliferation of a R0P2-specific human T-cell clone. Besides, it could be frequently 
recognized by peripheral blood mononuclear cells from T. go/2<izz-seropositive but not T. 
go/7(in-seronegative- individuals (Saavedra et al., 1996). The recognition of this epitope by 
a high percentage of the immune population points out its importance and potential as a 
vaccine candidate and thus this epitope was selected to be one of the important domain in 
the multi-epitopic vaccine construct. 
T- and B-cell epitope from GRA2 (aa 171-185) 
Besides P30 and R0P2 proteins, the products excreted/secreted by the T. gondii 
have also been demonstrated to be excellent vaccinating antigens. Several epitopes were 
predicted from the primary structure of GRA2 protein in accordance to their 
hydrophobicity, mobility and accessibility profiles. By using of the synthetic peptides, 
these epitopes were examined in the animal model for the determination of T lymphocyte 
epitopes (Duquesne et al, 1991)�Two C-terminal peptides, including the GRA2 epitope 
(aa 171-185) in the multi-epitopic antigen, had been identified as T cell epitopes as they 
could stimulate T-cell proliferation. Moreover, GRA2 (aa 171-185) peptide-specific T 
lymphocytes could be stimulated by native antigen of T. gondii, indicated that this epitope 
is an important T cell epitope. Furthermore, the adoptive transfer of T helper cells from 
GRA2 (aa 171-185) peptide-immunized rat into athymic rats gave a significant protection 
against infection although no antibody production was observed. The GRA2 (aa 171-185) 
epitope is also a B cell epitope since it could be recognized by specific antibodies 
(Cesbron-Delauw et al., 1992; Murray et al, 1993). 
b) Helper T-cell epitope from tetanus toxin 
A number of promoiscuous T-helper epitopes had been reported from malaria, 
influenza virus, meales virus and tetanus toxin, they could bind several isotypic and 
allotypic forms of MHC II molecules and were universally immunogenic. Table 2.1 
summarized some of the promiscuous T-helper epiotpes being identified. These epitopes 
can provide a potent source to activate the resting T cells and because of their binding 
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degeneracy, it can overcome the problems posed by the extreme polymorphism of MHC II 
molecules in human population (Kaumaya et al, 1993; Buus et al, 1987; Chicz et al, 
1993; Lairmore et al, 1995; Van der Burg et al, 1999; Kobayashi et al, 2000). Besides, 
vaccine with more potent T-helper activity might minimize the number of immunization 
required to achieve protection from infection (Alexander et al, 1998). It is also speculated 
that potentiation of helper T-cell response would lead to the increase in responsiveness in 
the elderly populations (Song et al., 1999). 
The promiscuous T-helper epitope from tetanus toxin (aa 951-968) was included in 
the multi-epitopic vaccine construct. It was originally identified and defined as DR5 
restricted (Demotz et al” 1989a; Demotz et al, 1989b). Later on, it was demonstrated to 
be universally immunogenic and it could be recognized in association with a large 
number of class II molecules (Panina-Bordignon, et al, 1989). This epitope contained at 
least three distinct "epitopes", each recognized by different MHC class II molecules 
(Panina-Bordignon, et al, 1989) and this restriction of specificity was determined at the 
level of peptide-MHC complex (as reviewed by Ng and Fung, 2002). The promiscuous 
binding of this epitope was further confirmed by the recognition by human CD4+ at a 
high frequency, irrespective of their HLA class II haplotypes (Diethelm-Okita et al., 
2000]). 
c) Linker 
Glycine (Gly,G) and proline (Pro, P) are commonly used amino acid residues in 
peptide linkers (Bulow and Mosbach 1991; Dakappagari et al, 2000; Jonathan and 
Samuel, 2003). Glycine is the simplest amino acid with only a hydrogen atom for a side 
chain. The absence of a larger side chain gives the polypeptide background at Gly 
residues much greater conformation flexibility than at other residues. On the other hand, 
proline offers a unique conformational property to protein structures. The restricted 
torsion angle for the N-Ca bind of Pro allows only a limited number of conformations 
and imposes stress on secondary structure. 
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A small peptide linker sequence (PGGGP) was introduced in between each of the 
epitopes, which has sufficient flexibility to allow the epitopes to be exposed to the outer 
surface of the recombinant antigen without masking each other. Glycine and proline are 
so called the “destmcting” amino acids and would interfere with secondary structure 
(Samuel et al., 2000; Reiersen and Rees 2001). Because of the lack of secondary 
structure which gives the extendibility and flexibility in the linker sequence, this allows 
each of the epitopes to fold properly and independently. 
Table 2.1. Examples for promiscuous T-helper epitopes being identified 
Sources Clone Sequence (a.a) References 
Malaria CST3 KKIAKMEKASSVFNV Sinigaglia a/., 1992 
Circumsporozoite (aa 381-395) 
Protein 
PfCS331-350 lEQYLKKIKNSISTEWSPCS Fern et al. 1992 
(aa 331-350) 






Malaria Sporozoite SSP2 61 RHNWVNHAVPLAMKLI Doolan et al, 2000 
Surface Protein-2 (aa 61 -76) 
SSP2 62 HNWVNHAVPLAMKLI 
(aa 62-76) 
SSP2 223 VK2WIGPFMKAVCVE 
(aa 223-237) 
SSP2 509 KYKIAGGIAGGLALL 
(aa 509-523) 
SSP2 527 GLAYKFWPGAATPY 
(aa 527-541) 
Malaria Liver LSAl 13 LVNLLIFHINGKJIKNS Doolan et al, 2000 
Stage Antigen-1 (aa 13-29) 
Malaria Exported EXPl 71 KSKYKLATSVLAGLL Doolan et al. 2000 
Protein-1 (aa 71-85) 
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Sources Clone Sequence (a.a) References 
Malaria Exported EXPl 82 AGLLGNVSTVLLGGV Doolan et al, 2000 
Protein-1 (aa 82-96) ‘ 
HER2/ner-derived HER2(776-788) GSPYVSRLLGICL Sotiriadou et al, 2001 
peptides (aa 776-788) 
Measles virus F F1 LSEIKGVIVHRLEGV Partidos et al, 1990 
Protein (aa 288-302) 
MAGE-A3 MAGE-A3ne-ieo FFPVIFSKASSSLQL Kobayashi et al, 2001 
Antigen (aa 146-160) 
Streptococcus sM5 DASREAKKQVEKALEEANSK Robinson et al.，1993 
pyogenes Group A (aa 300-319) 
5 M Protein 
HIV-1 Reverse RT171.190 FRKQNPDIVIYQYMDDLYVG Van der Burg et al, 1999 
Tramscriptase (aa 171-190) 
Mycobacterium p61 -80 VTGSWCTTAAGNVNIAGG Harris et al, 1995 
^ . 1 . (aa 61-80) tuberculosis ^ ^ 
19KMW protein 
Mycobacterium PI DPIELNATLSAVA Panigada et al, 2002 
� . (aa 163-175) tuberculosis � ‘ 






Tetanus toxin P2 QYIKANSKFIGITEL Panina-Bordignon et al.—— 
(aa 830-844) ‘ 1989 
P30 FNNFTVSFWLR VPKVSASHLE 
(aa 947-967) 




Influenza matrix MAT 17.31 SGPLKAEIAQRLEDV Scheirle z^/., 1992 
(aa 17-31) 
Influenza HA307-319 PKYVKQNTLKLAT Busch etal, 1990 
haemagglutinin (aa 307-319) 
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2.1.2 Escherichia coli Expression System 
When recombinant protein and antibodies are needed against a cloned gene, one 
excellent source of antigen is to over-express the recombinant protein in bacteria. When 
comparing with others expression systems, bacterial (prokaiyotic) expression system is the 
simplest and most inexpensive mean for over-expressing a desired polypeptide and 
Escherichia coli is the most commonly used bacterial expression system. A wide variety of 
genes were successfully expressed in bacteria either on their own or as fusion proteins. For 
expressing proteins in bacteria, there is an extensive collection of vectors available, driven 
by a range of bacterial or viral promoters. Some of promoters will drive the recombinant 
protein to be constitutively expressed while others may drive the inducible expression of 
the recombinant protein�The T7 plasmids from Studier and colleagues (Studier and 
Moffatt, 1986; Rosenberg et al,, 1987) are excellent promoter system for high-level and 
inducible expression of the recombinant protein and this system will be applied in the 
following experiments. 
Unlike systems based on E. coli promoters {e.g., lac, tac, pL), the pET System 
uses the bacteriophage T7 promoter to direct the expression of target genes. Since E. coli 
RNA polymerase does not recognize the T7 promoter, there is virtually no transcription 
of the target gene in the absence of a source of T7 RNA polymerase and the cloning step 
is thus effectively uncoupled from the expression step. Many genes that have been 
difficult to establish in E. coli promoter-based systems have been stably cloned and 
expressed in the pET System. 
a) The T7 RNA polymerase and T7 lac Promoter 
T7 RNA polymerase is a single polypeptide chain, composed of 883 amino acids, 
synthesized by bacteriophage T7 which belongs to the family of Podoviridas (Niles et al,, 
1974). It can effectively bind to the Class III T7 promoter and initiate its transcription. In 
the pET system, the target gene was cloned under the control of T7 promoter and 
expression is induced by providing a source of T7 RNA polymerase in the host cell. T7 
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RNA polymerase is very selective and active, upon induction by IPTG, the lacUV5 
promoter (in the expression host) will direct transcription of the T7 RNA polymerase, 
which in turn transcribes the target DNA in the plasmid. And when it is fully induced, 
almost all the cell's resources are converted to target gene expression. 
Moreover, the pET vector used in this experiment contains an addition lac 
operator sequence just downstream of the T7 promoter, this complex was called lilac 
promoter (Studier et al, 1990; Dubendorff and Studier，1991). They also carry the 
natural promoter and coding sequence for the lac repressor (lad), oriented so that the 
T7/ac and lad promoters diverge. When expressing the target gene in the expression 
host, the lac repressor acts both at the lacUV5 promoter in the host chromosome to 
repress transcription of the T7 RNA polymerase by the host polymerase and at the lilac 
promoter in the vector to block transcription of the target gene by any T7 RNA 
polymerase that is made. 
b) Other translational elements 
The transcriptional and translational pET vector used in this experiment contains 
the highly efficient ribosome binding site from the phage T7 major capsid protein and 
are essential for the expression of target genes without their own ribosomal binding site 
by stabilizing the formation of translation initiation complex. The 8-bp stem-and-loop 
structure, formed by the upstream sequence of the T7 promoter, confers some as yet 
undefined advantages probably the stability (Oakley and Coleman 1977). Furthermore, 
the formation of a potential stem-and-loop structure beyond the stop codon of the target 
gene may cause efficient termination of T7 RNA polymerase both in vivo and in vitro 
(Okaley et al., 1979). 
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c) Fusion partner 
Fusion tags can facilitate detection and purification of the target protein, or may 
increase the probability of biological activity by affecting solubility in the cytoplasm or 
export to the periplasm. Besides, the tags can be located at the N-terminus, C-terminus 
or both ends of the target protein, depending on the cloning strategy and the choices of 
cloning sites. In this research, the N-terminal six histidine tagged protein was chosen as 
the fusion partner which allows easy detection of the recombinant protein on Western 
blots and also facilitate the affinity purification using corresponding kits and buffers. 
Based on previous studies, histidine and cysteine were found to have the ability 
to selectively interact with transition elements (Porath, et al, 1975). And thus, the 
recombinant protein can be purified by its high-affinity and reversible binding capacity 
to immobilized nickel ions which allows the purification of the target protein to a high 
homogenicity of >95%. As the pET vector contains protease cleavage sites (thrombin, 
Factor Xa, enterokinase) between the 5' histidine tag and the target sequence, this allows 
optional removal of one or more tags after purification. On the other hand, as the 
polyhistidine tag is uncharged at physiological pH and it is poorly immunogenic, it 
would very rarely affect the function or structure of the fusion protein and thus, removal 
of the his-tag after purification is not a must. 
d) Choice of expression host strain 
After plasmids are established in a non-expression host, they are most often 
transformed into a host bearing the T7 RNA polymerase gene (DE3 lysogen) for 
expression of target proteins. BL21 (DE3) cells were used as the expression host for this 
experiment. It is a lysogens of bacteriophage DE3, a lamba derivative that has the 
immunity region of phage 21 carrying a DNA fragment which contains the lad gene, the 
lacUVS promoter and the gene encoding the T7 RNA polymerase (Studier and Mofatt, 
1986). This fragment is inserted into the int gene, preventing DE3 from integrating into 
or excising from the chromosome without a helper phage. In A.DE3 lysognes, although 
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some degree of transcription in uninduced state (lacking the induction of IPTG) was 
allowed, it is suitable for expression of many genes whose products have innocuous 
effects on host cell growth. 
Besides, this bacterial strain bears another advantage for the expression of 
heterologous proteins as it is the deficiency in many cellular proteases (e.g. Ion protease 
in cytoplasm, ompT on the outer membrane and the major ATP-dependent protease). 
And thus, the chances of degradation of the target protein during purification can be 
minimized and the stability of the recombinant protein can be greatly enhanced. 
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2.2 MATERIALS 
2.2.1 Bacterial Strains 
1. Escherichia coli (DH5a) 
2. E. coli expression host BL21 (DE3) 
2.2.2 Mouse strain 
1. BALB/c strain (Supplied by Laboratory Animal Service Center, CUHK) 
2.2.3 Chemicals 
1. Acetic acid, glacial Ajax 1 
2. Acrylamide Sigma A8887 
3. Agar (Bacteriological grade) Ajax 863 
4. Ampicillin Sigma A9518 
5. Ammonium persulfate Sigma A7460 
6. Antiform A emulsion Sigma A5758 
7. Bovine serum albumin Sigma B2518 
8. Bromophenol Blue Bio-Rad 161-0404 
9. Calcium chionde, hydrated form Sigma C3881 
10. Chloroform Ajax 152 
11. Coomassie Brilliant Blue R-250 Bio-Rad 161-0400 
12. Ethylenediamine-tetraacetic acid (EDTA) Sigma ED2SS 
13. Ethanol, absolute Ajax 214 
14. Glycerol Sigma G5516 
15. Glycine Sigma G7403 
16. Hydrochloric acid, 36% Ajax 1364 
17. Isoamyl alcohol Ajax 64 
18. Isopropyl-p-D-thiogalactopyranoside (IPTG) Sigma 16758 
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19. Kanamycin Sigma K0879 
20. Magnesium chloride Sigma M9272 
21. Magnesium sulfate Sigma M2773 
22. Manganese chloride, tetrahydrate Sigma M3634 
23. (3-mercaptoethanol Sigma M3184 
24. Methanol Ajax 2314 
25. N,N'-Methylene-bis-acrylamide Sigma M7256 
26. Rubidium chloride Sigma R2252 
27. Propanol-2-ol / isopropanol Ajax 425 
28. Sodium Chloride Sigma S9625 
29. Sodium phosphate Sigma S0876 
30. TAE buffer Amresco 796 
31. TEMED Pharmacia 17-1312-01 
32. Thimersol Sigma T8784 
33. Trizma Base Sigma T6791 
34. Tryptone Oxoid L42 
35.Tween 20 Sigma P1379 
36. Urea Amersco 0568 
37. Yeast extract Oxoid L21 
38. Complete Freund Adjuvant Sigma F5881 
39. Incomplete Freund Adjuvant Sigma F5506 
2.2.4 Nucleic acids 
1. ATP Pharmacia 27-1006-01 
2. Ultrapure dNTPs set Pharmacia 27-2035-03 
3. pBluescript SK (-) Stratagene 212206 
4. pET-30a (+) vector Novagen 69909-3 
5. pCRII-TOPO-MEA Synthesized by Intergrated 
• DNA Technologies, USA 
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2.2.5 Kits and Reagents 
1. Centricon-10 Amicon 4250 
2. dRhodamine terminator cycle sequencing kit Perkin Elmer 403044 
3- ECL detection kit Amersham RPN2209 
4. Protein Assay kit I Bio-Rad 500-0001 
5. PVDF membrane Biorad 162-0184 
6. Qiaex II gel extraction kit Qiagen 20021 
7. TALON affinity resin, 10ml Clontech 8901-1 
8. TALON metal affinity column Clontech 8903-1 
9. Wizard Plus SV Minipreps DNA purification system Promega A1460 
10. Hyperfilm ECL Amersham PRN2103K 
2.2.6 Antibodies 
1. Anti-His6, Mouse IgGi Boehringer Mannheim 1922416 
2. Anti-Human Polyvalent Ig-HRP Sigma A-4416 
3. Anti-Mouse IgG-HRP Sigma A-0412 
4. Anti-Mouse Polyvalent Ig-HRP Sigma A-8400 
5. Seropositive sera of human to T. gondii ** 
6. Seropositive sera of mouse to T. gondii * 
7. Seronegative sera of human to T. gondii * * 
8. Seronegative sera of mouse to T. gondii * 
*Reagents prepared in our laboratory 




1. 10% ammonium 0.5g ammonium persulfate and 5ml H2O 
persulfate, 5ml 
2. lOx TBS buffer 200mM Tris-HCl, pH 7.5 and 5M NaCl 
3. Ix TTBS buffer Ix TBS + 0.05% (v/v) Tween 20 
4. 5% BLOTTO 5% (w/v) Carnation nonfat dry milk in Ix TBS buffer, 0.01% 
(v/v) antifoam A and 0.002% (w/v) thimerosol, store at 4°C 
5. 5x SDS gel sample 0.6ml IM Tris-HCl, pH 6.8, 5ml 50% glycerol, 2ml 10% SDS, 
buffer, 10ml 0.5ml 2-mercaptoethanol, 1ml 1% bromophenol blue and 0.9m 
H2O 
6. Agarose gel, 1% 1% (w/v) agarose in Ix TAE buffer 
7. Amino black destain 50% (v/v) methanol, 7% acetic acid 
solution 
8. Amino black staining 0.1% (w/v) Amino black, 10% (v/v) methanol, 2% (v/v) 
solution acetic acid 
9. Coomassie blue 0.1% (w/v) Comassie blue, 40% (v/v) methanol, 10% (v/v) 
staining solution acetic acid 
10. Coomassie blue 40% (v/v) methanol, 10% acetic acid 
destaining solution 
11. Electrophoresis buffer 3g Tris, 14.4g glycine, Ig SDS and H2O to make 1 litre 
12. IX Elution Buffer 
13. IX Extraction AVash 
Buffer 
14. Inclusion body 50mM Tris-HCl, pH 8.0, ImM EDTA and 0.2mg/ml 
isolation buffer lysozyme 
15. LB broth / agar lOg NaCl, lOg Tryptone, 5g Yeast Extract and 15g 
bacterograde agar (for LB agar only). Add with 1 litre of 
distilled water and autoclaved. 
16. LB+AmplOO agar / LB agar/broth was prepared and added with filter-sterilized 
broth ampilicin to final concentration of lOOpig/ml. 
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17. LB+Kan agar / broth LB agar/broth was prepared and added with filter-sterilized 
kanamycin to final concentration of 50|ug/ml. 
18. RF 1 solution lOmM RbCl, 50mM MnCl�，30mM potassium acetate (pH 7.5； 
lOmM CaCl2, 15% (w/v) Glycerol. 
Adjust pH to 5.8 with 0.2M acetic acid and sterilize by 
filtration through a pre-rinsed 0.22jj.m membrane. 
19. RF 2 solution lOmM MOPS, lOmM RbCl, 75mM CaCl!，15% (w/v) 
Glycerol. 
Adjust pH to final pH 6.8 with NaOH and sterilize by filtration 
through a pre-rinse 0 . 2 2 j L i m membrane. 
20. SOB solution 2% Bacto-tryptone, 0.5% Bacto yeast extract, lOmM NaCl, 
2.5mM KCl, lOmM MgCk, lOmM MgSOi. 
21. SOC solution SOB medium plus 20mM glucose solution 
22. Solubilizing buffer 50mM NaEbPO*, pH 8.0; lOmM Tris-HCl, pH 8.0; 8M urea 
and lOOmM NaCl 
23. Solution A 30% acrylamide and 0.8% bis-acrylamide 
24. Solution B, 100ml 75ml 2M Tris-HCl, pH 8.8, 4ml 10% SDS and 21ml H2O 
25. Solution C, 100ml 50ml IM Tris-HCl, pH 6.8, 4ml 10% SDS and 46ml H2O 
26. 3M sodium acetate Dissolve 123.04g NaOAc in Mill-Q to a final volume of 
pH 4.6 SOOmL Adjust pH to 4.6 using glacial acetic acid then sterilize 
by autoclaved. 
27. Transblotting buffer 6g Tris Base, 14.4g Glycine, 200ml methanol and add H2O to 
make up 1 litre. Do not need to adjust pH 




1. Lysozyme Sigma LI526 
2. T4 DNA ligase Pharmacia 27-0870-04 
3 . T 4 DNA polymerase New England Biolab 203L 
4. Ncol Promega R6513 
5. Thermoprime plus DNA polymerase ABgene 301 
6. Platinum Pfx DNA polymerase Invitrogene 11708-013 
2.2.9 Primers 
Name of primers Sequence (5，to 3，） Tm / 
MF 661 CCG CGA AAT TAA TAG GAC TCA CTA ^ 
(T7 promoter primer) 
MF 596 CTA GTT ATT GCT CAG CGG M 
(T7 terminator primer) 
"MF734 GCA ATG GGA AAC AAC GTG GCC AG J l 
MF735 GTC CGC CTC CCA CCT GGA GAT ^ 
* Tm was calculated as (A+T) x2 + (C+G) x 4 
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2.3 METHODS 
2.3.1 Design and synthesis of the synthetic gene encoding the multi-epitopic antigen 
for Toxoplasma gondii 
Four linear T-cell epitopes from T, gondii antigens, P30, GRA2 and R0P2, and a 
universal helper T-cell epitope from tetanus toxin were selected as described in 1.3.3 and 
2.1.1.. Based on secondary structure prediction by GORIV (http://pbil.ibcp.fr/) (Gamier et 
a/., 1996) and the hydrophobicity plot (http://tw.expasy.org/cgi-bin/protscale.pl) using the 
scale of Kyte and Doolittle (Kyte and Doolittle, 1982), linker sequences between epitopes 
was designed as Pro-Gly-Gly-Gly-Pro (PGGGP). The amino acid sequences of the multi-
epitopic antigen were then converted back to the nucleotide sequences following the codon 
usuage of mouse. This synthetic gene was then ordered from Intergrated DNA 
Technologies, USA. 
2.3.2 Cloning of the MEA into the E, coli Expression Vector 
The multi-epitopic antigen (MEA) for Toxoplasma gondii was synthesized and 
subcloned in pCRII-TOPO vector (pCRII-TOPO-MEA) and purchased from Intergrated 
DNA Technologies, USA. The plasmid pCRII-TOPO-MEA was used as the starting 
material in this experiment. The MEA gene was amplified from the plasmid and then 
subcloned into a strong bacterial expression vector pET30a+ to form pET-His-tag MEA" 
for high level expression of recombinants his-tag MEA protein. The procedures were 
outlined in Figure 2.1. 
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Figure 2.1. Construction of pET-His-MEA 
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a) Preparation of plasmid : pCRII-TOPO-MEA and pET30a+ 
Freshly prepared bacterial colonies were obtained from glycerol stock. Some 
frozen bacteria-glycerol was scrapped from stock with a sterile inoculation loop and 
streaked on LB plates. The plates were incubated at 3TC overnight to allow the 
growth and formation of bacterial colonies. Single colony was picked and inoculated into 
20ml LB Kan50 broth and was shaken at 37�C, 250rpm for 16-18 hours. Plasmids were 
isolated by Wizard™;?to SV Minipreps DNA purification kit from the bacterial culture. 
10 to 15ml bacterial culture was transferred into a 15-ml falcon and bacterial cells 
were pelleted at 3000 x g for 5 minutes. The cell pellets were resuspended in 250jLil of Cell 
Resuspenion Solution and transferred into a 1.5-ml eppendorf. 2 5 0 j L i l Cell Lysis Solution , 
was then added and inverted gently to lyse the cells. After complete lysis of the cells, 10|LI1 
alkaline protease solution was added and mixed by inversion. The mixture was incubated 
at room temperature for 5 minutes and 350jj,l of Neutralization Solution was added to 
neutralize the cell lysate with immediate gentle inversion. The neutralized lysate was 
cleared by centrifuging in a microcentrifuge at 13000rpm for 30 minutes. 
850|ul of the cleared lysate was carefully removed from each minipreps and 
transferred to the mini-column assembly. It was spun at maximum speed for 1 minute and 
the elutant was discarded. The mini-column was washed twice with 750)LI1 and 2 5 0 j L i l 
Column Wash Solution respectively. The mini-column was then transferred to a new 1.5-
ml eppendorf and lOOjil sterile milli-Q water was added to elute plasmid DNA from the 
mini-column. The mini-column/eppendorf was spun at maximum speed for 1 minute to 
elute plasmid DNA. 2\i\ of the eluted plasmid DNA was added to 198^1 of milli-Q water 
for 100-fold dilution. The diluted DNA sample was used for measuring the optical density 
in spectrophotometer (Eppendorf 6131 000.012). The ratio OD260 /OD280 of the sample 
represents its purity whereas the yield of each preparation was estimated according to 1 
unit OD260 represent 50|ag/ml of dsDNA. 
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a) PGR Amplification of MEA from pCRII-TOPO-MEA 
MEA fragment was amplified from pCRII-TOPO-MEA (as prepared in 232.3.) by 
PCR using gene specific primers (MF734 and MF735). 0.5^g of plasmid DNA was used 
as template and was mixed with 5^1 of lOX Pfx DNA polymerase buffer with MgS04, ljul 
of each of the 25pmole gene specific primers, Ij^l lOmM dNTPs and 1.5 units Pfx DNA 
polymerase and finally made up to volume of 50)LI1 with milli-Q water in a sterile PCR tube. 
It was well-mixed, spun and then incubated in a PCR machine (MJ Research.). The 
template DNA was denatured at 94�C and then amplified for 20 cycles with a cycle profile: 
94°C 30 seconds, 60°C 30 seconds and 72°C 30 seconds. After the last cycle, the reaction 
was allowed to extend at 72�C for 4 minutes, then kept at 15�C until removed from the 
machine. 
b) Digestion and purification of the E, coli Expression vector pET30a+ with Ncol 
3|ag of pET30a+ plasmids prepared from 2.3.2.a. was restriction digested by 8 units 
of Ncol in 60^1 final volume of IX NEBuffer 4. The digestion mix was incubated at 37�C 
for 3 hours and then heat-inactivated by incubating at 65°C for 20 minutes. 4|il of the 
digestion mix was loaded on 1% agarose to check for complete digestion. Remaining Ncol 
cut pET vector was desalted by ethanol precipitation. 2.5 volume 100% ethanol and 1/10 
volume of 3M sodium acetate, pH 4.6 was added to the sample and then spun at 14000rpm 
for 30 minutes, then supernatant was discarded. DNA pellet was washed with 70% ethanol, 
spun at HOOOrpm for 15 minutes. After removing the ethanol, the DNA pellet was 
vaccum-dried and finally resuspended into 40|al milli-Q water. 
c) Fill-in Ncol cut pET30a+ 
Purified Ncol cut pET vector DNA prepared from 2.3.2.C. was fill-in to generate 
blunt-end for the ligation of MEA fragment prepared in 2.3.2.b. For the fill-in experiment, 
all the reagents were added on ice to prevent the action of T4 DNA polymerase being too 
strong. 40)al single cut pET vector DNA was fill-in by 9 units of T4 DNA polymerase in 
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lOOjil final volume of IX DNA polymerase buffer with the addition of 2.5|al lOmM 
dNTPs, 50}ig/ml BSA. The reaction mix was incubated at 20°C for 20 minutes to 
maximize the ratio of polymerase activity to the exonuclease activity. Heat-inactivation 
was then performed by incubating at 65°C for 15 minutes. 
d) Purification of DNA fragment from agarose gel 
MEA DNA fragment amplified from PGR (as prepared in 2.3.2.b) and the Ncol cut, 
fill-in pET vector prepared in 2.3.2.d were separated on 1% agarose gel by electrophoresis 
and then stained with EtBr and visualized under UV illumination. The DNA bands of 
corresponding sizes were excised from the gel by sterile blades under UV illumination and 
purified by QIAEX II Gel Extraction Kit as described below. 
Gel excised was put into a new eppendorf and 400)li1 of Buffer 0X1 was added o 
solubilize the agarose gel matrix. Then lOjal of reususpended QIAEX resin was added and 
incubated at 65�C for 10 minutes, with vortexing for every 2 minutes to keep QIAEX resin 
in suspension and thus enhancing DNA binding. The suspension was centrifliged at 
maximum speed for 30seconds and the supernatant was discarded�The resin pellet was 
washed with SOOjal QXl Buffer and then washed twice with SOOjul PE Buffer. Finally, the 
resin pellet was air-dried for 15 minutes to remove any volatile PE Buffer and then DNA 
was eliited by resuspending the pellet with 20ix) milli-Q water and centrifliged for 1 minute 
to pellet the resin. The eluted DNA was pipetted carefully into a sterile eppendorf tube. 
e) Ligation of MEA fragment and Ncol cut, fill-in pET30a+ 
6\il of MEA fragment (insert, as prepared in 2.3.2.e) and l^il of Ncol digested 
vector (as prepared in 2.3.2.e) were mixed together with 1)LI1 of lOX T4 DNA Ligase 
Buffer, l[xl of lOmM ATP, 7 Weiss unit of T4 DNA ligase (final volume of lOj^l). The 
reaction mix was incubated at 16°C overnight� 
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f) Preparation of DH5a competent cells 
Starter culture was prepared by inoculating a single colony from a freshly streaked 
LB agar plate and shaked at 250ipm, 3TC for 16-18 hours. 1 ml of overnight culture was 
added to 100ml pre-warmed LB medium (1:100 dilution) in a 1-L E-flask and shaked at 
250rpm, 37°C until the optical density of the culture at 550iim reach 0.2-0.4 (cell density 
around 4-9 x ICT cells/ ml). The culture was then collected and incubated on ice for 15 
minutes. The bacterial cells were harvested by centrifugation at lOOOg for 15 minutes at 
4°C. The cell pellet was resuspended with 30ml pre-chilled RPl solution. The cell 
suspension was allowed to incubate on ice for another 15 minutes before pelleted again 
with the same conditions. The resulting cell suspension was dispersed in 8ml pre-chilled 
RF2 and incubated for 15 minutes on ice. The resulting cell suspension was then aliquot 
into chilled 1.5ml Eppendorf tube with 150|il each. The tubes were flash freezed by liquid 
nitrogen and kept at -70°C freezer as stock of competent cells. 
g) Transformation of recombinant pET30a+-MEA 
An aliquot of competent cell (150|il) was taken out from -70°C freezer and was 
thawed on ice. lOjil of ligation mix prepared from 2.3.2.f. was added and the ligation-
competent cell mixture was kept on ice for 1 hour, then heat-shock was performed by 
putting the tube in 43°C water bath for 2 minutes and then chilled on ice immediately. 
600[il of pre-warmed LB was added and it was shaked at 250rpm at 37° for an hour. 
Bacterial cells were harvested by short spin at high speed and finally resuspended with 
200)il LB medium, afterwards spreaded on three LB Kan，。plates and incubated at 37°C 
overnight. 
h) PCR screening and plasmid preparation for the putative pET30a+-His-tag 
MEA 
Transformed bacteria are able to form colonies on LB plates with antibiotic 
selection. Bacterial cells were picked from individual colonies and resuspended into lOOjul 
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milli-Q water in an 1.5ml Eppendorf tube. The tube was capped and boiled for 10 minutes. 
After chilling on ice, the bacterial debris was spun down by high-speed centrifligation. 5^1 
clear supernatant (containing the recombinant plasmid) was used as template for PGR. The 
25|il PGR reaction contained 5^1 DNA template, 2.5jal lOX Buffer VI, 1.5|li1 25mM 
MgCb, l|il of each of the 25pmole specific primers, l^il lOmM dNTPs and O.lunits 
ThermoprimePius using gene specific upper primer (MF734) and lower terminator primer 
on vector (MF596). The template DNA was denatured at 94�C and then amplified for 30 
cycles with a cycle profile: 94�C 30 seconds, 56�C 30 seconds and 72�C 45 seconds. After 
the last cycle, the reaction was allowed to extend at 72�C for 4 minutes. The PGR products 
were subjected to agarose gel electrophoresis and the size of the EtBr-stained PGR 
products was visualized under UV illumination. Gel photos were taken as record. 
Bacterial colonies with desirable bands on PGR screening was grown on LB 
broth for 16-18 hours at 250rpm, 37�C and the putative pET30a+-His-tag MEA was 
prepared as described in 2.3.2.a. 
i) Cycle sequencing reaction on putative plasmid pET30a+-MEA 
Cycle sequencing reaction was performed on putative plasmid pET30a+-MEA by 
ABI Prism™dRhodamine Terminator Cycle Sequencing Ready Reaction Kit. 0.25jag of 
plasmid DNA was mixed with 4|li1 of Terminator Ready Reaction Mix, and 0.5|li1 of 
3.2pmole sequencing primer making up to final volume of lOjul with milli-Q water in a 
sterile PGR tube. Gene specific primers MF 734 and MF735, T7 terminator primer MF596 
were used for sequencing of the insert. It was well-mixed, spun and then incubated in a 
PCR machine (MJ Research) with a cycle sequencing thermal profile. The reaction 
mixture was heated at 96�C for 10 seconds to denature plasmid template and then 
incubated at 50°C for 5 seconds, which allowed specific primer to anneal on denatured 
template. The temperature was then kept at 60°C for further 4 minutes to perform dideoxy-
terminator sequencing reaction. This thermal profile was repeated for 25cycles. 
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After sequencing reaction，the reaction mix was transferred to a new 1.5ml 
Eppendorf tube for desalting by ethanol precipitation (as described in 2.3.2.c). The dried 
pellet was then resuspended in lO i^l ofHi-Di foramide and heated at 95�C for 5 minutes. 
The sample was immediately chilled on ice and transferred to MicroAmp® Optical 96-well 
Reaction Plate, covering by MicroAmp� Strip Caps. The sample was immediately chilled 
on ice and then loaded on ABI PRISM™ 3100 Genetic Analyzer. The sample was injected 
at 2.4kV for 30 seconds, and electrophoresis was run at 12.2kV at 42�C for 140 minutes. 
Raw data of the sequencing reaction were collected by ABI PRISM™ 3100 Genetic 
Analyzer Sequencing Analysis and SeqEd v. 1.0.3 software to obtain and edit the processed 
sequence information. 
2.3.3 Expression and purification of his-tag MEA 
In pET30-His-tag MEA, the synthetic gene encoding the multi-epitopic antigen 
(MEA) was cloned into the bacterial expression vector pET in which MEA was linked 
with fusion partner. The fusion partner is a N'-terminal histidine tag, containing 6 histidine 
residues，as tag for detection and purification. Besides, there is also an enterokinase 
cleavage site (EK) inbetween, so this fusion partner can be cleaved off by enterokinase 
digestion to release the MEA protein. The construct pET30a+-His-tag MEA was 
transformed into expression host BL21(DE3). Transformed cell was grown and induced to 
express his-tag MEA by IPTG induction. The his-tag MEA was then purified and 
characterized. 
a) Expression Profile of His-tag MEA Production by IPTG Induction 
Competent cells for the expression host BL21(DE3) was prepared as described in 
2.3.2.g. competent DE3 cell was transformed with 0.1 jug of the recombinant pET-MEA in 
total 10|il. A single colony from overnight grown LB plate was picked and 
inoculated into 15ml LB broth at 37�C, 250rpm for 16-18 hours. 1ml overnight 
culture was seeded into 100ml pre-warmed LB broth in a 1-L E-flask and shaked at 
37�C, 250rpm until the optical density at 600nm reached 0.6-0.8. Then IPTG was added to 
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the culture to final concentration of ImM. Upon addition of IPTG, it was shaken for 3 
hours. For every 30 minutes, 0.5ml culture was collected and spun. The pellet was washed 
with ice-cold Tris-buffer and then resuspended into lOO i^l IX SDS sample loading buffer 
and kept on ice. When samples at all the time points are collected, they were boiled for 8 
minutes, spun down and analyzed by SDS-polyacrlyamide gel electrophoresis. 
b) SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gel sandwich was assembled as the manufacturer's instructions and protein gel was 
set as standard protocol. A 12.5% separating gel solution was prepared by mixing 4.17ml 
of solution A, 2.5ml of solution B, 3.33ml of milli-Q water, 50^1 of 10% ammonium 
persulfate and 5jil of TEMED in a 50ml falcon tube and was mixed by gentle inversion to 
avoid excessive aeration. A 5% stacking gel solution was prepared as follow, 0.67ml of 
solution A, 1ml of solution C, 2.3ml milli-Q water, 30|il of 10% ammonium persulfate and 
5jLil of TEMED were mixed in a 50ml falcon tube with gentle swirling. 
After polymerization of the stacking gel, the comb was removed and the gel was 
placed into the electrophoresis chamber before being inserted into the electrophoresis tank 
where IX electrophoresis buffer was added. The wells were washed with electrophoresis 
buffer with the help of a syringe in order to remove any unpolymerized acrylamide. 
10|Lil of the samples prepared from 2.3.2.a and the broad range SDS protein marker 
were loaded into the SDS-polyacrylamide gel to perform gel electrophoresis under 
denaturing conditions at 150V constant voltage. The electricity supply was disconnected 
when the Coomassie blue dye front just reach the bottom of the gel, and the gel cassette 
was dissembled. The gel was stained in Coomassie blue staining solution for 1-2 hours 
with gentle shaking and then destained with destaining solution until distinct protein bands 
on gel observed and no blue color on the background of the gel The gel was dried and 
scanned as record. 
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c) Estimation of His-tag MEA Production in Induced Bacterial Lysate 
To estimate the yield of His-tag MEA production in induced bacterial lysate, SDS-
PAGE was performed (as described in 2.3.2.b)�20^1 of induced bacterial lysate was loaded 
in 12.5% SDS-polyacrylamide gel parallel with 7 dilutions of BSA standards, which are 1， 
2，4，6, 8 , 1 0 and 12jLig/lane. After electrophoresis, protein bands on the gel were visualized 
by Coomassie blue staining as described in 2.3.2.b. and the intensity of the inducible band, 
i.e. his-tag MEA, was compared to the intensity of BSA standards of different amount� 
d) Isolation of the soluble fraction and inclusion body of the induced bacterial 
lysate 
The cell pellet was resuspended (from 40ml of induced bacterial culture) in 10ml 
inclusion body isolation solution. The suspension was freeze-thaw five times in liquid 
nitrogen and a 37°C water bath. The lysate was centrifliged at 12000g for 15 minutes, and 
the supernatant (soluble fraction) was carefully transferred to a clean Eppendorf tube 
without disturbing the pellet. The pellet (inclusion body) was washed three times with 
inclusion body washing buffer and was dissolved in 10ml solubilizing buffer. 
e) Purification of His-tag MEA 
25ml of IPTG-induced bacterial culture, prepared following the procedures 
described on 2.3.2.a, was spun at 4500rpm for 5 minutes. The pellet was washed with ice-
cold Tris-buffer, followed by resuspension into 2ml ice-cold IX Extraction/ wash buffer, 
pH 7.0 where lysozyme was added to final concentration of 0.75mg/ml. The resuspended 
culture was incubated at room temperature for 30 minutes with gently agitation on 
platform shaker for lysozyme digestion. It was then freeze (in liquid nitrogen) and thaw (in 
37°C water bath) for 5 times. The lysate was spun again at HOOOrpm for 30 minutes at 4°C 
(JA-20, Beckman). 
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The clear supernatant was carefully transferred to 1 ml Extraction/ wash buffer 
equilibrated TALON metal affinity resin in a 50ml falcon tube. It was gently agitated at 
room temperature for 20 minutes on a platform shaker to allow the polyhistidine-tagged 
protein to bind to the resin. The resin-lysate mixture was spun at 700g for 5 minutes and 
supernatant was carefully removed with disturbing the resin pellet. The resin pellet was 
then washed with 20ml IX extraction/wash buffer and the resin pellet was recovered by 
centrifugation again. The pellet was resuspended in 1ml 1 extraction/wash buffer by 
vortexing and was transferred to a column with an end cap in place in which the 
suspension was allowed to settle. The end cap was then removed to allow draining of the 
buffer until its level reached the top of the resin bed. The column was washed further 10ml 
IX extraction/wash buffer until no more drops. Then 5ml IX elution buffer, pH 7.0 was 
added to the column and the eluted solution was collected in 0.5ml per fraction by 1.5ml 
eppendorf tubes. Samples were pooled and were concentrated by centricon-10. Protein 
content was then estimated by protein assay (as in 2.3.2.e). 
f) Braford Protein Microassay (Bio-rad) 
Bio-rad protein assay for determining concentration of solubilized proteins was 
based on the Bradford method. Bovine serum albumin (BSA) was used as protein standard 
and six dilutions were prepared as 0, 2, 4, 6, 8, and lOp^g/ml. 200jjl of each standard in a 
1.5ml eppendorf (in triplicate) was mixed with 50^1 of dye reagent concentrate by 
vortexing. The mixture was incubated at room temperature for 20 minutes and their 
absorbance at 595nm was measured. Standard curve was plotted based on the six dilutions 
of BSA standards. 
For protein sample His-tag MEA, after purification by the TALON metal affinity 
resin, fractions containing desired protein visualized by SDS-PAGE were pooled together. 
Sample was dilution to 20X, 40X and SOX to a final volume of 200|liL Then 50jil of dye 
reagent concentrate was added and was mixed by vortexing. The mixture was incubated at 
room temperature for 20 minutes and their absorbance at 595nm was measured. The 
concentration of purified His-tag MEA could be estimated from the standard curve. 
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2.3.4 Characterization of his-tag MEA 
Besides the inducible pattern on the SDS-PAGE of the induced bacterial lysate, 
production of the His-tag fusion protein was also demonstrated by western blotting with 
anti-his-tag antibody and amino acid sequencing. The antigenicity of the purified fusion 
protein was demonstrated by western blot with seropositive serum from infected animals 
or patients while the immunogenicity of this his-tag MEA was demonstrated by western 
blot of T. gondii lysate with antiserum of his-tag MEA 
a) Western Blot of Induced Bacterial Lysate by Monoclonal Anti-his-tag 
Antibody 
20ml IPTG-induced bacterial culture was prepared (as in 2.3.2.a). 500)il bacterial 
culture was taken out and was pellet by centrifligation. The pellet was resuspended in 
lOOji IX SDS sample loading buffer and boiled for 8 minutes. 15|ul of the sample was 
loaded in 12.5% SDS-polyacrylamide gel for electrophoresis. A PVDF membrane was cut 
with size fit to the polyacrylamide gel and soaked briefly with 100% methanol for 2-3 
seconds. The wet PVDF membrane was then washed in distilled water for 10 minutes and 
then kept in transblotting buffer in 4°C until use�After electrophoresis, semi-dry electro-
blotting was performed by a semi-dry electrophoretic transfer cell (BioRad) to transfer 
proteins on the gel onto the pretreated PVDF membrane. 
For semi-dry electro-blotting, the filter paper was pre-soaked with chilled 
transblotting buffer and placed onto the platinum anode. Air bubbles were removed by 
rolling a clean glass onto it. Then the gel was carefully placed in top and aligned on the 
center of the pretreated PVDF membrane. Another pre-soaked filter paper was placed on 
top of the gel. A clean glass rod was used to roll across the sandwich to exclude the air 
bubbles trapped and then the cathode was covered on the stack. Electro-transfer was 
performed at constant voltage of 15V for 20 minutes for 1 set or 35 minutes for 2 sets at 
room temperature. 
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After electro-blotting, the membrane was marked with ball pen at the top-left 
comer. The membrane was firstly blocked by 5% BLOTTO at room temperature for an 
hour with shaking. Then appropriate titer of primary antibody was added to the BLOTTO. 
In this case, the membrane was primed with 40|ig/ml monoclonal anti-his-tag antibody for 
1 hour at room temperature. Unbound antibody was washed with IX TBS, then IX TTBS 
twice and lastly with IX TBS. Secondary antibody conjugated with horse reddish 
peroxidase (HRP) was then applied for signal detection. 
A titer of 1:2000 anti-mouse IgG antibody conjugated with HRP was added to 5% 
BLOTTO where the membrane was incubated and shaked at room temperature. Similarly, 
the unbound secondary antibody was removed by washing with IX TBS and IX TTBS. 
After draining off the membrane, 1:1 Detection buffer 1 and detection buffer 2 (Amersham . 
Biosciences) was added onto the membrane and was allowed to incubate for 1 minute. 
Detection buffer was removed by soaking with a filter paper, then wrapped with cling 
warp and was ready for signal detection on film, 
b) N'-terminal Amino Acid Sequencing of His-tag MEA 
20|ig of purified his-tag MEA was loaded on 12.5% SDS-PAGE gel and 
electrophoresed and then blotted onto PVDF membrane. These his-tag protein bands were 
visualized by amino black stain, excised by sterile blade and processed with pre-
sequencing procedures. Firstly, it was wetted with methanol for 30 seconds and then put 
into 15ml falcon tube filled with 10ml milli-Q water. Then it was sonciated for 
approximately 10 minutes in a sonication water bath�Finally, the sample was sequenced 
by HP G1005A Protein Sequencing System (Hewlett Packard). 
c) Western Blot of His-tag MEA with Sero-positive Serum of Mice and Human 
2}ig of purified his-tag protein was blotted onto the PVDF membrane and then 
probed with 1:200 of primary sero-positive serum of mouse, rabbit and human. The 
secondary HRP conjugated antibodies used and the titers were shown in table 2.2. 
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Table 2.2. Table showing the titers of primary seropositive serum from different 
species of mammals and secondary antibody conjugated with HRP. 
Titer of sero- Secondary Titer of 
Positive serum Antibody used Secondary antibody 
Seropositive Polyvalent ^ H I o ^ 
and seronegative anti-human antibody 
1 1:1000 】 
human serum HRP-conjugated 
Seropositive 1:200 Polyvalent iTlO^ 
and seronegative anti-mouse antibody 
1:1000 
mouse serum HRP-conjugated 
d) Preparation of Toxoplasma gondii lysate 
The tachyzoite of a highly virulent RH strain of T. gondii were kindly provided 
by Prof. Wu ZhongShan from Zhong Shan Medical College, Sun Yat-Sen University, 
China. The parasites were maintained by serial intraperitoneal passages in BALB/c mice. 
Tachyzoites harvested was spun, followed by resuspension in PBS and then boiled for 30 
minutes. The tachyzoite suspension was squeezed through a syringe with a 26G needle for 
twice. Sonication was performed with 1 minute burst and 1 minute cooling for 50-100 
repeats. Protein content was estimated by Braford's standard assay. Before loading to 
SDS-PAGE, 1/4 volume of 5X SDS sample loading buffer was added and sample was 
boiled for 8 minutes. Remaining sample was stored at -20°C. 
e) Western blot of purified his-tag MEA and J. gondii Lysate by anti-serum of 
recombinant his-tag MEA 
3 ml induced bacterial culture was spun and the pellet was resuspended in 500|il 
IX SDS sample loading buffer. 500|li1 sample was then loaded into two 12.5% agarose gel 
for electrophoresis, then a light staining of the proteins in the gel with Coomassie blue 
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which permit localization without fixing and the gels were finally equilibrated in distilled 
water. The inducible band of his-tag MEA were excised and ground into granules by 
sterile glass slide. The gel granules were transferred to a L5ml eppendorf with a clean 
blade. They were mixed thoroughly with equal volume of Complete Freund Adjuvant in 
the eppendorf tube by strong vortexing. The content was then transferred to a sterile 1ml 
syringe with a need of 23.G. 
For primary immunization, ISOjul of the mixture (corresponding to SO i^g) was 
subcutaneously injected on either side of the dorsal skin near the base of the tail of the 
mice and 5 mice were immunized with this emulsified antigen. At day 14 and 28 after the 
first immunization, the mice were further immunized with booster injection for each 
booster injection; same amount of his-tag MEA was prepared by the same procedures but 
Incomplete Complete Freund Adjuvant was used instead of Complete Freund Adjuvant. 
Two weeks after the 2��booster (i.e. the immunization), the mice were killed, blood 
was collected by heart puncture and transferred into a 1.5ml eppendorf tubes. Blood 
sample were kept at 37°C for 1 hour to allow blood clotting and was then spun at 
14000rpm for 30 minutes at 4°C. The clarified serum were carefully pipetted out, pooled 
together, then divided into SOjul aliquots and kept at -70°C for storage. 
Ijig purified his-tag MEA (prepared in 2.3.2.d) and 20jul T. gondii lysate (prepared 
in 2.3.3.d) was loaded into 12.5% SDS-polyacrylamide gel. After electrophoresis and 
blotting, they were incubated with different titers of serum raised against the recombinant 
his-tag MEA in 5% BLOTTO. Purified his-tag MEA was primed with 1:8000 titer of 
serum while the T. gondii lysate was primed with 1:200 titer of serum. After 1-hour 
incubation, the membranes were washed and hybridized with 1:2000 titer of secondary 
antibody conjugated with HRP (goat anti-mouse IgG antibody). Signals were detected with 
ECL detection system as described in 2.3.3.a. 
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2.4 Results 
2.4.1 Design and synthesis of the synthetic gene encoding the multi-epitopic antigen 
for Toxoplasma gondii 
The five epitopes included in the multi-epitopic antigen were summarized in table 
2 . 3 �T h e y were linked with linker sequence (Pro-Gly-Gly-Gly-Pro). The secondary 
structure and the hydrophobic prolile of the MEA were then predicted by GOR IV and 
hydrophobicity plot of the scale ofKyte and Doolittle, 1982 (Figure 2.1). The amino acid 
sequences were then converted back to DNA sequences following the codon usuage of 
mouse (Figure 2.4). 
Table 2.3. Summary of the epitopes included in the multi-epitopic antigen for T. 
gondii 
Epitope Source Amino add sequence References 
(B/T) (Position) 
P30I (T) P30 (aal38-154) NNVARCSYGADSTLGPV Velge-Roussel 
et al, 1994 
P30II (T,B) P30 (aal91-209) CNEKSFKDILPKLTENPWQ Godard et al., 
1994 
GRA2 (T,B) GRA2 (aal71-185) PQQRAAHVPVPDFSQ Duquesne et al, 1991 
Cesbron-Delauw 
et al, 1992 
Murray et al., 1993 
R0P2 (T) ROP (aal97-216) TDPGDWIEELFNRIPETSV Saavedra et al, 1996 




et aL, 2000 
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Figure 2.1. GOR IV prediction and hydrophobicity plot for MEA. (A) Graphical 
representation of the GOR IV prediction and a graph of the probabilities of each amino 
acid's conformation (http://pbil.ibcp.fr/). (B) Plot of hydrophobicity of MEA using the 
scale of Kyte and Doolittle, 1982. (http://tw.expasy.org/cgi-bin/protscale.pl). Linker 
sequences were located at amino acid 20-24, 40-44，64-68 and 89-93 and were labelled as 
“ mmmm “. Distinct epitopes included in the MEA construct, P30I, GRA2, P30II, R0P2 
and TTP30 were shown on the Figures. 
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P30I 
1 ATG GGA AAC AAC GTG GCC AGG TGC TCC TAC GGC GCC GAC 3 9 
Met G N N V A R C S Y G A D ~ 
P30I ist linker GRA2 
4 0 AGC ACC CTG GGC CCA GTG CCT GGT GGT GGA CCA CCT CAG 7 9 
S T L G . P V P G G G P " p ~ ~ ~ 
GRA2 
80 CAG CGC GCC GCC CAC GTG CCT GTG CCC GAC TTC AGC CAG 119 
Q R A A H V P V P D F S Q 
2nd linker P30II 
12〇 CCT GGT GGT GGT CCA TGC AAC GAG AAG TCC TTC AAG GAC 159 
P G G G P ~ C N E ~ ~ K S F K D 
P30II 3rd 
160 ATC CTG CCC AAG CTG ACC.GAG AAC CCA TGG CAG CCA GGT 199 工 L P K L T E N P W Q P G 
Linker R0P2 
200 GGA GGT CCA ACC GAC CCT GGT GAC GTG GTC ATC GAA GAG 239 
g g p t d p g d v v i e e 
R0P2 4th linker 
240 CTG TTC AAC CGC ATC CCC GAG ACC AGC GTC CCA GGA GGA 279 
l f n r i p e t s v p g g 
TTP3 0 
280 GGT CCT TTC AAC AAC TTC ACC GTG TCC TTC TGG CTG CGC 319 
G P ~F N N F T V S F W L R ~ 
TTP3 0 
320 GTG CCT AAG GTG TCC GCC TCC CAC CTG GAG TGA 
V P K V S A S H L Stop 
Figure 2.2. Nucleotide sequence and amino acid of MEA. The shaded letters 
represente linker sequence (PGGGP) in-between each epitope. Sequence underlined 
represents individual epitope within the whole sequences. The and epitope were 
selected from P30. The epitope was selected from GRA2 while the epitope was 
from R0P2. Lastly was the epitope from tetanus toxin (details refer to L3.3 and 2.1.1). 
The complete coding sequence in this synthetic gene was flanked by start (ATG) and stop 
codon (TGA). 
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2.4.2 Cloning of MEA into E. coli Expression vector 
The plasmid pCRII-TOPO-MEA and the E. coli expression vector- pET30a+ were 
used as the starting material in this experiment. For construction of pET-His-tag MEA, the 
MEA gene was amplified from the plasmid by PGR using gene specific primers and then 
purified by the Qiagen II gel extraction kit. The plasmid pET30a+ was digested by Ncol 
cut and desalted by ethanol precipitation. This purified single cut plasmid was then fill-in 
by T4 DNA polymerase to generate blunt end for ligation. The MEA fragment was blunt-
end ligated with the Ncol cut, fill-in pET vector and the MEA gene was in-frame flised 
with the N-terminal polyhistidine tag with an enterokinase cleavage site inbetween. 
Ligation products were then transformed in DH5a competent cells. Transformed . 
bacterial cells were able to form colonies on LB agar plates under kanamycin selection. 
As the plasmid in the transformed cells was either the self-ligated vector or vector with 
insert, PGR screening was performed using MF734/596 and only plasmid with insert with 
right orientation could be screened. After PGR screening, plasmids DNA were prepared 
from the positive clones using Wiazard ™ SV purification kit. The nucleotide sequence 
of pET30a+-His-tag MEA was read and confirmed by cycle sequencing with gene 
specific primers and T7 terminator sequencing primer. The nucleotide sequences were 
edited by DNasis's Contig Manger program and shown in Figure 2.3. 
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His-tag 
1 A T G CAC CAT CAT CAT CAT CAT T C T T C T G G T C T G G T G CCA 39 
m h h h h h h s s g l v p 
4 0 C G C G G T T C T G G T A T G A A A G A A A C C G C T G C T G C T A A A T T C 7 9 
R g s g m k e t a a a k f 
8 0 GAA CGC CAG CAC A T G GAC AGC CCA GAT CTG GGT A C C GAC 119 
e r q h m d s p d l g t d 
F i l l - i n Ncol 
1 2 0 G A C G A C G A C A A G G C C A T G A T G G G A A A C A A C G T G G C C A G G 1 5 9 
d d d k a m m g n n v a r 
1 6 0 T G C T C C T A G G G C G C C G A C A G C A C C C T G G G C C C A G T G C C T 1 9 9 
C S Y G A D S T L G P V P 
2 0 0 G G T G G T G G A C C A C C T C A G C A G C G C G C C G C C C A C G T G C C T 2 3 9 
g g g p p q q r a a h v p 
2 4 0 G T G C C C G A C T T C A G C C A G T G C A A C G A G A A G T C C T T C A A G 2 7 9 
p d f s q c n e k s f k v 
2 8 0 G A C A T C C T G C C C A A G C T G A C C G A G A A C C C A T G G C A G C C A 3 1 9 
d i l p k l t e n p w q p 
3 2 0 G G T G G A G G T C C A A C C G A C C C T G G T G A C G T G G T C A T C G A A 3 5 9 
g g g p t d p g d v v i e 
3 6 0 G A G C T G T T C A A C C G C A T C C C C G A G A C C A G C G T C C C A G G A 3 9 9 
e l f n r i p e t s v g g 
4 0 0 G G A G G T C C T T T C A A C A A C T T C A C C G T G T C C T T C T G G C T G 4 3 9 
g p f n n f t v s f p w l 
4 4 0 C G C G T G C C T A A G G T G T C C G C C T C C C A C C T G G A G TGA 
R V P K V S A S H L E S top 
Figure 2.3. Nucleotide sequence of pET30a+-His-tag MEA. The sequence read by T7 
terminator primer, gene specific upper and lower primers were edited and manipulated by 
Contig Manger Program of DNasis. The shaded letters represented the 6X histidine tagged 
(his-tag) and enterokinase cleavage site in the pET vector. The complete coding sequence 
of his-tag MEA was flanked by start (ATG) and stop codon (TGA). The fill-in Ncol site 
was underlined. 
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2.4.3 Expression and Purification of His-tag MEA 
The pET30a+-His-tag MEA was transformed into bacterial expression host 
BL21(DE3). Transformed cell was induced with ImM IPTG for expressing his-tag MEA. 
Expression profile of his-tag MEA was determined and shown in Figure 2.4., his-tag MEA 
was highly expressed and reached a maximum at around three hours after induction (over 
20% of the total protein of cell lysate). It was around 21 kDa and existed in the soluble 
fraction of the induced bacterial lysate (Figure 2.5). 
The amount of his-tag MEA in the induced bacterial lysate was roughly estimated 
by SDS-PAGE with different amount of standard BSA proteins loaded onto the gel as 
reference (Figure 2.6). Based on the intensity of the bands after Coomassie blue staining, 
the yield of the recombinant his-tag MEA produced in the bacterial culture was estimated 
to be 0.12-0.15g/L after 3-hour induction. The his-tag MEA protein was purified from 
25ml bacterial culture by TALON's affinity resin as shown in Figure 2.7 and was 
concentrated by centricon-10. The amount of purified and concentrated his-tag MEA 
protein was estimated by Braford protein assay with BSA protein as standard. Referring to 
the standard curve (Figure 2.8), the concentration of the resin-purified his-tag MEA (total 
volume of 3ml) was 112.7|ag/ml (Table 2.4) and thus, the recovery of the his-tag MEA 
from the induced bacterial lysate was around 10%. 
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Figure 2.4. Expression profile of his-tag MEA by IPTG induction. 20ml bacterial 
culture of BL21(DE3) carrying the recombinant plasmid pET30a+-MEA at OD600 = 0.6-
0.8 was added with IPTG to a final concentration of ImM. It was then shaken at 350rpm at 
37°C for 3 hours. For every 30 minutes, SOOpil of the bacterial culture was pipetted out and 
spun. Supernatant was discarded, the pellet was resuspended with 0.5ml IX SDS sample 
loading buffer and store at 4°C. when all time points were colleted, they were boiled for 8 
minutes. 20|al of each sample was loaded on 12.5% polyacrylamide gel for electrophoresis 
at constant voltage: 150V. lane 2 (U) was the uninduced control. Lane 3 to 8 were induced 
bacterial culture harvested at different time points after IPTG induction (lane 3 to 8 = 0.5， 
1.0, 1.5, 2.0, 2.5 and 3.0 hours). The gel was stained by Commassie blue, destained and 
drided. Gel image was captured by scanning the dried gel, M=SDS broad range protein 
marker (Bio-rad) and the size of the protein marker was indicated as kDa and shown on the 
left. The putatuve his-tag MEA ( �2 1 kDa) was indicated by an arrow. 
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Figure 2.5. Estimation of His-tag MEA production in induced bacterial lysate. 60|il 
of induced bacterial lysate (lane 1) was loaded in 12.5% SDS-polyacrylamide gel parallel 
with 7 dilutions of BSA standards (lane 2-8), which are 1,2’ 4，6，8，10 and 12jLig/ lane. 
After electrophoresis, protein bands on the gel were visualized by Coomassie blue staining 
as described in 2.3.2.b. and the intensity of the inducible band, i.e. his-tag MEA, was 
compared to the intensity of BSA standards of different amount. Later on, the gel was 
drided. Gel image was captured by scanning the dried gel. M=SDS broad range protein 
marker (Bio-rad) and the size of the protein marker was indicated as kDa and shown on the 
left. The putatuve his-tag MEA (~21kDa) was indicated by an arrow. 
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Figure 2.6. Determination of the his-tag MEA protein in the soluble fracion of the 
induced bacterial lysate. Cell pellet from 40ml induced bacterial culturewas collected and 
resuspended in 10ml inclusion body isolation buffer. The bacterial cells were lysed with by 
lysozyme digestion and repeated freeze-thawing. After centrifugation at 10,000rpm in 4°C 
for 15 minutes, supernatant was collected as soluble fraction. Then the pellet was washed 
twice with 5ml inclusion body washing buffer and finally the pellet was solubilized with 
10ml solubilizing buffer. Samples were mixed and boiled with SDS sample loading buffer. 
20jjJ of each fractions was loaded on 12.5% polyacrylamide gel for electrophoresis at 
constant voltage: 150V. The gel was stained by Commassie blue, destained and drided. Gel 
image was captured by scanning the dried gel. The majority of the putatuve his-tag MEA 
was found in the soluble fraction indicated by an arrow. M, SDS broad range protein 
marker (Bio-rad) and the size of the protein marker was indicated as kDa and shown on the 
left. Lane 1: uninduced control; lane 2: induced bacterial lysate; lane 3 and 6: soluble 
fraction and inclusion body of the induced bacterial lysate and lane 4 and 5: first and 
second wash. 
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Figure 2.7. Purification of the his-tag MEA by TALON affinity resin. 25ml 
induced bacterial culture was harvested (Lane 1= uninduced control and Lane 2= induced 
bacterial lysate). Cell pellet was resuspended in 2ml IX Extraction/ Wash buffer, pH 7.0 
and was lysed with by lysozyme digestion and repeated freeze-thawing. After 
centrifugation at 10,000rpm in 4°C for 15 minutes, supernatant was collected as soluble 
fraction. This fraction was mixed with 1ml equlibrilized TALON affinity resin. The 
mixture was then loaded into gravity colume until no more drops (lane 3) and was washed 
twice with 5ml IX Extraction/ Wash buffer (lane 4 and 5). The resin-bound protiens was 
eluted with Ix Elution buffer and collected intoO.Sml fractions. The eluted fraction 
containing the target proteins were pooled (lane 6). 20jji of each fractions was mixed with 
5[i\ 5xSDS sample loading buffer and boiled for 8 minutes. They were then loaded on 
12.5% polyacrylamide gel for electrophoresis at constant voltage: 150V. The gel was 
stained by Commassie blue, destained and drided. Gel image was captured by scanning the 
dried gel. M=SDS broad range protein marker (Bio-rad) and the size of the protein marker 
was indicated as kDa and shown on the left. The putatuve his-tag MEA was indicated by 
an arrow. 
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Figure 2.8. Standard curve of Braford protein assay. Six dilutions of standard BSA 
were prepared 2.33.C. 
Table 2.4. Braford protein assay for his-tag MEA. 
Sample Dilution Factor Average values Protein conc. 
OfOD595 (j^g/ml) 
His-tag MEA 20 0.184 U Z l 
* Each sample was prepared in 200|il solution with duplication. The average of their corresponding 
absorbance values at 595nm, their dilution factors and their protein concentration were recorded. 
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2.4.4. Characterization of His-tag MEA 
Beside the inducible pattern shown on SDS-PAGE, production of his-tag fusion 
protein by the transformed bacterial cells was confirmed by Western blot with monoclonal 
anti-his-tag antibody which would specifically bind to the his-tag fusion (Figure 2.9). 
Moreover, the poly-histidine tag was read directly by N-terminal amino acid sequencing 
(Table 2.5). 
After confirming and purifying the target protein, His-tag MEA, its antigenicity 
and immunogenicity had to be proved. Antigenicity is referring to the ability of the antigen 
to be recognized by seropositive serum while immunogenicity refers to the capacity of a 
substance to induce a specific immune response as shown by the capacity of its anti-sera to 
recognize the native proteins of the parasite. 
The recombinant his-tag MEA fusion could be recognized by different titers of 
seropositive serum from mouse (Figure 2.10A) and human (Figure 2.10B) infected with 
Toxoplasma gondii. Thus the antigenicity of this recombinant antigen was confirmed. 
Recombinant his-tag MEA protein was then partially purified from the 
polyacrylamide gel for immunization. Anti-serum against the his-tag MEA was collected 
from immunized BALB/c mice. This antiserum was highly immunogenic, as his-tag MEA 
could be recognized with a titer of 1:8000 in western blot analysis (Figure 2.1 IB). 
Immunogenicity of His-tag MEA was further confirmed as the anti-sera could recognize 
several T. gondii antigens in T. gondii lysate (Figure 2.1 IC) with molecular weight of 
27.2kDa, 30.5kDa and 54.9kDa under reducing conditions (Table 2.6 and Figure 2.12) and 
were predicted to be GRA2, R0P2 and P30 antigens based on the estimated sizes. 
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Table 2.5. N-terminal amino acid sequence of putative his-tag MEA. 
N-terminal Expected amino acid sequence Sequencing result of the 
amino acid (deduced from DNA sequence) purified his-tag MEA 
1 Methionine (M) Methionine (M) 
2 Histidine (H) Histidine (H) 
3 Histidine (H) Histidine (H) 
4 Histidine (H) Histidine (H) 
5 Histidine (H) Histidine (H) 
6 Histidine (H) Histidine (H) 
7 Histidine (H) Histidine (H) 
8 Serine (S) Serine (S) 
9 Serine (S) Serine (S) 
10 Glycine (G) Glycine (G) 
11 Leucine (L) Leucine (L) 
12 Valine (V) Valine (V) 
13 Proline (P) Proline (P) 
14 Arginine (R) Arginine (R) 
rs Glycine (G) Glycine (G) 
16 Serine (S) Serine (S) 
17 Glycine (G) Glycine (G) 
18 Methionine (M) Methionine (M) 
19 Lysine (K) Lysine (K) 
20 Glutamic acid (E) Glutamic acid (E) 
* The putative 21kDa his-tag MEA was excised from the PVDF membrane and sequenced by the automated 
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Figure 2.9. Western blot of induced bacterial lysate with monoclonal anti-his-tag 
antibody. The expression of the his-tag MEA in 25ml bacterial culture of OD600 at 0.6, 
was induced by addition of IPTG to final concentration of ImM. It was shaken at 250rpm 
at 37°C for 3 hours. SOOjiil of both uninduced (U) and induced (I) bacterial cultures were 
collected. Bacterial pellets were resuspended in lOOjLil of IxSDS sample loading buffer and 
then boiled for 8 minutes. 20[i\ of the boiled samples were loaded on 12.5 % SDS-
polyacrylamide gel for electrophoresis. The resolved proteins were then transferred to 
PVDF membrane and hybridized with 0.4jLig/ml monoclonal anti-his-tag antibody. The 
arrow indicated the positive signal corresponding to the size of the putative his-tag MEA 
( � 2 1 KDa). Protein marker was indicated as kDa and shown on the left. 
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Figure 2.10. Western blot of the TALON affmity-purified his-tag MEA with 
seropositive sera from mice and human. Ijiig of purified his-tag MEA protein (Lane 1, 2 
and 3 ) and 20jil T gondii lysate prepared in 23.2.6. (Lane 4) were separately by 12.5% 
SDS-PAGE and blotted to PVDF membrane for western blot analysis. Panel A showed the 
western blot with seropositive and sero-negative mouse serum. Panel B showed the 
western blot with seropositive and sero-negative human serum. Lane 1 and 2: 1:200 and 
1:1000 seropositive serum probed with Ijig his-tag MEA; lane 3: 1:200 sero-negative 
serum probed with his-tag MEA and lane 4: 20\i\ T. gondii lysate was used as positive 
control for both the human and mouse seropositive serum (1:200). Secondary antibodies 
conjugated with HRP were used for signal development and detection. The titers of using 
different antibodies were shown in Table 2.2. and the size of the protein marker was 
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Figure 2.11. SDS-PAGE and western blot of Toxoplasma gondii lysate with 
antiserum against his-tag MEA from mice. (A) 20jal T. gondii lysate (prepared in 2.3.2.d) 
and Ijig his-tag MEA were separated by 12.5% SDS-PAGE and blotted to PVDF 
membrane for western blot analysis�Panel A showed the Commassie Blue stained gel 
photo. M: SDS broad range marker, showing the MW (kDa) on left; lane 1: T. gondii 
lysate. Panel B represented the positive control for this western blot, anti-serum against 
His-tag MEA (1:8000) was reacted with l\xg his-tag MEA. Panel C and D showed the 
western blot analysis of T. gondii lysate with 1:200 anti-serum against His-tag MEA (C) 
and 1:200 seronegative serum which acted as a negative control for this experiment (D). 
The antiserum could recognize five antigens of the T. gondii lysate (band 1-5) with three 
dominating with molecular weights of 28kDa, 31kDA and 55kDa under reducing 
conditions and the size of the protein marker was indicated as kDa and shown on the left. 
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Figure 2.12. Standard curve showing the relationship between the log of the 
molecular weight (logMW) of the broad range standards and the relative mobility 
(Rf). 
Table 2.6. Rf values and the corresponding molecular weight of the T, gondii 
antigens identified by anti-serum against His-MEA (Western blot as described in 
2.3.2.e and Figure 2.15). 
^ B a n d Rf value LogMW MW Predicted 
No. T. gondii antigen 
1 0.618 4.435 ^ GRA2 
2 0.566 4.484 ^ ^ 
3 0.395 4.642 419 -
4 0.289 4.740 R0P2 
5 0.263 4.764 ^ -
* The molecular weight of each protein was calculated by the standard curve as shown in figure 2.16, with 
the correlation of the long molecular weight and the Rf values equal to y = -0.9257x + 5.0077, where y-axis 
represents logMW and x-axis represents Rf values. ‘‘-“ refers to discussion section. (2.5.4). 
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2.5 Discussion 
2.5.1 Design and synthesis of the synthetic gene encoding the multi-epitopic antigen 
for Toxoplasma gondii 
After selecting the epitopes for constructing the multi-epitopic antigen, these 
epitopes have to be linked. The spacer sequence should give an extended and flexible 
structure so that each of the epitopes would not overlap each other, allowing each epitopes 
to fold properly and independently. Based on the unique conformational property, glycine 
and proline were chosen as the major residues in the linker sequences. Based on prediction 
of the secondary structure with GOR IV method, among different combination of P and G 
residues, PGGGP was chosen as the linker sequence. GOR IV is a method for secondary 
structure prediction based on empirically derived residues propensities for different 
conformational states (statistical methods) with the mean accuracy of 64.4% for a three 
states (helix, sheet and coil) prediction. As shown in Figure 2.1 A, the linkers (aa20-24, 40-
44，64-68 and 89-93) beared a random coil structure, separating different epitopes which 
appeared to be distinct domains in the overall secondary structure� 
Antigenic determinants of a protein are usually surfaced located, containing 
charged and polar residues; so many methods have been presented to locate hydrophilic 
regions of a protein (Hopp and Woods. 1981; Kyte and Doolittle. 1982). Although as 
shown by Hopp and Woods (Hopp and Woods. 1981), the relationship between the 
antigenicity and hydrophilicity is not always true, prediction of this profile gives a rough 
estimation on the potentially antigenic region. The hydropathic profile of a protein is 
calculated by assigning each amino acid a numerical value - hydropathy index and then 
repetitively averaging these values along the peptide chain. By subjecting the amino acid 
sequences of MEA to the hydrophobicity plot (Figure 2. IB), the PGGGP linkers (aa20-24, 
40-44, 64-68 and 89-93) were poorly hydrophobic and thus they should not be antigenic 
and antigenic domain of MEA fell on the five epitope domains. Based on the prediction 
from GOR IV and hydrophobicity plot, PGGGP was the ideal linker sequences for 
conjugating different epitopes in the multi-epitopic antigen. 
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The codon of the multi-epitopic antigen followed the mouse's codon usuage and 
was GC-rich. The codon chosen for each amino acid are not in rare codon used in plant 
{Arabidopsis thaliana) or E. coli (Table 2.7A and 2.7B). Although the codon usuage of the 
synthetic gene is favor mouse codon usuage, it is predicted that the codon usuage will not 
hinder the expression of this synthetic gene in plant and E. colL 
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Table 2.7A. Codon usuages in A, thaliana，E. coli and Mus musculus muculus and 
the multi-epitopic antigen. 
Amino Codon A. thaliana E, coli (%) Mus musculus Multi-epitpoe 
acids Musculus (%) antigen (%) 
Phe UUU 2.25 (52.08) 2.21 (57.40� 1.31 (29.71) 0.00 (0.00) 
Ul^C 2.07 (47.92) 1.64 (42.60) 3.10 (70.29) 5.22 (100.00) . 
Ser UCU 2.46 (28.21) 0.95 (15.83) 1.15 (16.41) —0.00 (0.00) 
UCC 1.08(12.39) 0.89 (14.83) L55 (22.11) 4.35 (62.50) 
UCA 1.78 (20.41) 0.80 (13.33) 0.90 (12.84) 一 0.00 (0.00) 
UCG 0.89(10.21) 0.87 (14.50) 0.28(3.99) 0.00(0.00) 
AGU 1.40 (16.06) 0.93 (15.50) 一0.90 (12.84) 0.00 (Q.QQ)一 
AGC 1.11 (12.73) L56 (26.00) 2.23 (31.81) 2.61 (37.50) 
Tyr UAU 1.52 (52.60) ~T68 (57.93) (34.67) 0.00 (0.00)— 
^^C 137(47.40) 1.22 (42.07) 1.79 (65.33) 0.87(100.00) 
Cys UGU 1.08 (60.00) 0.52 (45.22) 0.66 (44.00) 0.00(0.00)~~ 
UGC 0.72 (40.00) 0.63 (54.78) 0.84 (56.00) 1.74(100.00) 
Leu CUU 2.43 (25.85) 1.14 (10.99) 0.93 (11.79) 0.00 (Q.QQ)~~ 
CUC 1.59(16.91) 1.06(10.22) 1.35 (17.11) 0.00 (0.00) 
CUA 1.00 (10.64) 0.40 (3.86) 0.72 (9.13) 0.00 (0.00) 
CUG 0.99 (10.53) 5J)6 (48.79) 3.32 (42.08) 5.22 (100.00) 
UUA 1.29 (13.72) ~139 (13.40) —0.44(5.58) “ Q.QQ (0.00) 
UUG 2.10(22.34) 1.32 (12.73) 1.13 (14.32) 0.00 (0.00) 
Pro CCU 1.83 (38.33) 0.72(16.67) 1.37(29.72) 6.09 (41.18) 
CCC 1.53 (11.04) 0.54 (12.50) L67 (36.23) 2.61 (17.65) 
CCA 1.61 (3833) ~0,85 (19.68) — 1.17(25.38) 6.09(41.18) 
CCG 0.83 (17.29) 2.21 (51.16) 1 4 0 (8.68) Q.QQ (Q.QQ) 一 
His CAU 1.40 (61.67) ~L21 (56.95) 2.39 (33.66) 0.00 (0.00) 
CA C 0.8 7 (38.33) (196 (43.05) 4,71 (66.34) 1.74 (100.00) 
Arg AGA ~L87 (35.15) ~0.28 (5.05) ~ 0.82 (17.71) 0.00 (0.00)~~ 
A GG /. 09 (2(149) 汉 17 (3.06) /.21 (26.13) 0.8，(25.00) 
CGU 0.89 (16.73) 2.06 (37.12) 0.50 (10.80) 0.00(0.00) 
CGC 0.37(6.95) 0(37.84) O.S2( 17.71) 2.61 (75.00) 
CGA 0.62(11.65) — 0.37 (6.67) — 0.52 (11.23) 0.00 (0.00) 
CGG 0.48 (9.02) 0.57 (10.27) 0.76 06.41) 0.00 (0.00) 
^Percentage (%) frequency of the corresponding codons usage calculated based on known 
sequences of the whole genomes {A. thaliana, Mus musculus muculus and E. coli) and was 
adopted from codon database (http://www.kazusa.or.jp/codon/) or the artificial gene (multi-
epitopic antigen). Figures in parenthesis indicate the relative % frequency of codon usage for 
each individual amino acid. The codon usage of the multi-epitopic antigen was bolded. 
75 
Table 2.7B. Codon usuages in A, thaliana, E, coli and Mus musculus muculus and 
the multi-epitopic antigen. 
Amino Codon I A. thaliana E. coli (%) Mus musculus Multi-epitpoe 
acids (o/o)a Musculus (%) Gene (%) 
lie AUU 2.20 (41.20) 2.99 (49.92) 1.07 (32.04) O.QQ fO.QQ) 
• 1-^5(34.64} 2.45(40.90) LH7 (55.99) 2.61 (100.00) 
AUA 1.29 (24.16) 0.55 (9.18) 0.40 m Q?^� 
Thr ACU 1.78 (34.50) 0.97(17.80) 1.39 (27.52) 0.00 ro.om 
-drC 1.03 (19.96) 2.21 (4L65) L53 (30.30) ~7J5 (100.00) 
ACA 1.59 (30.81) 0.81 (14.86) 1.71 (33.86) 一0.00 (O.QQ) 
ACG 0.76 (14.73) 1.40 (25.69) (8.32) O.QQ (O.QQ) 
Met AUG 2,45 (100.00) 2.71 (100.00) 7.7? n00.00) 0 87(100.00) 
Asn AAU 2.27 (52.06) 1.89 (46.67) 
桃 2.09(47,94) 2.16 (5333) 2.01 (63.61) 6J)9n()O nO) 
Lys AAA 3.10(48.47) 3.45 (75.00) 1.85 (41.48) —0.00 (0.00) 
^^G 3.26 (51,26) LIS (25.00) 2.61 (58.52) 3.48 (100.00) 
Gin CAA 1.97 (56.45) 1.48 (33.94) 1.37(9.24) 一0.00 (0.00) 
CAG 1.52 (43.55) 2.88 (66.06) 13.45 (90.76) 3.48 (100.00) 
Trp UGG 1.27(100.00) ~L44 (100.00) 1.43 (100.00) “ 1,74(100.00)—  
Val GUU 2.73 (40.38) 1.92 (27.12) 
GUC 1.27(18.79) 1.48(20.96) 1.55 ( 30.51) 1,74(20.00) 
GUA 1.01 (14.94) 1.13 (16.01) 0.30 (5.91) ~~0.00 (0.00) 
GUG 1.75 (25.89) 2,53 (35.83) 2.41 (47.44) 6.96 (HO.OO) 
Ala GCU 2.80 (43.28) 1.64(17.47) 1.81 (31.70) —0.00(0.00) 
GCC 1.03 (15.92) 2.49 (26.52) 2.13(37.30) 4.35(100.0) 
GCA 1.76 (27.20) T 0 6 (21.94) ~T.43 (25.04) 0.00 (0.00) 
GCG 0.88 (13.60) 3.20 (34.08) 0.34 (5.96) O.QQ (0.00) 
Asp GAU 3.60 (67.54) 3.24 (62.67) 1.33 (27.77) O.QQ (0.00) 
GAC L 73 (32.46) 1.93 (37J3) 3.46 (72.23) 4.35 (100.00) 
Glu GAA 3.44(51.65) 3.94(68.17) (16.67)~ 
GAG 3.22 (48.35) / . ( ^ � j Z I ^ 权 
Gly GGU 2.22 (34.00) 2.52(34.33) 1.29(24.34) 7.83 (56.25) 
CCC 0.90 (13.78) 2.84 (38.69) 1,61 (30.3H) ~T.74 (12.50) 
GGA 2.39 (36.60) 0.87(11.85) jjg (22.45) 4.35 (31.25) 
I GGG I 1.02(15.62) 1.11 (15.12) 1.21 (22.83) 0.00(0.00)  
•Percentage (%) frequency of the corresponding codons usage calculated based on known 
sequences of the whole genomes (A. thaliana, Mus musculus muculus and E. coli) or the 
artificial gene (multi-epitopic antigen). Figures in parenthesis indicate the relative % 
frequency of codon usage for each individual amino acid. The codon usage of the multi-
epitopic antigen was bolded. 
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2.5.2 Cloning of MEA into E. coli Expression vector (pET30a+-MEA) 
The MEA gene fragment was amplified from the pCRJI-TOPO-MEA by PCR 
using gene specific primers. It was then subcloned into the Ncol cut, fill-in E. coli 
expression vector- pET30a+. Tranformed clones carrying the putative plasmid were 
screened by PCR. Finally, sequences was confirmed by cycle sequencing (Figure 2.3). 
In the pET30a+His-tag MEA, the MEA was in-frame fused with the N-terminal 
His-tag, thrombin, 15 aa S-tag and enterokinase (EK) cleavage site under the control of T7 
lac promoter. Thrombin and enterokinase are site-specific proteases commonly used to 
cleave fusion proteins. S-tag and His-tag are peptide tag which facilitate detection and 
purification. This plasmid was transformed into the expression host, BL21(DE3), bearing 
the T7 RNA polymerase gene for expression of target gene. 
2.5.3 Expression and Purification of His-tag MEA 
After IPTG induction, the recombinant antigen, his-tag MEA, was highly expressed 
and reached at maximal level after 3 hours (Figure 2.4). It was around 21kDa. By 
estimation on SDS-PAGE, milligram of this antigen can be easily produced by liter of 
induced bacterial cultures. 
After isolation of the soluble and insoluble fraction of the induced bacterial lysate， 
his-tag MEA was found in the soluble fraction (Figure 2.5). This protein could be easily 
purified from the soluble fraction by TALON resin which can bind to the polyhistidine tag 
of the fusion protein with high affinity. The procedures of this TALON-resin system for 
affinity purification of his-tag fusion proteins are simple and the quality of the purified 
protein is satisfactory. Resin-bound his-tag MEA could be eluted by the addition of 
competing salt, such as imidazole. As imidazole competed with the his-tag MEA for 
binding to TALON resin, pure his-tag MEA could be easily eluted from the resin-binding 
stage by the addition of elution buffer containing imidazole. The recombinant antigen 
could be purified from bacterial lysate to nearly homogeneity of more than 95% purity by 
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one-step (Figure 2.7) and the purity was high enough for subjecting to N-terminal amino 
acid sequencing. During purification, an unexpected protein band of very small size was 
found in the soluble fraction and the elutant, this was probably the degradation product of 
his-tag MEA. To maximize the yield and the quality of the recombinant protein purified, 
sample should always be kept on ice during purification process. 
Although the binding capacity of TALON resin is high, 1ml resin would become 
saturated with small volume of IPTG-induced bacterial culture (around 350|ig of his-tag 
MEA was purified from 1ml resin and by estimation, less than 10% of the recombinant 
protein could be recovered). As the yield of the recombinant protein recovered from the 
resin would be very limited by its binding capacity, it was not economical to purify his-tag 
MEA in large scale with this method especially for purification of antigen for 
immunization as S-SO i^g protein was required for each immunization. 
An alternative method was to purify the antigen from the polyacrylamide gel after 
separating the samples on SDS-PAGE. Antigens purified this way often induce good 
antibody responses. After the injection of the protein-containing gel granules into the 
experimental animal, the antigen would be slowly released from the gel granules and thus 
mimicking an adjuvant-like effect. Since the antigen is denatured by this route of 
preparation, the resulting antibodies are usually particularly good for techniques that need 
or benefit from denaturation-specific antibodies. However, some of the resulting 
antibodies may not bind to the native antigen. 
2.5.4 Characterization of His-tag MEA 
His-tag MEA was a fusion protein containing a N-terminal polyhistidine-tag and 
the multi-epitopic antigen. The histidine-tag was detected by monoclonal anti-his-tag 
antibody. This antibody showed a high binding specificity to the his-tag as only a single 
band was detected in the total lysate of the induced bacterial culture (Figure 2.9). 
Moreover, the histidine-tag was evident by N-terminal amino acid sequencing. 20 cycles 
of sequencing reaction was performed on the resin-purified his-tag MEA in which the 
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amino acid sequence obtained from the experiment was completely matched with the 
expected sequences (Table 2.5) and the N-terminus of the protein was not blocked. 
There were two cleavage sites, the enterokinase and thrombin cleavage sites, 
present in-between the MEA and the N-terminal histidine-tag. As the histidine-tag could 
be recognized by anti-his-tag antibody and to be selectively bound by the transition-
metal containing resin, it was important for characterization and purification. After the 
his-tag fusion protein was characterized and purified, the histidine-tag could be released 
by enterokinase or thrombin cleavage. However, as the histidine-tag was small and 
poorly immunogenic, the recombinant protein without prior removal of the tag, could be 
used as an antigen to generate antibodies against the protein of interest. 
After purification and characterization of the recombinant antigen, MEA, its 
antigenicity and immunogenicity was tested and these are the basic criteria for MEA to be 
a vaccine candidate. The antigenicity of the multi-epitopic antigen was demonstrated as it 
could be recognized by different titers of T. gondii-infQcXQd mouse (Figure 2.1 OA) and 
human (Figure 2.1 OB) serum with distinct sharp band detected by western blotting which 
could not detected the corresponding seronegative serum. 
Recombinant his-tag MEA protein was then partially purified from the 
polyacrylamide gel for immunization (with Complete/ Incomplete Freund's adjuvant). 
Anti-semm against the his-tag MEA was collected from immunized BALB/c mice. This 
antiserum was highly immunogenic, his-tag MEA could be recognized with a titer of 
1:8000 in western blot analysis (Figure 2.11 IB). Immunogenicity of His-tag MEA was 
further confirmed as the anti-sera could recognize several T. gondii antigens in T. gondii 
lysate (Figure 2.1 IC) with molecular weight of 27.2kDa (Figure 2.1 IC, band 1)，30.5kDa 
(Figure 2.1 IC, band 2) and 54.9kDa (Figure 2.1 IC, band 4) under reducing conditions 
(Table 2.6 and Figure 2.12) and were predicted to be GRA2, R0P2 and P30 antigens based 
on the estimation by sizes. 
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When a mixed populations of antigens were used for immunizations, an antibody 
response to several components of the preparation is expected. If all the compounds in a 
preparation are equally immunogenic, then the resulting antibodies would mimic this 
situation. However, in the more likely case that the immunogenicity of the compounds 
varies, antibodies to some of the compounds would dominate the response. This could only 
be determined empirically and there are numerous examples of immunizations succeeding 
particularly well or particularly poorly because of immunodominant compounds. In the 
multi-epitopic antigen, 4 epitopes from T. gondii were included. To test whether the all of 
the 4 epitopes were immunogenic and were able to generate specific antibodies which 
could recognize the corresponding antigens in the T. gondii lysate, the antiserum against 
His-tag MEA was used to probe with the T. gondii lysate. Five major bands (Figure 2.1 IC, 
band 1-5) were detected with 3 bands dominating (Figure 2.11C，band 1, 2 and 4) at 
molecular weight of 27.2kDa, 30.5kDa and 54.9kDa which represented GRA2 (Klaren et 
al, 1998), P30 (Kasper et al, 1983) and R0P2 (Herion et al, 1993; van Gelder et aL, 
1993) under reducing conditions respectively. As SAG, GRA and ROP are representing a 
large family of antigens, the 2 minor bands detected on the western blot of molecular 
weight of 43.9kDa and 58.1kDa, may indicate the cross-reactivity of the anti-serum to 
other members of these family. For example the R0P2 epitope (aa 197-216) shares 85% 
identity in amino acid sequence to the ROP8 protein. 
GRA2 epitope in the vaccine construct, as reported, was also a B-cell epitope 
(Cesbron-Delauw et al, 1992; Murray et al” 1993). P30II epitope (aa 191-209) might also 
contain a B-cell epitope as it could induce B-cell response with the induction of multiple 
antibody isotypes (Gordard et al., 1994). So, it was not surprising that anti-serum against 
His-tag MEA could recognize the native GRA2 and P30 proteins in the T. gondii lysate. 
However, R0P2 epitope (aa 197-216, Saavedra et al., 1996) included in the multi-epitopic 
antigen had not been reported to be a B-cell epitope. The ability of the anti-serum against 
His-tag MEA to detect R0P2 on T. gondii implies that the T-cell epitope selected from 
R0P2 protein (aa 197-216) may also contain B-cell epitopes of the native protein. The 
recognition of GRA2, P30 and R0P2 by the anti-serum against His-tag MEA would be 
further discussed in the next chapter. Moreover, the T-cell responses would be 
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demonstrated as it was important in Toxoplasma infection. T-cell from immunized mice 
was taken out and stimulated to proliferate by the addition of total lysate of T. gondii and 
the cytokines expression profile in the immunized mice would be studied. More 
importantly, challenge experiment of virulent tachyzoite was performed on immunized 
mice to demonstrate the protective efficacy of the vaccine. 
� 
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Chapter 3 Immunological Studies of the Multi-epitopic 
Antigen (MEA) for Toxoplasma gondii in Mouse 
Models 
3.1 INTRODUCTION 
For a successful vaccine, it should be immunogenic, that means the antibodies 
raised by the vaccine construct should be able to recognize the native protein(s). When 
hybridizing the anti-serum against His-tag MEA with T. gondii lysate, three major bands 
of molecular weight of 27.2kDa, 30.5kDa and 54.9kDa were detected and were predicted 
to be GRA2, P30 and R0P2 protein of T. gondii based on their sizes. These three antigens 
were then expressed in E. coli for testing the cross-reactivity of the anti-serum against His-
tag MEA to these recombinant antigens. 
3.1.1 Expression of P30, GRA2 and ROP2 in R coli expression system 
a. Expression of P30 
P30 is the iirmiimodorniriant surface antigen of Toxoplasma gondii tachyzoites 
(Kasper et al, 1983) and it is also a highly conformational antigen. It can elicit a protective 
immune response against lethal challenge with virulent strain of T. gondii in many model 
animals (Bulow and Boothroyd, 1991; Khan et al, 1991; Khan et al, 1994). As P30 is a 
vaccine candidate against toxoplasmosis and also a diagnostic reagent, production of 
recombinant P30 antigen have been demonstrated in a variety of expression systems. 
Bacterial expression could give a high yield production of P30 at a low cost but usually 
with truncated conformation and the immunogenicity of the recombinant antigen might be 
lost due to the incorrect folding. Since native SAGl adopts a specific tertiary structure 
defined by intramolecular cysteine bridges that give rise to immunologically relevant 
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conformational epitopes (Cesbron-Delauw et al, 1994), production of correctly folded 
recombinant protein in other eukaryotic systems was recommended. Recombinant P30 
protein have been expressed in many systems, including animal cells (Xiong et al., 1993; 
Kim et al, 1994), insert cell lines (Hunter et al” 1999; Chen et aL, 1999)，methylotrophic 
yeast (Letoumeur et al, 2001), primitive protozoans or parasites (Howe et al, 1997; Marti 
et al, 2002) and even in transgenic mice (Moleon et al, 1994; Seng et al” 2000). The 
immunogenicity of E, coli expressed recombinant P30 antigen could be enhanced by 
removing the signal sequence at the N-terminus and the hydrophobic stretch of amino acid 
at the C-teraiinus which caused mis-folded of the mature protein (Chen et al., 2001). In 
this research, a truncated SAGl gene was expressed in E. coli with an N-terminal 
polyhistidine tag as fusion partner, the antigenicity and immunogenicity of this antigen 
was demonstrated by Lo, 1999. 
b. Expression of ROP2 
The R0P2 antigen expressed in 3 stages of T. gondii life cycle (Sadak et al, 1988), 
and it involved in the parasite invasion into the host cell. Three T-cell epitopes (aa 197-216, 
393-410, and 501-524) within the R0P2 had been characterized (Saavedra et al, 1996) 
and it had high antigenic value. However, the expression of recombinant R0P2 protein in 
E. coli is a difficult task due to low levels of expression or degradation and solubility 
problems. 
C-terminal fragment of R0P2 had been successfully expressed in E. coli 
expression system with different fusion partners, for example, R0P2 (aa231-561) fused 
with 48 aa of phage lambda, E. coli proteins and his-tag (van Gelder et al�, 1993), R0P2 
(aa 196-464) fused with thioredoxin or maltose-binding protein (Jacquet et al., 1999) and 
R0P2 (aal96-561) fused with poly-histidine tag (Nigro et al, 2000). In this research, ROP 
(aa 27-230) was fused with thioredoxin which could increase the solubility of the 
recombinant protein and was expressed under the pET expression system in E. coli. 
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c. Expression of GRA2 
Dense granules proteins are the major components of the excreted-secreted 
antigens (ESAs) of T. gondii which can induce protective immunity in many experimental 
animals (Duquesbe et al., 1990; Darcy et al., 1992). Eight distinct dense granule proteins 
have been characterized and analyzed. Among these antigens, GRA2 is probably the most 
immunogenic. GRAl, GRA4 and GRA7 had been expressed in different expression 
systems (Nockemaim et al, 1998; Jacobs et al., 1998; Hiszczynska-Sawicka et aL, 2003). 
GRA2 had been transiently expressed in parasite Neospora caninum (Howe et al., 1997) 
and also expressed in E. coli (Jegerlehner et al, 2002; Meek et al., 2003). In this research, 
full-length of GRA2 was successfully expressed in E. coli with thioredoxin as fusion 
partner. 
3.1.2 Immunizations 
a. Choice of animals 
A wide range of vertebrate species can be used for the production of anti-sera and 
for performing immuno-assays. The five most commonly used laboratory animals are 
rabbits, mice, rats, hamsters and guinea pigs. For collecting anti-sera, rabbits represent a 
good choice as they can be repeatedly bled and the antibodies they produced can be easily 
characterized and purified. However, as most laboratory rabbits are outbred and relatively -
little is known of the genetics of the immune responses in this species, they are not suitable 
for performing immuno-assays. On the other hands, many inbred strains of mice are 
available in most laboratories. As the genetic of the immune response have been 
extensively studied, though genes that affect both the qualities and quantities of the 
immune responses occur in many distinct loci, the genes associated with the MHC are 
often the most important. Using inbred strains of animals allow a more precise and detail 
study of the immune responses of the immunized hosts against a target protein. Besides, in 
nature mice are the intermediate host for T. gondii, this would suggest that the mice 
immune responses are well-adapted, in evolutionary terms, to cope optimally with T. 
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gondii. Furthermore, the life cycle of the parasite in mice closely resembles that in human, 
making mouse to be a good model for studying human toxoplasmosis. So, we used two 
inbred mouse strains, BALB/c and C57, of different haplotypes in this research. Based on 
the study in the mucosal and systemic cellular immune responses in mice orally injected 
with T. gondii cyst antigens, mice carrying H-2^ haplotype (CBA/J) is a high responder 
mouse strain in the induction of mesenteric and splenic T-lymphocyte blastogenesis while 
mice of haplotypes ofH-2'^ (BALB/c) and H-2^ (C57BL/6J) are the intermediate responder 
and low responder respectively (Chardes et al” 1993). Animals from various species reach 
immune maturation at different times post birth. Mice are common considered to be 
mature at 6 weeks post birth, and thus, mice of 6-8 weeks post birth were used for these 
experiments. 
b. Adjuvants 
Non-specific stimulators of the immune response are known as adjuvants. Its use is 
to induce a strong antibody response to the antigen. The action of adjuvants is not fully 
understood, but most adjuvants incorporate two components. The first one is that it should 
be a substance designed to form a deposit protecting the antigen from rapid catabolism. 
The second components needed for an effective adjuvant is a substance that will stimulate 
the immune system non-specially. They act by raising the level of a large set of soluble 
peptide growth factors known as lymphokines which stimulate the activity of antigen-
processg cells directly and cause a local inflammatory response at the site of injection. — 
The adjuvant used for this research work is Freund's adjuvant which us a water-in-
oil emulsion prepared with non-metabolizable oils. It was designed to provide continuous 
ewlwase of antigens necessary for stimulating a strong and persistent immune response 
(Freund and McDermot, 1942). Complete Freund's adjuvant which contains killed 
Mycobacterium tuberculosis was used for first immunization while incomplete Freund's 
adjuvant, without containing the bacteria, was used for booster immunization. The 
mycobacteria in Complete Freund's Adjuvant attracts macrophages and other cells in the 
injection site which enhances the immune responses. For this reason, Complete Freund's 
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Adjuvant was used for initial injections. To minimize size effects, Incomplete Freund's 
Adjuvant was used for the boosts. 
3.1.3 Measurement of cellular immune responses in vaccinated mice 
Cell-mediated immunity is mediated by the direct action of T-cells which make it 
distinguishable from the B-cell immunity which is mediated by the action of antibodies. 
There are two distinct subpopulations of T cells, cytotoxicity T-cell (Tc) and helper T-cell 
(Th), which play two major different roles. Cytotoxic T cells direct killing of infected cells 
while helper T cells are required for activation and differentiation for other immune cells, 
such as B cells. Based on the cytokine expression profile, helper T cells are classified into 
two main subtypes- Thl and Th2. Thl cells, also called inflammatory T cells, produced 
high level of IFN-y, TNF-a and IL-2 and are predominately involved in mediating 
inflammatory immune responses through the activation of macrophages. Th2 cells are 
characterized by the production of IL-4, IL-5 and IL-6 and mainly contribute to the B cell 
differentiation and maturation, thus are important for induction of humoral immunity. 
After immunizations, spleenocytes, containing effector T-cells, was isolated from 
the spleen of the vaccinated mice. Immuno-reactivity of lymophycytes could be measured 
by their ability in the short-term primary tissue culture to undergo re-stimulation and 
clonal proliferation in response to appropriate antigens, for example, total T. gondii lysate. 
Cell proliferation couid then be quantified based on the measurement of 5-bromo-2，-
deoxyuridine (BrdU) incorporation during DNA synthesis in proliferation cells which can 
be detected by immunoassay (Porstmann et al., 1985; Magaud et al, 1988; Huong et al” 
1991; Muir et al, 1990; Heil and Reifferscheid 1992). The cytokine expression profile of 
the stimulated effector T-cells would also be assayed by RT-PCR using specific primers. It 
is generally accepted that Thl-polarized T-cell immunity is the major effector against 
toxoplasmosis. The major arms of immunity elicited in vaccinated mice can be determined 
based on the cytokine subtypes detected. 
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3.2 MATERIALS 
3.2.1 Mouse strain 
1. C57BL/6J (Supplied by Laboratory Animal Service Center, CUHK) 
3.2.2 Chemicals 
1. Ammonium chloride Ajax 32 
2. Bovine serum albumin Sigma B2518 
3‘ Cesium Chloride Sigma C4036 
4. Chloroform Ajax 152 
5. DEPC (Diethyl pyrocarbonate) Sigma D5758 
6. Guanidinium Thiocyanate (GT) Sigma G9277 
7. Potassium bicarbonate E-Merck 
8. Sodium bicarbonate Sigma S8875 
3.2.3 Culture Medium, buffer and other solutions 
1. RPMI Medium 1640 powder Gibco BRL 23400-021 
2. Dulbecco，s phosphate-buffered saline powder Gibco BRL 21600-010 
3. Fetal Bovine Serum (FBS) Gibco BRL 16000-044 
4. PSN antibiotic mixture Gibco BRL 15640-055 
5. L-glutamine Gibco BRL 25030-081 
3.2.4 Nucleic acids 
1. pET32a (+) vector Novagen 
2. pET32a+MIH From Prof. Sun's lab 
87 
3.2.5 Kits and Reagents 
1. Cell Proliferation ELISA, BrdU (colorimetric) Roche 1 647 229 
2. RNeasy Mini Kit Qiagen 74106 
3.2.6 Solutions 
1. 5.7M Cesium chloride Dissolve 96.0g CsCl in 100ml O.IM EDTA (pH 8.0). Treat 
with DEPC and then autoclaved. 
2. DEPC-treated Milli-Q DEPC was added to Milli-Q with final concentration of 0.1 % 
and was then shaked vigorously. After treating overnight, the 
solution was autoclaved to degrade the remaining DEPC in 
solution. 
3. 0.5M EDTA, pH8.0 Dissolve 18.61g EDTA in 100ml Milli-Q. Adjust pH to 8.0 
with NaOH. Treated wit DEPC and then autoclaved. 
4. Erythrocyte lysis 155 mM NH 4 CI, 10 mM KHCO 3 ,0 .1 mM EDTA, adjust 
buffer with IN NaOH to pH - 7.3, then autoclave. 
5. PBS 9.6g Dulbecco's phosphate-buffered saline powder in 1 litre 
of Milli-Q and autoclaved. 
6. RPMI 1640 / IL Dissolve 16.2g RPMI Medium 1640 powder and 2g NaHCOs 
in Milli-Q, adjust pH to 7.0 with IN HCl and NaOH. Sterilize 
by filtration through a pre-rinsed 0.22 i^m membrane. 
7. 3M sodium acetate Dissolve 123.04g NaOAc in Mill-Q to a final volume of 
pH 5.2 (for RNA) 500ml. Adjust pH to 5.2 using glacial acetic acid. Treated 
with DEPC and then autoclaved. 
3.2.7 Enzymes and reagents 
1. EcoRV Promega R635A 
2. M-MLV Reverse Transcriptase Gibco BRL 28025-013 
3. RNaseOUT (Recombinant Ribonuclease inhibitor) Gibco BRL 10777-019 
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3.2.8 Primers 
Name of primer Sequence (5，to 3，) — X m / T 
MF74 TTG ACA AGC AAT GAG ACG ATG AG ^ 
MF 75 CAG TTT GAG GCC AGC CTG CG ^ 
MF83 AGG AAC TGG CAA AAG GAT GGT G ^ 
MF 84 GTG CTG GCA GAA TTA TTC TTA TTG ； ^ 
MF 142 一 ACA GTA TCA GCA ACG TCA AGC AA ^ 
MF 143 CCG ATC TTG TTC TTT GGT GGC A ^ 
MF 144 GAG CTT CAG GCA GGC AGT ATC ^ 
MF 145 GTA TAG ATT CTT TCC TTT GAG GC ^ 
MF 146 TGA CGC ACA GAG CTA TTG ATG G ^ 
MF 147 ATG ATG CTC TTT AGG CTT TCC AG ^ 
MF 154 TGG TCT ACA GCC TCT CAG CAC ^ 
MF 155 AAG GGG ATA TCA GTC AGA CCG GT ^ 
MF 208 TGC CAG GTG TCT TAG CCA GTC ^ 
MF209 ATT TTC ACT CTG TAA GGG TCT GC ^ 
MF211 CAG CTT CTT CAT CAG GGA CAT C ^ 
MF212 TTT CCT TTC CAA CGT TGC ATC CT ^ 
MF214 ACC ACA GTC CAT GCC ATC AC ^ 
MF215 TCC ACC ACC CTG TTG CTG TA ^ 
'MF 229 TGA GAA AAG AGT TGT GCA ATG GC ^ 
MF 230 GAA TGT CCA CAA ACT GAT ATG CTT ^ 
MF 248 AGC GAC TGT TGA TCC ACC TAC ^ 
MF249 GCA GGA GGT ACA TAG TTA TTG AG ^ 
MF520 ATT TAA CCC TCA CTA AAG GG 56 
MF521 TAA TAC GAC TCA CTA TAG GGC GA 56 
MF736 AGC CGG GAA GAC AAT AAC TGC A ^ 
MF 737 AAT TCA TTC ATG GCC TTG TAG ACA ^ 
MF1034 CAC GTA CAG CAA GGC GCT GG ^ 
MF1035 TTA GGA CAC TAG ATG GTT GGC GTT C ^ 
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MF1036 ATG TTC GCC GTA AAA CAT TGT TTG CTG GTT 70 
MF1037 GCC GAG TTT TCC GGA GTT AA ^ 
MF1038 TTA CTG CGA AAA GTC TGG GAC GG ^ 
*Tm was calculated as (A+T) x2 + (C+G) x 4 
3.3 METHODS 
3.3.1 Construction of pET-P30, pET-GRA2 and pET-ROP2 
As the 4 linear T-cell epitopes in the multi-epitopic antigen (MEA) were selected 
from three T-cell target proteins of T. gondii. Each of these antigens were cloned into the E. 
coli expression vector (pET), to test whether the antiserum against MEA can cross-reactive 
with these E. coli expressed his-tag fusion proteins, His-tagP30, his-tag GRA2 and His-tag 
R0P2. pET-P30 was constructed by Lo，Chi-shing and was used for the expression of the 
recombinant protein, his-tag P30, in this experiment. 
For construction of pET-GRA2, T. gondii tachyzoite RNA was used as the 
starting material Full-length of GRA2 gene was cloned by RT-PCR using gene specific 
primers and then subcloned into a strong bacterial expression vector pET to form pET-
GRA2 for high level expression of the recombinant his-tag GRA2. The procedures were 
outlined in Figure 3.1. 
For construction of pET-R0P2, the plasmid pTYB4-ROP2 (constructed by 
maxin) was used as the starting material in this experiment. Part of the R0P2 gene was 
amplified from the plasmid and then sub-cloned into a strong bacterial expression vector 
pET to form pET-R0P2 for high level expression of recombinant his-tag R0P2. The 
procedures were outlined in Figure 3.2. 
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Figure 3.1 Construction of pET-GRA2 
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a) Construction of pET-GRA2 
i) Preparation of total RNA from tachyzoite of T. gondii (RH strain) 
Around 1 x 10^ tachyzoites (RH strain) was used for RNA extraction using 
RNeasy® mini kit. Tachyzoites were washed with PBS, then spun down by 
centrifligation at SOOOrpm for 5 minutes. The pellet was resuspended in 600^1 of Buffer 
RLT with 1% freshly added P-mercaptoehtanoL The solution was mixed by vortexing 
until a clear solution was formed. Sample was then homogenized by passing through a 
20-G needle fitted to a syringe for at least 5 times. 1 volume of 70% ethanol was added 
to the homogenized lysate and was mixed by pipetting. Sample was then applied to an 
RNeasy mini spin column in a 2-ml collection tube, centrifliged for 15 seconds at 
ISOOOrpm and the elutant was discarded. The mini column was washed once with 700|il 
Buffer RWl and then washed twice with 500^1 Buffer RPE. The mini column was then 
transferred to a new 1.5ml eppendorf and 30|li1 DEPC-treated Milli-Q water was added 
to elute RNA from the mini column. The mini column was spun at 13000rpm for 1 
minute to elute RNA. 2\i\ of the eluted RNA was added to 198jal DEPA-treated IM 
Tiis-HCl, pH 7,5，for 100-fold dilution. Then it was taken to estimate the quantities of 
RNA prepared. The ratio OD260/ OD280 of the sample represents its purity whereas the 
yield was estimated according to 1 units OD260 represent 40|ig/ml of RNA. 
ii) Reverse-transcription polymerase chain reaction (RT-PCR) 
First strand cDNA was synthesized from tachyzoite total RNA using oligo d(T)i2-i8 
as primer. For a better pipetting accuracy, the total RNA sample was diluted to 0.l\xg/\i\ 
before reverse transcription. A volume of lOjLil containing l|ug of total RNA in DEPC-
treated Milli-Q water was incubated at 65°C for 5 minutes to denature the RNA and then 
immediately chilled on ice. The reverse transcription was initiated by the addition of a 
reaction mix of lO i^l containing 200U of Moloney murine leukemia virus (M-MLV) 
reverse transcriptase, 0.2mM of each dNTPs, 0.1|Lig oligo d(T)i2-i8, IX M-MLV reverse 
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transcriptase buffer, lOmM dithiothreitol (DTT) and 40 units RNaseOUT. The reaction 
mix with final volume of 20|LI1 was incubated for 1 hour at 3TC. 
For RT-PCR, a total volume of lOjil of the diluted cDNA derived from O.ljug total 
RNA was boiled for 10 minutes and was used as template for each SOjul PCR reaction. 
Full-length of the GRA2 gene was amplified using gene specific primers (MF 1036 and MF 
1038) as described in 2.3.2.b. Band of corresponding size (~558bp) was purified from 
agarose gel (as in 2.3.2.e) and finally resuspended in 25|LI1 Milli-Q water. 
iii) Cloning of pET-GRA2 
pBluescript II SK (-) (prepared as in 2.3.2.a) was restriction digested with Smal 
as described in 2.3.2.C and was ligated with GRA2 fragment (prepared in 3.3.Laii) (as in 
2.3.2.f). This ligation product was transformed into DH5a competent cells (as in 2.3.2.h). 
Recombinant plasmid pBluescript/GRA2 was purified from positive transformants as 
2321 and the sequence of the putative plasmid was confirmed by cycle sequencing (as 
described in2.3.2.j). 
Recombinant plasmid pBluescript/GRA2 and the E. coli expression vector 
pET32a(+) were purified as described in 2.3.2.a. The GRA2 gene was amplified from 
pBluescript/ GRA2 by PCR (as in 2.3.2.b) using gene specific primers (MF 1036/1038), 
then purified from agarose gel as described in 2.3.2.e. pET32a(+) was restriction digested 
with EcoRV and was ligated to the GRA2 DNA fragment. It was transformed into DH5a 
competent cells (as in 2.3.2.h). Recombinant plasmid pET-GRA2 was purified from 
positive transformants as 2321 and the sequence of the putative plasmid was confirmed 
by cycle sequencing (as described in 2.3.2.j). This recombinant plasmid was ready for 
transforming into E. coli expression host-BL21(DE3) for expression of recombinant 
protein, his-tag GRA2. 
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b) Construction of pET-ROP2 
Plasmid pTYB4-ROP2 was used as the starting material for this sub-cloning. 
Part of the R0P2 gene was amplified from the pTYB4-ROP2 by PCR (as in 2.3.2.b) 
using gene specific primers (MF1034 and MF1035). R0P2 gene fragment was resolved 
by agarose gel electrophoresis, purified (as in 2.3.2.e) and then ligated with EcoR V cut 
pET32a(+) (prepared in 3.3.1.aiii), This ligation product was transformed into DH5a 
competent cells by CaCla-heat shock transformation (as in 2.3.2.h). Recombinant 
plasmid pET-R0P2 was purified from positive transformants as 2.3.2.i and the 
sequences of the putative plasmid was confirmed by cycle sequencing (as described in 
2.3.2.j). This recombinant plasmid was ready for transforming into E. coli expression 
host-BL21(DE3) for expression of recombinant protein, his-tag R0P2. 
3.3.2 Expression and characterization of his-tag P30, his-tag GRA2 and his-tag 
ROP2 
The three T. gondii antigens, GRA2, R0P2 and P30, were cloned into the bacterial 
expression vector pET in which they were linked with fusion protein. The fusion partner is 
either a N'-terminal histidine tag (in pET30a(+)) or internal his-tag (in pET32a(+)), as tag 
for detection and purification. The constructs, pET30a(+)-P30, pET32a(+)-GRA2 and 
pET32a(+)-ROP2, were transformed into the expression host, BL21(DE3). Transformed 
cells were grown and induced to express his-tag P30, his-tag GRA2 and his-tag R0P2 by 
IPTG. These his-tag fusion proteins were characterized by western blot with anti-his-tag 
antibody and anti-serum against his-tag MEA. The antigenicity of these proteins was 
demonstrated by western blot with seropositive serum from infected animals or patients 
while the immunogenicity of these proteins was demonstrated by western blot of T. gondii 
lysate with anti-serum against these proteins. 
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a) Expression profile of his-tag P30, his-tag ROP2 and his-tag GRA2 
Recombinant plasmids, pET30a(+)-P30, pET32a(+)-GRA2 and pET32a(+)-
R0P2, were transformed into BL21(DE3) competent cells (as described in 2.3.2.a). 
Cells carrying pET30a(+)-P30 were selected on LB plates with SO i^g/ml kanamycin 
while cells carrying either pET32a(+)-GRA2 or pET32a(+)-ROP2 was selected by 
100|ig/ml ampicillin. Expression of his-tag P30 and his-tag GRA2 were induced by the 
addition of ImM IPTG for 3 hours at 37�C (as in 2.3.2.a). 1ml of uninduced and induced 
bacterial culture were collected and spun. The pellets were resuspended in 200|il IX 
SDS loading buffer and boiled for 8 minutes. lOjLil sample was loaded onto 12.5% SDS-
polyacrylamide gel for electrophoresis and the gel was stained by Coomassie blue (as in 
2.3.2.b). The gels were dried and scanned as record. 
For the expression of his-tag R0P2 protein, the cells were cultured with TB 
Ampioo instead. When the cells were grown to the optical density at 600nm reached 0.4-
0.6, IPTG was added to the culture to final concentration of 0.3mM for induction of his-
tag R0P2 expression. Upon addition of IPTG, it was shaken for 8 hours. 1ml culture 
was collected at time 0 hour, 3 hours, 4 hours and 8 hours after IPTG induction. Samples 
were spun, resuspended into 200jLil IX SDS sample loading buffer and then and boiled 
for 8 minutes. 5|nl sample was loaded onto 12.5% SDS-polyacrylamide gel for 
electrophoresis and the gel was stained by Coomassie blue (as in 2.3.2.b). The gel was 
dried and scanned as record. 
b) Western blot of induced bacterial lysate with mono-clonal anti-his-tag 
antibody 
Samples of both the induced and uninduced bacterial culture resuspended in IX 
SDS sample loading buffer, prepared in 3.3.2.a was loaded in 12.5% SDS-polyacrylamide 
gel for electrophoresis. Proteins were then transferred to PVDF membrane by semi-dry 
electro-blotting (as in 2.2.3.a). 
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After electro-blotting, the membrane was blocked with 5% BLOTTO followed by 
hybridizing with 0.4|Lig/ml monoclonal anti-his-tag antibody for 1 hour at room 
temperature. Unbound antibody was removed by washing with IXTBS and IXTTBS, then 
1:2000 secondary antibody (HRP-conjugated anti-mouse IgG antibody) and substrates 
could be applied for signal detection (as described in 2.2.3.a). 
c) Western blot of induced bacterial lysate with anti-serum against his-tag MEA 
Both the induced and uninduced bacterial culture of BL21(DE3) carrying the E. 
coli expression vector, pET30a+P30, pET32a+ROP2, pET32a+GRA2 and pET32a+MIH 
(from professor Sun's laboratory) which expresses the molt-inhibiting hormone (MIH) as a 
his-tag fusion protein, were resuspended in IX SDS sample loading buffer, prepared in 
3.3.2.a) and they were loaded in 12.5% SDS-polyacrylamide gel for electrophoresis. 
Proteins were then transferred to PVDF membrane by semi-dry electro-blotting (as in 
2.2.3.a). 
After electro-blotting, the membrane was blocked with 5% BLOTTO followed by 
hybridizing for overnight with 1:1000 anti-serum to the his-tag MEA which was pre-
absorbed with 1:10 induced bacterial lysate of BL21(DE3) cells carrying pET32a+MIH for 
16-18 hours at 4°C. Unbound antibodies were removed by washing with IXTBS and 
IXTTBS, then 1:2000 secondary antibody (HRP-conjugated anti-mouse IgG antibody) and 
substrates could be applied for signal detection (as described in 2.2.3.a). 
d) Purification of his-tag P30, his-tag GRA2 and his-tag ROP2 from induced 
bacterial lysate 
Twenty-five milliliter of IPTG-induced bacterial culture, prepared following the 
procedures described on 3.3.2.a, was spun at 4500rpm for 5 minutes. The pellet was 
washed with ice-cold Tris-buffer, followed by resuspension into 5ml IX SDS loading 
buffer. Cell pellet was mixed by strong vortexing and was then boiled for 8 minutes. 150|il 
to 300)il sample was loaded onto each 12.5% SDS-polyacrylamide gel for electrophoresis. 
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Protein bands were visualized by Coomassie Blue staining, after destaining and 
equilibrating in distilled water, band of desirable size was excised from the gel with a 
clean blade. The gel was then grinded into fine powder with mortar and pestle and 
transferred into a 15-ml falcon with the addition of 1:4 diluted Buffer B. This gel mixture 
was gently agitated on a platform shaker at 4°C, overnight for eluting the protein from the 
gel. After centrifugation at maximum speed for 10 minutes, supernatant which contained 
the target protein, was collected and protein content was estimated by protein assay (as in 
23.2.0). 
e) Western blot of his-tag P30, his-tag GRA2 and his-tag ROP2 with sero-
positive serum of mice and human 
One microgram of each of the T. gondii antigens, his-tag P30, his-tag GRA2 and 
his-tag R0P2 were blotted on the PVDF membrane (as described in 3.3.2.b) and then 
probed with different titers of seropositive serum of mouse and human. The secondary 
antibodies of HRP-conjugated and the titers used were shown in table 3.1. 
Table 3.1 Titers of primary sero-positive serum from different species of 
mammals and secondary antibody conjugate with HRP. 
E. coli expressed T. gondii antigens 
His-tag P 3 0 H i s - t a g GRA2 His-tag R0P2 
岳 Sero-positive 1:200 1:200 1:200 
I Mouse serum 1:1000 1:1000 1:1000 
03 — 
Sero-positive 1:200 1:200 1:200 
S  
£ Human serum 1:1000 1:1000 1:1000 
-f Anti-mouse poly- 1:1000 1:1000 1:1000 
I valent Ig Ab-HRP ^  
召 Anti-human poly- 1:1000 1:1000 1:1000 
c 
I valent Ig Ab-HRP 
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f) Western blot of His-tag MEA with pre-absorbed anti-serum against his-tag 
GRA2，his-tag P30 and his-tag ROP2 
Anti-serum against his-tag P30, his-tag GRA2 and his-tag R0P2 were raised from 
mouse as described in 2.3.3.e. Ijug of each purified protein (prepared in 3.3.2,d) and Ijig of 
His-tag MEA (prepared in 2.3.2.d) was loaded into 12.5% SDS-polyacrylamide gel. After 
electrophoresis and blotting, they were incubated with different titers of serum raised 
against the recombinant his-tag fusion proteins in 5% BLOTTO. Purified his-tag P30, his-
tag GRA2 and his-tag R0P2 were primed with 1:5000 titer of anti-serum while the 
purified his-tag MEA was primed with 1:200 titer of anti-serum. After 1-hour incubation, 
the membranes were washed and hybridized with 1:2000 titer of secondary antibody 
conjugated with HRP (goat anti-mouse IgG antibody). Signals were detected with ECL 
detection system as described in 2.3.3.a. 
3.3.3 Measurement of cellular immune responses in his-tag MEA vaccinated mice a 
a) Isolation of spleenocytes from control and vaccinated mice 
Vaccinated BALB/c mice, immunized with SOjug his-tag MEA or 50jug his-tag P30 
for 3 times, (as described in 2.2.3.e) and the age-matched control group (3 mice/ groups) 
were killed four days after the last immunization while mice immunized with T, gondii 
antigens were killed 18 days after the last immunization. Spleens from immunized and 
control mice were aseptically collected, pooled and gently homogenized to obtain single-
cell suspension. The red cells were lysed by hypotonic shock by incubating in ammonium 
chloride/ potassium carbonate lysing buffer (Erythrocyte lysis buffer) for 10 minutes. Cell 
debris was removed by passing through a cell strainer. The cells were then washed twice 
with RPMI 1640 and resuspended in RPMI supplement with 10% FCS, 1% PSN, 2mM 
glutamine and 0.05mM 2-mercaptoethanoL The viability of the cells used in the 
experiments was determined by Trypan blue exclusion. 
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b) T-cell proliferation assay 
Spleenocytes were stimulated with filter-sterilized T. gondii antigens (prepared in 
2.3.3.d) used at a final concentration of 25jLig/ml while for negative control, cells were 
leave un-stimulated. Cells was cultured for 5 days at 37°C in the humidified CO2 incubator 
in a flat-bottomed microplate at 1 x ICf cells per well. After 5-day incubation, lO^l/well 
BrdU labeling solution was added and re-incubated for 18 hours. Signal was detected 
according to the instruction manual for Cell Proliferation ELISA, BrdU (colorimetric) 
(Roche). In brief, after centrifuging the plate at 700g for 10 minutes, medium was removed 
by suction and the plate was allowed to dry in 65�C for 10 minutes. 200|il/well FixDenat 
was then added to the cells. After incubating at -20�C for 30 minutes, FixDenat was 
removed and 100|il/well anti-BrdU-POD working solution was added. After incubating at . 
15-25°C for another 90 minutes, antibody conjugate was removed and the wells was 
washed three times with washing solution. Finally, lOOjul substrate solution was added per 
well and was further incubated at 15-20°C for 5-30 minutes until color development was 
sufficient for photometric detection at 370nm (with reference wavelength of approximate 
492nm). 
c) Determination of Thl/ Th2 cytokines expression profile by RT-PCR 
Spleenocytes were resuspended in RPMI supplement with 10% FCS，1% PSN, 2mM 
glutamine O.OSmM and 2-mercaptoethanol and were stimulated with filter-sterilized T. 
gondii antigens (prepared in 233.6) at a final concentration of 25jLig/ml. As the negative 
control, the spleenocytes were leave un-stimulated. Cells were cultured for 10 hours at 
37°C in the humidified CO2 incubator in a flat-bottomed 6-well plate at 5 x lO^cells/ml. 
After incubation, cells were collected by centrifugation and RNA was extracted by CsCl-
gradient. 
In brief, cells were washed twice with RPMI medium, the cell pellet was 
resuspended in 200)il PBS and was added to 4ml 4M GT solution drop wise with 
vigorously vortexing. After homogenizing with 20G syringe, sample was loaded on top of 
100 
Im CsCl solution in a centrifuge tube. It was centrifuged at 32000rpm at 18°C for 18 hours 
(rotor and machine). Supernatant was then removed by aspiration and the RNA pellet (on 
the bottom of the tube) was allowed to dry at room temperature with the tube placed invert. 
After resuspending the RNA pellet with DEPC-treated Milli-Q, it was subjected to ethanol 
precipitation and was finally resuspended in 50^1 DEPC-treated Milli-Q. The quantity of 
each of the RNA samples was measured by spectrophotometer. 
RNA was then converted to cDNA by reverse transcription (RT) (as described in 
3.3.1.aii). Afterwards, they were normalized by the amplification of the house-keeping 
gene, GAPDH, with primers MF214/ 215 using RT-PCR. Expression of Thl or TH2 
cytokines in un-stimulated and T. go^Jzz-stimulated spleenocytes was then determined by 
RT-PCR with 40 or 50 cycles using different gene-specific primers listed in the following 
table (Table 3.2). 
Table 3.2 Summary for primers used in RT-PCR for determination of Thl/ Th2 
cytokines expression profile 
Gene Primers Annealing Temp/ Expected size / bp 
GADPH MF 214/215 56 
Mouse IL-2 MF 248/249 ^ m 
Mouse IFN-y MF 83/84 ^ ^ 
Mouse IL-4 MF 146/147 ^ 412 
Mouse IL-10 MF 736/737 ^ ‘ 
Mouse IL-5 MF 74/75 ^ Wl 
Mouse TNF-a MF 79/80 ^ ？H 
Mouse GM-CSF MF 154/155 ^ 
Mouse IL-1 a MF 142/143 ^ ^ 
Mouse IL-lp MF 144/145 ^ ^ 
Mouse IL-6 MF 229/230 ^ 
Mouse IL-12p35 MF 208/209 ^ 477 
Mouse IL-12p40 MF 211/212 ^ ^ 
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3.3.4 Protection efficacy of different vaccine constructs against lethal challenge 
In order to test the protective efficacy of the MEA as a vaccine construct, four 
strains of mice, BALB/c, C57and MRL mice, were immunized with 50[ig his-tag MEA or 
50[ig his-tag P30 or 50|Lig total T. gondii lysate for 3 times (as described in 2.2.3.e). 
Vaccinated mice and the age-matched negative control group (10 mice per each group) 
were challenged intraperitoneal (i.p.) with 1 x 10^  T. gondii tachyzoites (RH strain) three 
days after the last immunization and the time until death was recorded. The Kaplan-Meier 
method was used to compare the survival times of the studied groups. 
3.4 RESULTS 
3.4.1 Construction of pET-GRA2 and pET-ROP2 
For construction of pET-GRA2, total T. gondii tachyzoite RNA and pBluescript 
II SK (-) were used as the starting material in this experiment. The tachyzoite RNA was 
converted to complementary DNA (cDNA) by reverse transcription by MMLV-RT. The 
GRA2 gene was amplified from the cDNA by RT-PCR using gene specific primers and 
the house-keeping gene, GAPDH, was also amplified with specific primer as positive 
control for this RT-PCR and the GRA2 gene fragment then purified by the Qiagen II gel 
extraction kit. The pBluescript II SK (-) was digested by Smal cut and desalted by ethanol 
precipitation and this Smal cut vector was then ligated with the GRA2 gene to generate 
pBluescript II SK (-)/GRA2. Putative clones were identified by PCR screening. 
Afterwards, pET-GRA2 was constructed using E. coli expression vector - pET32a+ 
and pBluescript II SK (-)/GRA2 as the starting material. The GRA2 gene was amplified 
from the recombinant plasmid, pBluescript II SK (-)/GRA2 by PCR using gene specific 
primers and then purified by the Qiagen II gel extraction kit. The plasmid pET32a+ was 
digested by EcoRV and desalted by ethanol precipitation and this EcoRV cut vector was 
then ligated with the GRA2 fragment to generate pET-GRA2. 
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For construction of pET-R0P2, the plasmid pTYB4-ROP2 and the E. coli 
expression vector - pET32a+ were used as the starting material in this experiment. The 
R0P2 gene was amplified from the plasmid, pTYB4-ROP2, by PCR using gene specific 
primers and then purified by the Qiagen II gel extraction kit. The plasmid pET32a+ was 
digested by EcoRV and desalted by ethanol precipitation and this EcoRV cut vector was 
then ligated with the R0P2 fragment to generate pET-R0P2. 
The R0P2 gene fragment or the flill-length of GRA2 gene were ligated with the 
EcoRV cut pET vector and were in-frame fused with the N-terminal Trx-tag and internal 
his-tag followed with an enterokinase cleavage site. Transformed bacterial cells were able 
to form colonies on LB agar plates under ampicillin selection. As the plasmid in the 
transformed cells was either the self-ligated vector or vector with insert, PCR screening 
was performed using gene specific primer). After PCR screening, recombinant plasmid 
DNA were prepared and the nucleotide sequence and the orientation of the insert of 
pET32a+-ROP2 or pET32a+-GRA2 was read and confirmed by cycle sequencing with T7 
promoter and T7 terminator sequencing primers. The nucleotide sequences were edited by 
DNasis's Contig Manger program and shown in Figure 3.3 and 3.4. 
For pET30a+P30 (in which the P30 gene was in-frame fused with the N-terminal 
polyhistidine tag with an enterokinase cleavage site in-between), it was already 
constructed by Mr. Jack, C. S. Lo, recombinant plasmids were prepared with Wiazard ™ '' 
SV purification kit and it was ready for transforming into the E. coli expression host for 
expression of the recombinant proteins 
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1 A T G A G C G A T A A A A T T A T T C A C CTG A C T G A C G A C A G T T T T 39 
m s d k i i h l t d d s f 
4 0 G A C A C G G A T G T A C T C A A A GCG G A C GGG GCG A T C C T C G T C 7 9 
d t d v l k a d g a i l v 
8 0 G A T T T C T G G G C A GAG T G G T G C G G T CCG T G C A A A A T G A T C 1 1 9 
D F W A E W C G P C K M I 
1 2 0 G C C CCG A T T CTG G A T G A A A T C G C T G A C G A A T A T CAG G G C 1 5 9 
A P I L D E I A D E Y Q G 
1 6 0 A A A C T G A C C G T T G C A A A A C T G A A C A T C G A T CAA A A C C C T 1 9 9 
K L T V A K L N I D Q N P 
2 0 0 G G C A C T G C G CCG A A A T A T G G C A T C C G T G G T A T C CCG A C T 2 3 9 
G T A P K Y G I R G I P T 
2 4 0 CTG C T G CTG T T C A A A A A C G G T G A A G T G GCG G C A A C C A A A 2 7 9 
L L L F K N G E V A A T K 
2 8 0 G T G G G T G C A CTG T C T AAA. G G T CAG T T G A A A GAG T T C C T C 3 1 9 
V G A L S K G Q L K E F L 
3 2 0 G A C G C T A A C CTG G C C G G T T C T G G T T C T GGC C A T A T G C A C 3 5 9 
D A N L A G S G S G H M H 
Hi a-Tag 
3 6 0 C A T C A T C A T C A T C A T T C T T C T G G T C T G G T G C C A C G C G G T 3 9 9 
H H H H H S S G L V P R G 
4 0 0 T C T G G T A T G AAA GAA A C C G C T G C T G C T AAA T T C G A A CGC 4 3 9 
S G M K E T A A A K F E R 
4 4 0 CAG C A C A T G G A C A G C C C A G A T CTG G G T A C C GAC G A C G A C 4 7 9 
Q H M D S P D L G T D D D 
4 8 0 G A C A A G G C C A T G G C T G A T A T G T T C G C C G T A A A A C A T T G T 5 1 9 
D K A M A D M F A V K H C 
5 2 0 T T G C T G G T T G T T GCC G T T G G C G C C CTG G T C A A C G T C T C G 5 5 9 
L L V V A V G A L V N V S 
5 6 0 G T G A G G G C T G C C GAG T T T T C C G G A G T T G T T A A C CAG G G A 5 9 9 
V R A A E F S G V V N Q G 
6 0 0 C C A G T C G A C G T G CCT T T C A G C G G T A A A C C T C T T G A T G A G 6 3 9 
P V D V P F S G K P L D E 
64 0 A G A G C A G T T GGA GGA A A A G G T GAA CAT A C A C C A C C A C T C 6 7 9 
R A V G G K G E H T P P L 
6 8 0 CCA G A C GAG A G G CAA CAA GAG CCA G A A G A A CCG G T T T C C 7 1 9 
P D E R Q Q E P E E P V S 
7 2 0 CAA C G T G C A T C C A G A G T G G C A G A A CAA CTG T T T C G C A A G 7 5 9 
Q R A S R V A E Q L F R K 
7 6 0 T T C T T G A A G T T C G C T G A A A A C GTC GGA C A T CAC A G T G A G 7 9 9 
F L K F A E N V G H H S E 
8 0 0 A A G GCC T T C A A A A A A G C A A A G G T G G T G G C A G A A AAA G G C 8 3 9 
K A F K K A K V V A E K G 
8 4 0 T T C A C C GCG G C A A A A A C G C A C A C G G T T A G G G G T T T C A A G 8 7 9 
F T A A K T H T V R G F K 
8 8 0 GTG GCC AAA GAA GCA GCT GGA AGG GGC ATG GTG A C C G T T 9 1 9 
V A K E A A G R G M V T V 
9 2 0 GGC AAG AAA CTC GCG A A T GTG GAG A G T GAC A G A AGC A C T 9 5 9 
G K K L A N V E S D R S T 
9 6 0 ACG A C A ACG CAG GCC CCC GAC AGC CCT A A T GGC CTG GCA 9 9 9 
T T T Q A P D S P N G L A 
1 0 0 0 GAA A C C GAG G T T CCA GTG GAG CCC CAA CAG CGG GCC GCA 1 0 3 9 
E T E V P V E P Q Q R A A 
1 0 4 0 CAC GTG CCC GTC CCA GAC T T T TCG CAG TAA 
H V P V P D F S Q S t o p 
Figure 3.3. Nucleotide sequence of pET32a+-GRA2. The sequence read by T7 terminator primer, T7 
promoter primer and gene specific upper an primer were edited and manipulated by Contig Manger Program 
of DNasis. The shaded letters represented the 6X histidine tagged (his-tag) in the pET vector. The complete 
coding sequence of his-tag GRA2 was flanked by start (ATG) and stop codon (TAA). 
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1 ATG AGC GAT AAA ATT ATT CAC CTG ACT GAC GAC AGT T T T 39 
M S D K I I H L T D D S F 
4 0 GAC ACG GAT GTA CTC AAA GCG GAC GGG GCG ATC CTC GTC 79 
D T D V L K A D G A I L V 
80 GAT TTC TGG GCA GAG TGG TGC GGT CCG TGC AAA ATG ATC 1 1 9 
D F W A E W C G P C K M I 
120 GCC CCG ATT CTG GAT GAA ATC GCT GAC GAA TAT CAG GGC 1 5 9 
A P I L D E I A D E Y Q G 
16 0 AAA CTG ACC GTT GCA AAA CTG AAC ATC GAT CAA AAC CCT 1 9 9 
K L T V A K I J N I D Q N P 
2 00 GGC ACT GCG CCG AAA TAT GGC ATC CGT GGT ATC CCG ACT 2 3 9 
G T A P K Y G I R G I P T 
24 0 CTG CTG CTG TTC AAA AAC GGT GAA GTG GCG GCA ACC AAA 2 7 9 
L L L F K N G E V A A T K 
2 8 0 GTG GGT GCA CTG TCT AAA GGT CAG TTG AAA GAG TTC CTC 3 1 9 
V G A L S K G Q L K E ' F L ‘ 
3 2 0 GAC GCT AAC CTG GCC GGT TCT GGT TCT GGC CAT ATG CAC 3 5 9 
D A N L A G S G S G H M H 
H i s - T a g 
3 6 0 CAT CAT CAT CAT CAT TCT TCT GGT CTG GTG CCA CGC GGT 3 9 9 
H H H H H S S G L V P R G 
4 0 0 TCT GGT ATG AAA GAA ACG GCT GCT GCT AAA TTC GAA CGC 4 3 9 
S G M K E T A A A K F E R 
44 0 CAG CAC ATG GAC AGC CCA GAT CTG GGT ACC GAC GAC GAC 4 7 9 
Q H M D S P D L G T D D D 
4 8 0 GAC AAG GCC ATG GCT GAT CAC GTA CAG CAA GGC GCT GGC 5 1 9 
D K A M A D H V Q Q G A G 
52 0 GTT GTG CGG CCT CGC CAC TGG CAG AAC TCG GAA GCC GCT 5 5 9 
V V R P R H W Q N S E A A 
5 6 0 GTT AGT GTC CGG CCG CCG GGA GGC GCG TCC CCT AGA CAT 5 9 9 
V S V R P P G G A S P R H 
6 0 0 TTC CAC AGC CCA ATT GAG CCA GTA GCA TTT ATT GAT GGG 6 3 9 
F H S P I E P V A F I D G 
640 GAG CAC GTT GAA GAC AAG CAT GGA GGC TCA TGG CTG GAG 6 79 
E H V E D K H G G S W L E 
680 CAG GAA GGG GCC GAG GAA GTG ACC CCC TTA CTG AAC AGC 7 1 9 
Q E A A E E V T P L L N S 
7 2 0 CAC ACA GAG ACC CCG AGA CAG TCC CCC AGT GCT TTT AGA 7 5 9 
H T E T P T Q S P S A F R 
760 AGG TTA CTC AGG CGT TTG CGT TTT TGG CGA CGT GGG AGG 7 9 9 
R L L R R L R F W R R G R 
800 ACA GGC GGA TCA GAT GGC GGA GGA GAA CCA CCG CAG ACG 8 3 9 
T G G S D G G G E P P Q T 
840 CCT CGC CCT TCC CTA CCG ACC CGA CTG TTT CAG CAT TTG 8 7 9 
P R P S L P T R L F Q H L 
880 CGG CGT GCG GCA GCA GCA A T T CCC GCG GCG GCA TCT AGA 9 1 9 
R R A A A A I P A A A S R | 
9 2 0 TTC TTT AGG AGA TTT CGA CGA GTC CAA GAA CCT GTA TTC 9 5 9 FL 
F F R R F R R V Q E P V F 
9 6 0 CCT CCC GAC GAG T T T CCG GAG GAT GTC GAC ACG AAC CCT 9 9 9 
P P D E F P E D V D T N P 
1 0 0 0 ATG TAT TTC CGC GGT ACG GAT CCT GGA GAC GTC GTC A T T 1 3 9 9 
M Y F R G T D P G D V V I 
1 4 0 0 GAG GAG CTG TTC A A T CGT ATA CCG GAA ACA AGC GTA TGG 1 7 9 9 
E E L F N R I P E T S V W 
1 3 0 0 AAT GAG AAC GAA CGC GTC CTG TCG AAC GCC AAC CAT CTA 2 1 9 9 
N E N E R V L S N A N H L 
2 2 0 0 GTG TCC TAA 
V S S t o p 
Figure 3.4. Nucleotide sequence of pET32a+-ROP2. The sequence read by T7 terminator primer, T7 
promoter primer and gene specific upper an primer were edited and manipulated by Contig Manger Program 
of DNasis. The shaded letters represented the 109aa Trx*Tag™ thioredoxin protein，the 6X histidine tagged 
(his-tag) and enterokinase cleavage site in the pET vector. The complete coding sequence of his-tag R0P2 
was flanked by start (ATG) and stop codon (TAA). 
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3.4.1 Expression and characterization of his-tag P30, his-tag GRA2 and his-tag 
ROP2 
The pET30a+-P30, pET32a+GRA2 and pET32a+ROP2 were transformed into 
bacterial expression host BL21(DE3). Transformed cell was induced with IPTG for the 
expression of his-tag P30, his-tag GRA2 and his-tag R0P2. Expression profile of these 
three recombinant proteins were determined and shown in Figure 3.5, 3.6 and 3.7. His-tag 
P30 was around 35kDa, his-tag GRA2 was around 45kDa and his-tag R0P2 was around 
52kDa. The amount of histidine-tag fusion proteins in the induced bacterial lysate was 
roughly estimated by SDS-PAGE with different amount of standard BSA proteins loaded 
onto the gel as reference. The recombinant T. gondii antigens were then purified by from 
polyacrlyamide gel and were shown in Figure 3.8. The concentration of the purified 
recombinant proteins was estimated by Branford protein assay with BSA protein as 
standard. Referring to the standard curve, the concentration of these recombinant proteins 
was calculated (Table 3.3 and Figure 3.11). 
These his-tag fusion proteins were detected by monoclonal anti-his-tag antibody 
(Figure 3.9) and by pre-absorbed anti-semm against his-tag MEA protein (Figure 3.10). 
The antigenicity of these recombinant T. gondii antigens was proved as they could be 
recognized by sero-positive serum from mammals infected with Toxoplasma gondii 
\ 
(Figure 3.12 and 3.13). The three recombinant T. gondii antigens were highly ^ 
immunogenic in animals. Anti-semm collected from immunized hosts could recognize the 
corresponding E. coli expressed Toxoplasma antigens and the presence of thioredoxin and/ 
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Figure 3.5. Expression profile of his-tag P30 by IPTG induction. 20ml bacterial 
culture of BL21(DE3) carrying the recombinant plasmid pET30a+-P30 at ODeoo = 0.6-0.8 
was added with IPTG to a final concentration of ImM. It was then shaken at 350rpm at 
37°C for 3 hours. For every 30 minutes, SOOjil of the bacterial culture was pipetted out and , 
j 
spun. Supernatant was discarded, the pellet was resuspended with 0.5ml IX SDS sample 丨 
loading buffer and store at 4°C. when all time points were colleted, they were boiled for 8 
minutes. 20\i\ of each sample was loaded on 12.5% polyacrylamide gel for electrophoresis 
at constant voltage: 150V. lane 2 (U) was the uninduced control. Lane 3 to 8 were induced 
bacterial culture harvested at different time points after IPTG induction (lane 3 to 8 = 0.5， 
1.0，1.5，2.0, 2.5 and 3.0 hours). The gel was stained by Commassie blue, destained and 
drided. Gel image was captured by scanning the dried gel. M=SDS broad range protein 
marker (Bio-rad) and the size of the protein marker was inducated as kDa and shown on 
the left. The putatuve his-tag P30 (�35kDa) was indicated by an arrow. 
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Figure 3.6. Expression profile of his-tag GRA2 by IPTG induction. 20ml bacterial 
culture of BL21(DE3) carrying the recombinant plasmid pET32a+-GRA2 at ODeoo 二 0.6-
0.8 was added with IPTG to a final concentration of ImM. It was then shaken at 350rpm at 
3TC for 3 hours. For every 30 minutes, 500|jJ of the bacterial culture was pipetted out and 
spun. Supernatant was discarded, the pellet was resuspended with lOOjLil IX SDS sample 
loading buffer and store at 4°C. when all time points were colleted, they were boiled for 8 
m i n u t e s . 1 5 j j l o f e a c h s a m p l e w a s l o a d e d o n 1 2 . 5 % p o l y a c r y l a m i d e g e l f o r e l e c t r o p h o r e s i s 
at constant voltage: 150V. lane 2 (U) was the uninduced control. Lane 3 to 8 were induced 
bacterial culture harvested at different time points after IPTG induction (lane 3 to 8 = 0.5, 
1.0，1.5, 2.0, 2.5 and 3.0 hours). The gel was stained by Commassie blue, destained and 
drided. Gel image was captured by scanning the dried gel. M=SDS broad range protein 
marker (Bio-rad) and the size of the protein marker was inducated as kDa and shown on 
the left. The putatuve his-tag GRA2 (�45kDa) was indicated by an arrow. 
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Figure 3.7. Expression profile of his-tag ROP2 by IPTG induction. 20ml bacterial 
culture of BL21(DE3) carrying the recombinant plasmid pET32a+-ROP2 at ODeoo = 0.4-
0.6 was added with IPTG to a final concentration of 0.3mM. It was then shaken at 350rpm 
at 37°C for 8 hours. At time 0 hour, 3 hour, 4 hour and 8 hour after induction, 1ml of the | 
1 
bacterial culture was pipetted out and spun. Supernatant was discarded, the pellet was 丨 
resuspended with 200|il IX SDS sample loading buffer and store at When all time 
points were colleted, they were boiled for 8 minutes. 5|LI1 of each sample was loaded on 
12.5% polyacrylamide gel for electrophoresis at constant voltage: 150V. Lane 1 was the 
uninduced control. Lane 2 to 4 were induced bacterial culture harvested at different time 
points after IPTG induction (3, 4 and 8 hours). The gel was stained by Commassie blue, 
destained and drided. Gel image was captured by scanning the dried gel. M=SDS broad 
range protein marker (Bio-rad) and the size of the protein marker was inducated as kDa 
and shown on the left. The putatuve his-tag R0P2 (�52kDa) was indicated by an arrow. 
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Figure 3.8. Purification of his-tag P30, his-tag GRA2 and his-tag ROP2. Production of 
his-tag GRA2 (A), his-tag R0P2 (B) and his-tag P30 (C)was induced in transformed 
bacterial cells as described in 3.3.2.a. Recombinant antigens were purified from induced 
bacterial lysate as described in 3.3.l.d. and was then quantified by Braford protein assay. ? 
i I 
Lane 1, 4 and 7 represented the uninduced bacterial lysate while lane 2, 5 and 8 
represented the induced bacterial lysate for bacterial lysate expressing his-tag GRA2, his-
tag R0P2 and his-tag R0P2 respectively. l|ig of purified recombinant antigens was loaded 
on gel. Lane 3 was purified his-tag GRA2, lane 6 was purified his-tag R0P2 and lane 9 
was purified his-tag P30. The gel was stained by Commassie blue, destained and drided. 
Gel image was captured by scanning the dried gel. M=SDS broad range protein marker 
(Bio-rad) and the size of the protein marker was inducated as kDa and shown on the left. 
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Figure 3.9. Western blot of induced bacterial lysate with monoclonal anti-his-tag 
antibody. His-tag P30, his-tag GRA2 and his-tag R0P2 were induced to express as 
described in 3.3.2.a. SOOjal of both uninduced (U) and induced (I) bacterial cultures were 
collected and the bacterial pellets were resuspended in lOOjul of IxSDS sample loading 
buffer. (A) For western blot of his-tag P30, 15)1x1 of the boiled samples were loaded on 12.5 
% SDS-polyacrylamide gel for electrophoresis. (B) For western blot of his-tag GRA2， 
15jjl of the boiled samples were loaded on 12.5 % SDS-polyacrylamide gel for 
electrophoresis. (C) For western blot of his-tag R0P2, 5jal of the boiled samples were 
loaded on 12.5 % SDS-polyacrylamide gel for electrophoresis. The resolved proteins were 
then transferred to PVDF membrane and hybridized with monoclonal anti-his-tag antibody. 
Positive signal were detected at corresponding size of the putative his-tag P30 (35kKDa) 
and his-tag GRA2 (45kDa). 
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Figure 3.10. Western blot of induced bacterial lysate with anti — serum against his-
tag MEA. His-tag P30, his-tag GRA2, his-tag R0P2 and his-tag MIH were i n d u c e d to 
express as described in 3.3.2.a, 500jLil of both uninduced (U) and induced (I) bacterial 
cultures were collected and the bacterial pellets were resuspended in lOOjil of IxSDS 
sample loading buffer. (A) For western blot of his-tag P30, ISjul of the boiled samples 
were loaded on 12.5 % SDS-polyacrylamide gel for electrophoresis. (B) For western blot 
of his-tag GRA2, I5[x\ of the boiled samples were loaded on 12.5 % SDS-polyacrylamide 
gel for electrophoresis. (C) For western blot of his-tag R0P2, 5^1 of the boiled samples 
were loaded on 12.5 % SDS-polyacrylamide gel for electrophoresis. (D) For western blot 
of his-tag MM, 15jal of the boiled samples were loaded on 12.5 % SDS-polyacrylamide 
gel for electrophoresis. The resolved proteins were then transferred to PVDF membrane 
and hybridized with pre-absorbed anti-semm against his-tag MEA (as described in 3.3.2.C). 
Positive signal were detected at corresponding size of the putative his-tag P30 (35KDa), 
his-tag GRA2 (45kDa) and his-tag R0P2 (52kDa). 
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Figure 3.11. Standard curve of Braford protein assay. Six dilutions of standard BSA， 
0, 2, 4, 6 and 8)Lig/ml were prepared in a final volume of 200)^ 1. The six standards, together 
with 200|LI1 of each sample (of different dilutions) were mixed with 50)il dye reagent. 
These mixture were allowed to incubate at room temperature for half an hour, afterwards, 
their absorbance at 595nm were measured. Standard curve based on known quantities of 
BSA was plotted such that concentration of purified his-tag P30, his-tag R0P2 and his-tag 
GRA2 were estimated from the standard curve. 
Table 3.3. Results of the Braford protein assay for his-tag P30, hid-tag GRA2 and 
his-tag ROP2. Each sample were prepared in 200jLil solution with duplication. The 
average of their corresponding absorbance values at 595mn, their dilution factors and their 
protein concentration were recorded. 
Sample Dilution Factor Average values Protein conc. 
O f O D 5 9 5 ( j L i g / m l ) 
His-tag P30 20 0.367 14^0 
‘ H i s - t a g GRA2 ^ 0.299 
His-tag R0P2 40 0.210 U ^ 
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Figure 3.12. Western blot of his-tag P30，his-tag GRA2 and his-tag ROP2 with 
seropositive sera from mice. Panel A: l|Lig his-tag P30; Panel B: l\xg his-tag GRA2 and 
Panel C: Ijig his-tag R0P2 were blotted onto PVDF membrane and probed with different 
titers of antibodies. Primary antibodies, serum of mice of both seropositive, 1:200 (Lanel), 
1:1000 (Lane2) and sero-negative (Lane3) were used to probe with the three T, gondii 
antigen, P30, GRA2 and R0P2. Secondary antibodies conjugated with HRP were used for 
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Figure 3.13. Western blot of his-tag P30, his-tag GRA2 and his-tag ROP2 with 
seropositive sera from human. Panel A: l\xg his-tag P30; Panel B: l\ig his-tag GRA2 
and Panel C: l[ig his-tag R0P2 were blotted onto PVDF membrane and probed with 
different titers of antibodies. Primary antibodies, serum of human of both sero-positive, 
1:200 (Lanel), 1:1000 (Lane2) and sero-negative (Lane3) were used to probe with the 
three T. gondii antigen, P30, GRA2 and R0P2. Secondary antibodies conjugated with 
HRP were used for signal development and detection. The titers of using different 
antibodies were shown in Table 3.1. 
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1.4.1 Measurement of cellular immune responses in his-tag MEA vaccinated 
BALB/c mice 
BALB/c mice immunized with 50jj,g his-tag MEA (inununization procedures were 
shown in 2.3.4e) and the age-matched control group was killed four days after the last 
immunization. Spleenocytes were prepared from immunized and control mice and were 
cultured in assay medium (Table 3.4). 
For T-cell proliferation assay, spleenocytes were either stimulated with 25|ig/ml T. 
gondii antigens or leave un-stimulated. Cells were cultured for 5 days at 37°C in the 
humidified CO2 incubator to allow clonal expansion of T cells which could specifically 
recognize T. gondii antigens. The extent of proliferation of the spleenocytes was then 
measured by cell proliferation ELISA based on BrdU labelling of the actively proliferating 
cells (Figure 3.14). For the determination of the cytokine expression profile, spleenocytes 
were either stimulated with 25jig/ml T. gondii antigens or leave un-stimulated. Cells were 
cultured for 10-hour at 37�C in the humidified CO2 incubator for induction of cytokine 
expression in T. Jc/^JzY-speciflc T cells. The cells were then harvested and RNA was 
extraction. Cytokine expression profile was determined by RT-PCR using gene specific 
primers (Figure 3.15). 
Table 3.6 Spleenocytes prepared from vaccinated and age-matched control mice 
Spleenocytes Concentration Yield (Viable) Viability 
(cells/ml) (cells) (%) 
Age-matched control group 2.33 x lO? 3.50 x 10^  ^ 
P30-vaccinatedmice 2.55 x 10^  5.10x ^ 
MEA-vaccinated mice 4.93 x lO? 9.86 x 10' ^ 
T. gondii lysate-vaccinated 1.28 x lO'^  7.68 x lO? ^ 
mice 
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T-cell proliferation assay of MEA-immunized, T. gondii 
lysate-immunized and control BALB/c mice 
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Figure 3.21 Proliferative responses of spleenocytes from vaccinated mice and 
non-immunized mice (negative control group) after stimulation with total T. gondii 
a n t i g e n . S p l e e n o c y t e s f r o m t h r e e m i c e w e r e h a r v e s t e d f r o m MEA-vaccinated 4 d a y s 
a f t e r t h e t h i r d i m m u n i z a t i o n a n d a l s o f r o m T. gondii B A L B / c m i c e i m m u n i z e d w i t h T. 
gondii l y s a t e a t d a y 1 8 a f t e r t h e l a s t i m m u n i z a t i o n . F o l l o w i n g 1 2 0 h o u r s s t i m u l a t i o n 
w i t h t o t a l T. gondii a n t i g e n s w i t h f i n a l c o n c e n t r a t i o n 2 5 | L i g / m l , B r d U l a b e l i n g s o l u t i o n 
w a s a d d e d a n d w a s i n c u b a t e d f o r a n o t h e r 1 6 - 1 8 h o u r s . T h e i n c o r p o r a t i o n o f B r d U i n 
actively proliferating cells was measured by Cell Proliferation ELISA, BrdU 
( c o l o r m e t r i c ) . C o n t r o l s p l e e n o c y t e s w e r e f r o m a g e - m a t c h e d c o n t r o l m i c e w i t h o u t 
r e c e i v i n g a n y i m m u n i z a t i o n s . E x p e r i m e n t s w e r e p e r f o r m e d i n t r i p l i c a t e , r e s u l t s s h o w n 
r e p r e s e n t t h e m e a n s 土 s t a n d a r d d e r i v a t i o n ( S D ) a n d t h e d a t a w a s a n a l y z e d b y o n e - w a y 
A N N O V A w i t h L S D ( f i s h e r ' s l e a s t - s i g n i f i c a n t - d i f f e r e n c e ) . * : 0 . 0 5 > P > 0 . 0 1 ; * * ; 0 . 0 1 � 
P > 0 . 0 0 1 ; n s : n o n - s i g n i f i c a n t a t t h e 0 . 0 5 l e v e l . 
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Figure 3.22 Cytokine expression profiles of total T. gondii-antigen stimulated or un-
stimulated spleenocytes from vaccinated mice and non-immunized mice (negative control 
group). S p l e e n s from three mice were h a r v e s t e d four days after the third i m m u n i z a t i o n , 
s p l e e n o c y t e s w e r e p r e p a r e d a n d w e r e s t i m u l a t e d 1 0 h o u r s w i t h t o t a l T. gondii a n t i g e n s . R N A w a s 
t h e n p r e p a r e d b y C s C l - g r a d i e n t m e t h o d a n d c y t o k i n e e x p r e s s i o n p r o f i l e w a s d e t e r m i n e d b y R T -
P C R ( a s d e s c r i b e d i n 3 . 3 . 3 . C ) . R T - P C R w a s n o r m a l i z e d b y t h e h o u s e - k e e p i n g g e n e , G A P D H , t h e n 
c y t o k i n e s u b t y p e s e x p r e s s e d w a s d e t e r m i n e d u s i n g d i f f e r e n t g e n e s p e c i f i c p r i m e r s . 1 0 - 1 5 | x l o f t h e 
P C R p r o d u c t w a s l o a d e d o n t o 2% a g a r o s e g e l f o r g e l e l e c t r o p h o r e s i s . C y t o k i n e e x p r e s s i o n p r o f i l e 
o f u n - s t i m u l a t e d s p l e e n o c y t e s w a s s h o w n o n t h e l e f t c o l u m n w h i l e f o r c y t o k i n e e x p r e s s e d i n 
s t i m u l a t e d s p l e e n o c y t e s w e r e s h o w n i n t h e right c o l u m n . P a n e l A : I L - 1 0 ; P a n e l B : T N F a ; P a n e l C : 
I L - 2 ; P a n e l D : I F N - y ; P a n e l E : I L - l a ; P a n e l F : I L - 1 (3; P a n e l G : I L - 1 2 p 3 5 ; P a n e l H : I L - 1 2 p 4 0 ; 
P a n e l I s h o w e d t h e n o r m a l i z a t i o n o f t h e R T - P C R u s i n g t h e h o u s e - k e e p i n g g e n e , G A P D H a n d p a n e l 
J s h o w e d t h e n e g a t i v e c o n t r o l f o r t h e R T - P C R . L e f t c o l u m n s h o w e d t h e u n s t i m u l a t e d s p l e e n o c y t e s 
w h i l e r i g h t c o l u m n s h o w e d t h e T. gondii l y s a t e s t i m u l a t e d s p l e e n o c y t e s i s o l a t e d f r o m n e g a t i v e a g e -
m a t c h c o n t r o l m i c e ( c o n t r o l ) , P 3 0 - i m m u n i z e d m i c e ( P 3 0 ) a n d M E A - i m m u n i z e d m i c e ( M E A ) . 
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3.4.4 Protection efficacy of different vaccine constructs against lethal challenge 
Two different mice strains of two inbred mice strains with haplotypes of li-2^ and 
H-2^ were used for challenge experiment (details were summarized in Table 3.8). Mice 
were immunized for three times with 50jag his-tag MEA or 50jag his-tag P30. Mice were 
challenged i.p. with 1 x 10^  T. gondii tachyzoites (RH strain) 4 days after the last 
immunization the time until death was recorded (Figure 3.23 and 3.24). The protective 
efficacy of the mice could be determined by the survival of the mice after challenge. 
Table 3.8 Mice strains used in this experiment and their phenotype, haplotype 
and the breeding system 
Strain/ Line Phenotype Breeding Haplotype 
/Genotype System 
1 BALB/c Albino inbreeding H ^ 
2 C57 Black inbreeding H-2^ 
(C57BL/6J) 
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Challenge infection of 已alb/c mice immunized with different vaccine construct 
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Figure 3.23 Survival of BALB/c and C57 mice immunized with recombinant HisMEA protein 
with Freud's as adjuvant compared with mice immunized with recombinant HisP30 with Freud's as 
adjuvant or non-immunized age-matched control mice. Mice were immunized for three time with either 
50^g His-tag MEA or HisP30 and were challenged with T. gondii tachyzoites (RH strain) three days after the 
last immunization (as described in 3.3.4). The time until death was recorded. ( ) represents un-immunized 
mice (negative control); ( ) represented mice immunized with His P30; ( ') represents mice 
immunized with His-tag MEA and "n" represent the number of mice per group. 
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3.5 DISCUSSION 
3.5.1 Construction of pET-GRA2 and pET-ROP2 
The GRA2 gene fragment was amplified from total tachyzoite RNA by RT-PCR 
using gene specific primers. The R0P2 gene fragment was amplified from the 
recombinant plasmid pTYB4-ROP2 constructed by Maxin. The GRA2 and R0P2 gene 
were then separately subcloned into the EcoRV E. coli expression vector- pET32a+. 
Transformed clones carrying the putative plasmid were screened by PCR. Finally, 
sequences were confirmed by cycle sequencing. In both of the pET32a+ROP2 and 
pET32a+HisGRA2, the transgenes were in-frame fused with the 109aa thioredoxin 
protein His-tag at N-terminus, thrombin and also contained His-tag and S-tag sequences 
for detection and purification. These tags could be cleavable by site-specific proteases, 
such as enterokinase, and the transcription of the transgenes was driven by T7 lac 
promoter. The recombinant plasmids were transformed into the expression host, 
BL21(DE3), bearing the T7 RNA polymerase gene for expression of target gene for 
expression of recombinant antigens. 
3.5.2 Expression and characterization of his-tag P30, his-tag GRA2 and his-tag 
ROP2 
Recombinant plasmid pET30a+P30 expressing a truncated form of P30 antigen 
with an N-terminal polyhistidine tag as fusion partner was constructed by Mr. C.S. Lo and 
this plasmid was used for expressing the recombinant P30 antigen in E. coli. The plasmid 
was purified and then transformed into the expression host, BL21(DE3). After IPTG 
induction, the recombinant antigen, his-tag P30, was highly expressed and reached at 
maximal level after 2.5 hours (Figure 3.5). It was around 35kDa and was found in the 
insoluble fraction of the induced bacterial lysate, in the other words, recombinant P30 
formed inclusion bodies (data not shown). For expression of recombinant GRA2, after 
IPTG induction, the recombinant antigen of molecular weight of 45kDa was highly 
expressed and reached at maximal level after 2.5 hours (Figure 3.6). By estimation on 
121 
SDS-PAGE, milligram of recombinant P30 and GRA2 antigens could be easily produced 
by milliliter of induced bacterial cultures. 
However, expression of recombinant R0P2 (aa 27-230) antigen faced significant 
challenge. R0P2(aa 27-230) was originally cloned into the pET30a+ vector with N-
terminal his-tag as fusion partner, however, no inducible band was observed after inducing 
DE3 cells carrying pET32a+ROP2 under standard induction protocol (data not shown). 
Even by varying different parameters, such as temperature and IPTG concentration 
(Schein and Notebom, 1989), during induction which had been reported to be optimal for 
expression of some proteins with specific characteristic, no recombinant protein could be 
detected by western blot (data not shown). The problems of extremely low expression 
level and solubility were commonly encountered in expression of R0P2 antigen in E, coli 
(Jacquet et al, 1999). 
Based on previous studies, fusing the R0P2 with thioredoxin could greatly increase 
the yield and the solubility of this recombinant antigen in E. coli (Jacquet et al., 1999). 
Thioredoxin is a well-established fusion partner for facilitating expression and enhancing 
the solubility of the proteins of interest (LaVallie et al, 1993). Moreover, it may have 
stabilizing effect on the fusion partners, especially to those sensitive to proteolysis 
(Marinez et al, 1995). So, pET30a+ vector was replaced by pET32a+ vector in which the 
proteins of interest can fused with the 109aa thioredoxin tag for expression of the 
- recombinant ROP2(aa27-230). Finally，recombinant ROP2(aa27-230) of molecular weight 
of 52kDa was induced to be expressed and reached at maximal level after 8 hours of IPTG 
induction (0.3mM) in TB broth (Figure 3.7). 
Recombinant P30 was a fusion protein containing an N-terminal polyhistidine-tag 
while recombinant GRA2 and R0P2 carried an internal polyhistidine-tag. Theoretically, 
the histidine-tag could be detected by monoclonal anti-his-tag antibody. This antibody 
showed a high binding specificity to the recombinant P30 and GRA2 antigens as only a 
single band was detected in the total lysate of the induced bacterial culture (Figure 3.9). 
However, the internal his-tag of recombinant ROP (aa27-230) could not be recognized by 
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the mono-clonal anti-his-tag antibody as this internal-tag of 6 histidine residues might be 
hindered by its large fusion partners, for example, thioredoxin of 109aa and R0P2 
fragment of 248aa. 
Based on the inducible patterns on SDS-PAGE and the recognition by the anti-his-
tag antibodies, the present of the recombinant antigens in the induced bacterial lysate could 
be confirmed. Besides，they could be confirmed by western blot with anti-serum against 
the HisMEA (Figure 3.10A-C). Distinct epitopes from P30, GRA2 and R0P2 were 
included in MEA and thus antibodies against this protein should have cross-reactivity with 
the other three T, gondii antigens. As the His-tag MEA protein also contained an N-
terminal his-tag fusion, anti-serum against this protein was firstly pre-absorbed with the 
induced bacterial lysate of an un-related his-tag fusion protein, His-tag MIH, to eliminate 
non-selective binding of the antibodies to the his-tag fusion of the three recombinant T. 
gondii antigens (Figure 3.10D). Moreover, the immunogenicity of the epiotpes selected 
from P30, GRA2 and R0P2 could be demonstrated by the capacity of the pre-absorbed 
anti-MEA antibodies for recognizing these three recombinant antigens (Figure 3.10D). 
These recombinant antigens were partially purified by gel excision and their 
antigenicity was further characterized by western blot analysis. The antigenicity of these 
antigens was demonstrated as they could be recognized by sero-positive mouse (Figure 
3.12) and human (Figure 3.13) serum but not the seronegative serum. The additional 
bands shown on the western blot of the purified R0P2 antigen (Figure 3.12G1 and Figure 
3.13C1) were probably the degradation products of the R0P2 proteins which could also be 
recognized by the sero-positive serum. The present of fusion tag on the recombinant 
antigens did not alter their antigenicity�The partially purified antigens were also used for 
immunization. Anti-serum against these antigens was collected from immunized hosts. 
Anti-serum against these recombinant antigens was highly immunogenic and recombinant 
P30, GRA2 and R0P2 could be recognized at a titer of 1:5000 (data not shown) and the 
presence of thioredoxin and/ or his-tag did not interfere with the immunogenic properties 
of the recombinant antigens. 
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3.5.3 Measurement of cellular immune responses in his-tag MEA vaccinated 
BALB/c mice 
To analyze whether spleenocytes from vaccinated mice were able to proliferation 
and the profile of cytokines expression after stimulation with T. gondii antigens, 
spleenocytes was prepared from mice of immunized and control groups and were 
stimulated in vitro with total T. gondii (RH) antigens. Spleenocytes from ME A-vaccinated 
mice specifically proliferated when stimulated with T. gondii antigens when compared to 
the un-stimulated control group, analysis of these data by one-way ANNOVA with LSD 
(fisher's least-significant-difference) indicated that they were significantly different (0.05 
> P > 0.01) while no specific proliferation could be detected between the in vitro 
stimulated and un-stimulated spleenocytes isolated from negative control mice (no 
significant differences at the 0.05 level) (Figure 3.14). Moreover, a strong proliferative 
response was observed in animals received T. gondii antigens in the presence of Freund's 
adjuvant (0.01 > P > 0.001) (Figure 3.14). 
Although T-cell proliferation can be detected in MEA-vaccinated mice, the 
proliferative response is relatively low when compared to previous reports in which 
animals were immunized with recombinant Toxoplasma antigens (Velge-Rouseel et al, 
1997). It may due to the imperfect setup of the experiment, for MEA-vaccinated mice, 
spleenocytes were harvested four days after third immunization, thus antigens reactive T-
cells may not have not enough time to reach the peak level, while for mice immunized 
with total T. gondii lysate, were killed 18 days after the last immunization, therefore 
stronger proliferative response was observed. For better results, this assay can be improved 
by modifying the time for harvesting spleenocytes from vaccinated mice, may be 
approximately between 10-14 days after receiving the last immunization (for 
immunization with protein). 
For the determination of cytokine pattern produced ex vivo by spleenocytes in 
response to T. gondii antigens stimulation indicated a decreased in type 1 response with 
reduced IFN-y expression in both P30 vaccinated and MEA-vaccinated mice relative to the 
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age-match control mice (Figure 3.15 Panel D). However, unlike in P30-vaccinated mice, 
the expression of the other Thl cytokine, e.g. IL-2, was not significant altered by 
immunization with MEA antigen (Figure 3.15 Panel C). IL-10 which is a Th2 cytokine 
was up-regulated in P30- and MEA-vaccinated mice (Figure 3.15 Panel A), although the 
other three Th2 cytokines, IL-4, IL-5 and IL-6 were undetectable in all experimental and 
control animals analyzed (data not shown). These results are reminiscent of those reported 
by Godard et al and Letscher-bru et al., who immunized animals with recombinant 
Toxoplasma antigens and found that these immunizations induced type 2 humoral 
immunity with exclusive IgGl production when they were administrated substaneously or 
intravenously to mice (Godard et al., 1994; Letscher-bru et aL, 1998). 
TNF-a is one of the key cytokines involved in the immunity against 
toxoplasmosis, it can act synergistically with IFN-y to mediate killing of tachyzoites and 
was found to be up-regulated upon stimulation in spleenocytes isolated from both P30-
and MEA-vaccinated mice when compared to the control group (Figure 3.15 Panel B). 
However, induction of TNF-a alone was unable to confer anti-toxoplasmal activity as it 
cannot direct killing of T. gondii, it can only trigger IFN-y-primed macrophages to kill or 
inhibit intracellular T. gondii (Sibely et al., 1993). Moreover, T cell-independent T. 
gondii-ViWmg mechanism can only be initiated by the combination of IFN-y and TNF-a. 
Many cytokines are demonstrated to be involved in toxoplasmosis in in vitro 
studies with inducible secretion in different cell models by stimulating with T. gondii 
antigens although some of their in vivo roles may not be identified, for example, IL-1 
(Kelly et al, 1989; Bala et al., 1994; Pelloux et al., 1994), IL-12 (Gazzinelli et al； 1993; 
Khan et al., 1994) and GM-CSF (Bala et aL, 1994). The expression profile of these 
cytokines in in vitro stimulated spleenocytes was also studied. IL-1 and IL-12 were up-
regulated in spleenocytes isolated from MEA-vaccinated mice upon stimulated, but their 
expression were not significantly modified by immunization with P30 antigens while 
GM-CSF were undetectable in all experimental and control animals analyzed (data not 
shown). In natural infection, tachyzoites stimulate macrophages to produce IL-12 and 
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TNF-a (Gazzinelli et al., 1996; Sher et al., 1998). IL-12, in turn, activates natural killer 
cells and T cell to produce IFN-y, which is crucial for resistance (Gazzinelli et al,, 1996). 
Altogether, these results suggested that the cellular immune response could also be 
elicited, in addition to the B-cell response and was oriented to a Th2 profile in MEA-
vaccinated mice. Although the helper T-cell subtype shifted to Th2 but not the preferable 
Thl responses, the cytokine expression profile in MEA-vaccinated mice were more similar 
and comparable to the natural T. gondii infection than P30-vaccinated mice. The induction 
of specific humoral type 2 immunity can be further confirmed by determination of the IgG 
subtypes by ELISA. The presence of specific IgGl and the absence of IgG2 in serum 
collected from vaccinated animals will demonstrate that the immunization preferentially 
induces type 2 humoral immunity. 
3,5.4 Protection efficacy of different vaccine constructs against lethal challenge 
As significant humoral and cellular immune responses were elicited by 
immunization with His-tag MEA, mice were then used as model animals to test whether 
this vaccination could afford protection against a lethal T. gondii RH strain infection. 
Virulence among the various strains of T. gondii for different laboratory animals can be 
quite varying (Krahenbuhl and Remington, 1982). This virulence diversity may have 
considerable impact on immunology, pathology and host-parasite relationship. Based on 
the time taken before infected animals die, percentage of mortality or the number of 
parasites needed to kill infected animals, virulence of different isolates of T. gondii can be 
estimated (Kaufman et al, 1959; Dubey and Frenkel, 1973). Some of the strains are 
extremely virulent, for examples, the RH strains used in this experiment which have lost 
the ability to form oocysts in the cat, only a few tachyzoites can be lethal to the mice 
within a week after i.p. injection while other avirulent strains (e.g. S-1 strain), after 
challenged with 1000 oocysts (equivalent to 8000 tachyzoites), these mice survived 
without ill effects although cysts formed in the brains of the mice (Dubey and Frenkelk, 
1973). 
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Based on previous studies, susceptibility of different host species and host strains 
to T. gondii infection also varies. A T. gondii strain which exhibits little clinical effect on 
adult rat even challenged with a high dose of parasites, may be lethal for mice and the 
differences in susceptibility among different inbred and outbred strains of mice are well-
studied (McLeod et al, 1984). The variation in the susceptibility is probably due to the 
differences in genetic background of the laboratory animals. For the mice chosen in the 
challenge experiment, BALB/c and C57 (summarized in Table 3.5), as the difference in 
haplotypes, different susceptibility to the T. gondii tachyzoites of RH strain was observed. 
Among the two mice strain used, BALB/c was less susceptibility to lethal challenge with T. 
gondii, with the control mice all died 7 days after infection (Figure 3,16) while C57 mice 
had a higher susceptibility to T, gondii infection with infected mice died at day 6.5 of post-
infection (Figure 3.16). 
As T, gondii tachyzoite of RH strain is a very virulence strain, till now there is no 
vaccines that can completely protected the animals from challenge with tachyzoites of RH 
strain, this can explain why both the P30- and MEA-immunization could only prolonged 
the survival of the vaccinated mice and they would eventually die. Based on previous 
studies, DNA-immunization of P30/ SAGl could completely protect the immunized 
animals from lethal challenge (reference) while immunization with recombinant P30 
antigen could only prolong the survival of the animals (Chardes et al, 1993). Similar 
protective efficacy was observed in his-tag PSO-immunized mice in challenge experiment 
as reported by Chardes et al (Chardes et al, 1993), mice carrying Yi-2^ haplotype (BALB/c) 
with better responses to the vaccination with recombinant P30 antigen, in term of the 
survival rates after the lethal challenge (Figure 3.16). 
Immunization with His-tag MEA gave better protection in BALB/c and C57 mice 
used in the challenge experiment and the variation in the responsiveness in His-tag MEA-
immunized mice against the lethal T. gondii challenge was not obviously observed, when 
compared to His-tag P30-immunized mice. This may due to the inclusion of the 
promiscuous T-cell epitope (TTP30) (Demotz et al, 1989a; Demotz et al, 1989b) in the 
multi-epitopic vaccine construct which could help to overcome genetic restriction and to 
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enhance the immunogenicity of the vaccine construct (Kaumaya et al, 1993; Buus et al, 
1987; Chicz et al, 1993; Lairmore et al, 1995; Van der Burg et al, 1999; Kobayashi et al, 
2000). However, as we had not included MEA antigen without the TTP30 flision as 
control for comparison, no conclusive conclusion could be drawn. As MEA showed better 
protection efficacy than P30 which is a well-established vaccine candidate that gives 
relatively good protection among different toxoplasma antigens analyzed, results from the 
challenge experiment thus supporting that the MEA would be an ideal vaccine candidate 
against toxoplasmosis, even better than the well-established vaccine candidate of single 
antigen, P30. 
In this experiment, although the multi-epitopic antigen conferred a significant 
protective effect in the vaccinated mice, this antigen could only prolong the survival of the 
mice instead of completely protected the mice from beginning develop to toxoplasmosis. 
The protective efficacy of this vaccine construct may probably be limited by the nature of 
the vaccine. As commonly known, immunization with antigens of protein nature will elicit 
strong humoral immune responses but low-to-no level of cell-mediated immunity, 
especially Thl subset as demonstrated by the cytokine expression profile performed 
(Figure 3.16). As T. gondii is an intracellular parasite, CMI is the major arm of the host's 
immune response that confers protection against the infection. To direct the T-cell immune 
responses to the preferable Th-1 subtypes, recombinant MEA antigen can be administrated 
to IL-12 as an adjuvant. IL-12 besides acting as an important mediator for the protective 
immunity in the acute phase of toxoplasmosis (Hunter et al,, 1995; Khan et al., 1997), it 
can rapidly and strongly orient the immune responses toward a Thl response (Trinchieri 
and Gerosa 1996; Wolf et al, 1994) and it was demonstrated to be a immunoadjuvant with 
Th-1 inducing effect (Afonso et al, 1994; Mountford et al, 1996; Noll and Autenrieth 
1996). On the other hand, DNA-based immunization may be an alternative approach for 
immunization to protect animals and human against toxoplasmosis as DNA vaccine can 
induce both potent humoral and cellular immunity (Wolff et al., 1990; Tang et al., 1992; 
Ulmer et al., 1993), especially cytotoxic T cells (Donnellt et al., 1997), probably through 
IL 12 and IFN-y-dependent pathways (Stacey et al., 1999; Kowalczyk et al” 1999). 
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Chapter 4 Expression of the Synthetic Gene Encoding 
the Multi-epitopic Antigen for Toxoplasma 
gondii in Arabidopsis thaliana 
4.1 INTRODUCTION 
As the cost for production, maintenance and delivery of traditional vaccine are 
too high for them to be distributed widely in developing countries; there is an urgent 
need for affordable and reliable vaccines. Transgenic plants provide a safe and 
inexpensive means for mass production of recombinant pharmaceutical proteins when 
compared to those derived from animals and bacteria. By targeting the expression of the 
recombinant protein in specific organs, such as seeds, transgenic plant can act as a long-
term storage for recombinant protein. Except to act as a bioreactor, expression of 
antigens in plants, especially vegetables and fruits, has opened a new avenue for the 
development of edible vaccine. In this chapter, the possibility and feasibility of using 
transgenic plant to produce recombinant MEA was investigated. 
4.1.1 Transgenic plants as vaccine production systems 
After successfully expressed the human growth hormone fusion protein (Barta et 
al., 1986), an interferon (De Zoeten et al., 1989) and human serum albumin (Sijmons et 
al, 1990) in plants, the potential of using plant as bioreactor to produce recombinants 
pharmaceuticals becomes an attractive tropic for biologists. A wide variety of proteins 
have been successfully expressed in plants, such as industrial enzyme (Ponstein et al 
1996), recombinant antibodies (Ma and Hein, 1995), plasma protein (Sijmons et al, 
1990), hormones and cytokines (Magnuson et al” 1998) and vaccines (summarized in 
Table 4.1). 
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(a) Advantages of using plants as bioreactor 
Although the bacterial expression systems take the advantage of simple 
procedures and low production cost for the expression of target proteins, they are not an 
ideal expression system for expressing some mammalian proteins as they are incapable 
of most of the important mammalian post-translational modifications, result in improper 
folding and unnatural conformation of the expressed proteins (Fischer and Emans 2000; 
Fischer et aL, 2000). Mammalian cells can synthesize the recombinant mammalian 
proteins correctly but this expression system is extensive sensitive to environment 
changes especially when cultured at industrial scale (Giddings et al., 2000; Fisher and 
Emans 2000; Fischer et al., 2000), labour- and cost-intensive and more importantly, 
there is potential risk of human/ animal pathogens contaminations (Giddings et al,, 
2000). Exploration of plants as bioreactor gives a cheap, safe and efficient alternative. 
Plant shares higher eukaryotic protein synthesis pathway and plant cells have 
similar pathway when compared with animal cells with only minor differences in 
glycosylation (Cabanes-Macheteau et al” 1999; Fischer et al., 2000). The plants can 
grow locally and cheaply using standard growing methods of a given region, this allows 
high level production of functionally active recombinant protein in plant at a relatively 
lower cost. Kusnadi et al had estimated the cost of producing recombinants in plants 
could be 10- to 50-fold lower (depended on crop types) than producing the same protein 
by E. coli through fermentation (Kusnadi et al.’ 1997). 
The stable accumulation of recombinant proteins in plant is also an advantage of 
plant being a bioreactor. Depending of the promoters used, transgenic proteins can be 
expressed and deposited through the plant or in specific parts (e.g. seeds) or in specific 
organs of the plant cells (e.g. storage vesicle). Expression of recombinant proteins to 
specific intracellular compartments of plant cells in which the target proteins can be 
stably accumulated is one of the approaches for stable accumulation of recombinants in 
plants (Jiang and Sun 2002). Besides, proteins produced in seeds were reported to 
exhibit remarkable stability (Schenk et aL, 1999; Zhang et aL, 2000). So, the vaccine 
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can be easily delivered all over the world, especially to consumers in developing 
countries where the cost of transportation and the lack of refrigeration can make the 
conventional vaccine administration impractical. 
Plant-derived vaccine are considered to be safer as the expression of vaccine in 
plant eliminates the risk of contamination of human and animal pathogens (such as HIV 
and hepatitis viruses) and toxins (Fisher and Emans 2000; Fischer et al,, 2000)，as well 
as the ethical considerations with the use of animals. Moreover, as an edible vaccine, 
injection-related hazards can also be eliminated. And lastly, purification requirements, 
which is potentially costly, can be eliminated as plant tissues containing the recombinant 
proteins can be used directly as feed, thus generating an edible vaccines. 
(b) Transgenic plants for vaccine production 
Many recombinant vaccines have been expressed in plant (summarized in Table 
4.1). They can be used as edible vaccines for feeding humans and other commercially 
important animals. The lost cost and easy administration makes oral-derived vaccine an 
attractive alternative to injection. After ingesting the oral vaccines, the antigens will 
enter the body across the mucosal surfaces, and thus enhancing the chances of acquiring 
mucosal immunity against infectious agents. This edible vaccine would be extremely 
useful for inducing immunity to the pathogen that colonizes mucosal surfaces where 
large does are needed to induce strong IgA response. Furthermore, plant tissues can 
serve as bio-encapsulation vehicles which can protect the protein components from 
degradation in stomach and gut before they can elicit an immune response. 
To be a successful edible vaccine, the recombinant proteins should be expressed 
at a high level as soluble proteins in the transgenic plants and should be stable for long-
term storage. Seed is a protein-rich component among different plant tissues. Expression 
of the recombinant proteins in seeds can increase the concentration of antigens per gram 
of plant tissues and thus decrease the dose size. Besides, the small size of seeds makes 
the storage and transportation of the edible vaccine more easily. Crop plants and fruits 
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are particularly suitable for expressing the antigen as many of them can be consumed 
raw without processed as treating the plant tissues with heat and pressure may destroy 
the antigen. 
Several vaccines produced in plants, for example vaccine against hepatitis B 
(Richter et al,, 2000) and foot-and-mouth disease (Wigdorovitz et aL, 1999), had been 
tested in animal model. Moreover, plant-produced recombinant enterotoxin (Tacket et al., 
1998) and Norwalk virus capsid protein (Walmsley et al., 2000) had been subjected to 
clinical trials for assessing the human immune responses to these antigens. These 
landmark papers described the first few clinical trails of plant-derived edible vaccine. 
Oral-delivery of the plant-derived vaccine could prime the gut mucosal immune system 
in human. Moreover, antibody-secreting cells could be detected in tested individuals. 
These studies highlight the possibility of using transgenic plant tissue as edible vaccine. 
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Table 4.1a. Example of recombinant vaccines expressed in plants 
Year Vaccine/ Antigen expressed References 
1 9 9 2 H e p a t i t i s v i r u s B s u r f a c e a n t i g e n M a s o n et a l , 1 9 9 2 
1 9 9 5 M a l a r i a p a r a s i t e a n t i g e n T u r p e n e ^ a / . , 1 9 9 5 
1 9 9 5 R a b i e s v i m s g l y c o p r o t e i n M c G a r v e y tz/ . , 1 9 9 5 
1 9 9 5 E. coli h e a t - l a b i l e e n t e r o t o x i n H a q et al, 1 9 9 5 
1 9 9 6 H u m a n r h i n o v i r u s 1 4 ( H R V - 1 4 ) P o r t a et a l , 1 9 9 6 
A n d h u m a n i m m u n o d e f i c i e n c y v i r u s t y p e - 1 
( H I V - 1 ) e p i t o p e s 
1 9 9 6 N o r w a l k v i m s c a p s i d p r o t e i n M a s o n et a l , 1 9 9 6 
1 9 9 7 D i a b e t e s - a s s o c i a t e d a n t o a n t i g e n M . ' d . e t a l , 1 9 9 7 
1 9 9 7 H e p a t i t i s B s u r f a c e p r o t e i n s E h s a n i e广 <3/.，1997 
1 9 9 7 M i n k E n t e r i t i s V i m s e p i t o p e D a l s g a a r d et a l , 1 9 9 7 
1 9 9 7 R a b i e s a n d H I V e p i t o p e s Y u s i b o v et a l , 1 9 9 7 
1 9 9 8 F o o t a n d m o u s e d i s e a s e v i r u s CdiuiWo et al, 1 9 9 8 
V P 1 s t r u c t u r a l p r o t e i n 
1 9 9 8 E. coli h e a t - l a b i l e e n t e r o t o x i n M a s o n et al” 1 9 9 8 
1 9 9 8 E. coli h e a t - l a b i l e e n t e r o t o x i n T a c k e t et al, 1 9 9 8 
1 9 9 8 R a b i e s v i r u s M o d e l s k a a / . , 1 9 9 8 
1 9 9 8 C h o l e r a t o x i n B s u b u n i t A r a k a w a et a l , 1 9 9 8 a 
1 9 9 8 H u m a n i n s u l i n - C h o l e r a t o x i n B s u b u n i t f u s i o n A r a k a w a et a l , 1 9 9 8 b 
p r o t e i n 
1 9 9 9 F o o t a n d m o u s e d i s e a s e v i m s V P l s t r u c t u r a l W i g d o r o v i t z a / . , 1 9 9 9 
p r o t e i n 
1 9 9 9 H e p a t i t i s B v i r u s s u r f a c e a n t i g e n K a p u s t a et a l , 1 9 9 9 
1 9 9 9 H u m a n c y t o m e g a l o v i r u s g l y c o p r o t e i n B T a c k a b e r r y <3/., 1 9 9 9 
1 9 9 9 D i a b e t e s - a s s o c i a t e d a u t o a n t i g e n P o r c e d d u a / . , 1 9 9 9 
2 0 0 0 P o r c i n e t r a n s m i s s i b l e g a s t r o e n t e r i t i s v i r u s s p i k e T u b o l y et a l , 2 0 0 0 
p r o t e i n 
2 0 0 0 H u m a n r e s p i r a t o r y s y n c y t i a l v i r u s ( R S V ) G - B e l a n g e r et al., 2 0 0 0 
p r o t e i n 
2 0 0 0 R S V f u s i o n ( F ) p r o t e i n S a n d h u et a l , 2 0 0 0 
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Table 4.1b. Example of recombinant vaccines expressed in plants 
Year Vaccine/ Antigen expressed References 
2 0 0 0 H e p a t i t i s B s u r f a c e a n t i g e n R i c h t e r et al,, 2 0 0 0 
2 0 0 0 R e c o m b i n a n t a n t i g e n f o r H e p a t i t i s C v i r u s N e m c h i n o v et al., 2 0 0 0 
2 0 0 1 R e c o m b i n a n t a n t i g e n f o r v i r u l e n t c a n i n e G i l et a l , 2 0 0 1 
p a r v o v i r u s ‘ 
2 0 0 1 M e a s l e s v i m s h e m a g g l u t i n i n p r o t e i n H u a n g et al., 2 0 0 1 
2 0 0 1 E, coli e n t e r o t o x i n s u b u n i t B L a u t e r s l a g e r et al, 2 0 0 1 
2 0 0 1 F o o t a n d m o u s e d i s e a s e v i m s C a r r i l l o et a l , 2 0 0 1 
V P 1 s t r u c t u r a l p r o t e i n 
2 0 0 1 C h o l e r a t o x i n ( C T ) B a n d A 2 s u b u n i t f u s i o n Y u a n d L a n g r i d g e 2 0 0 1 
p r o t e i n 
2 0 0 1 M o d i f i e d M a n n h e i m i a h a e m o l y t i c a A l L e e et al., 2 0 0 1 
l e u k o t o x i n 
2 0 0 1 C h o l e r a t o x i n B s u b u n i t D a n i e l l et al, 2 0 0 1 
2 0 0 1 H e p a t i t i s B s u r f a c e a n t i g e n K a p u s t a et aL, 2 0 0 1 
2 0 0 2 R e c o m b i n a n t a n t i g e n f r o m f o o t a n d m o u s e v i r u s D u s S a n t o s et al., 2 0 0 2 
2 0 0 2 H I V - 1 p 2 4 p r o t e i n Z h a n g et a l , 2 0 0 2 
2 0 0 2 H u m a n p a p i l l o m a v i r u s 1 6 E 7 o n c o p r o t e i F r a n c o n i et al., 2 0 0 2 
2 0 0 2 V P 6 p r o t e i n o f b o v i n e g r o u p A r o t a v i r u s M a t s u m u r a et al., 2 0 0 2 
2 0 0 2 H e p a t i t i s B s u r f a c e a n t i g e n S m i t h et a l , 2 0 0 2 
2 0 0 2 E. coli h e a t l a b i l e e n t e r o t o x i n B s u b u n i t C h i k w a m b a et al., 2 0 0 2 
2 0 0 2 P r o t e c t i v e a n t i g e n a g a i n s t a n t h r a x A z h a r A z i z et al., 2 0 0 2 
2 0 0 2 R a b i e s v i r u s g l y c o p r o t e i n f u s i o n p r o t e i n Y u s i b o v et a l , 2 0 0 2 
2 0 0 3 H e p a t i t i s B v i m s s u r f a c e a n t i g e n R u k a v t s o v a et a l , 2 0 0 3 
2 0 0 3 H e m a g g l u t i n i n p r o t e i n o f r i n d e r p e s t v i r u s K h a n d e l w a l et al., 2 0 0 3 
2 0 0 3 M e a s l e s v i r u s h e m a g g l u t i n i n f u s i o n p r o t e i n B o u c h e et a l , 2 0 0 3 
2 0 0 3 H e p a t i t i s B s u r f a c e a n t i g e n f u s i o n p r o t e i n S o j i k u l et a l , 2 0 0 3 
2 0 0 3 M e a s l e s v i r u s h e m a g g l u t i n i n M a r q u e t - B l o u i n et a l , 2 0 0 3 
2 0 0 3 H e p a t i t i s B v i r u s s u r f a c e a n t i g e n G a o et a l , 2 0 0 3 
2 0 0 3 G l y c o p r o t e i n B ( g B ) o f h u m a n c y t o m e g a l o v i r u s T a c k a b e r r y et al., 2 0 0 3 
2 0 0 3 H u m a n P a p i l l o m a v i r u s - L i k e P a r t i c l e s W a r z e c h a et a l , 2 0 0 3 
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(c) Limitations 
Although the strategy for expressing the edible vaccine in plants was 
demonstrated to be feasible and was theoretically proved in animal models, many issues, 
such as yield of recombinant proteins produced and the immunogenicity of the plant-
derived vaccine which may be altered by plant-specific glycans, must still be addressed. 
(i) Low yields 
One of the major challenges for the production of plant-derived vaccine is to 
maintain a high yield production of the recombinant protein in transgenic plant and to 
minimize the variation in yields between plants. Although some of the pharmaceutical 
proteins can be produced with high yields, for example, antibodies produced in 
transgenic Nicotiana tahacum plants with yield reaching 8% of total soluble proteins 
(Ma et al., 1995) and production levels of xylanase (Herbers et al., 1995) and phytase 
(Verwoerd et al, 1995) in transgenic tobacco and avidin from transgenic maize (Hood et 
al., 1997) were all above 1% of total soluble proteins, the level of accumulation of the 
recombinant proteins in different plant expression systems are quite variable. The 
expression level achieved for some proteins can be as low as 0.001%, such as the 
expression of enterotoxin (LT) in tobacco leaves (Haq et al., 1995) and rarely exceeds 
0.4% of total soluble protein (Ma and Vine 1999). Expression of cholera toxin in 
transgenic potatoes can only reach the yields of 0.3% (Arakawa et al, 1997) while the 
yields of the capsid protein of Norwalk virus produced in tobacco and potatoes are of 
0.23% and 0.37% respectively (Mason et al., 1996). Besides, the variation in yield 
between plants should also be concerned. Based on previous study, the yield between 
different transgenic plants can vary for over three-fold (Tacket et al., 2000). 
(ii) Plant-specific glycans 
Another concern for plant-derived vaccines is the extent and exact nature of 
glycosylation which are sometimes different from animal，s glycoprotein. In eukaryotic 
cells, secretory and membrane-bound proteins are frequently the subject of post-
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translational modifications. One of the most important post-translational modifications is 
the covalent attachment of sugar chains, so called glycosylation. Two major types of 
protein glycosylation are known, N- and 0-glycosylation. N-glycans are attached to 
asparagine residues of the polypeptide backbone while 0-glycans are linked to serine or 
threonine by the action of glycosyltransferases. Plant-expressed proteins had higher level 
of glycosylation than animal and glycosylation in plant are quite differing from 
mammalian glycosylation. While the core glycans are identical, plant glycans can 
contain xylose and fructose in linkages not found in humans (Cabanes-Machetau et al.， 
1999). 
As the glycosylation in plant is slightly different from that in animals, plant-
expressed vaccine might induce undesirable immune responses in the vaccinated host. 
Plant-produced antibodies had been demonstrated to have a greater diversity of glycan 
structures than the animal-derived antibodies, although no plant-specific antibodies was 
detected (Cabanes-Macheteau et al., 1999). We are constantly exposed to plant glycan in 
food without ill effect observed; however, regular administration of plant-specific glycan 
may also present an antigenic challenge to the immune system and thus the possibility of 
altered immunogenic in plant-derived vaccines should not be under-estimated. 
4.1.2 Model plant - Arabidopsis thaliana 
Arabidopsis thaliana which belongs to the family of Brassicaceae, is a small 
flowering plant that is widely used as a model organism in plant biology. Unlike the 
closely-related cultivated species such as cabbage and radish, A. thaliana is not of major 
agronomic significance, but it offers important advantages for basic research in genetics 
and molecular biology. 
It has the smallest genome among higher plants, which is around 125Mb and was 
completely sequenced in the year of 2000 (Arabidopsis Genome Initiative 2000) with 
extensive genetic and physical maps available for all five chromosomes which allow the 
identification of the location of the mutant genes easily. Besides, a large number of 
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mutant lines and genomic resources are available in different stock centres around the 
world. 
As the small physical size of A. thaliana, they can be easily cultivation in 
restricted areas and the prolific seed production makes large-scale mutagenesis easy. 
Besides, it has a very rapid life cycle, in optimal conditions; it takes about 6 weeks from 
germination to mature seeds. Self-pollination allows selection and identification of 
homozygous transgenic lines with single insertion through mendelian segregation means, 
on the other hand, different hybrid traits can be obtained by artificial cross-pollination. 
Efficient transformation methods utilizing Agrobacterium tumefaciens allow simple and 
easy construction of transgenic A�thaliana for studying the factors involved in gene 
expression or functions. These advantages have made Arabidopsis a model organism for 
studies of the cellular and molecular biology and thus A. thaliana was used as the plant 
expression system in this research. 
4.1.3 Strategies for expressing the transgene (MEA) in plant 
Plants sometimes grow poorly when they start to produce large amount of 
foreign proteins. Depend on promoters used, the expression of transgene in plant can be 
constitutive or tissue-specific or developmental stage-specific. In this research, seed-
specific phaseolin promoter was used for driving the expression of the recombinant 
antigen (with different fusion partners) in the protein-rich organ, seeds, in which the 
antigen could be stably accumulated. In this research, lysine-rich protein (LRP) which 
had been successfully expressed in A. thaliana at a high level, was used as a fusion 
partner with MEA for enhancing the stability of the recombinant protein expressed. On 
the other hand, by fusing with different sorting determinants, the MEA protein was 
targeted to either the lytic vacuole (LV) or the protein storage vacuole (PSV) in which 
they were separated form many of the proteolytic systems within the plant cell. 
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(a) Seed-specific phaseolin promoter 
Phaseolin is the major storage protein of common bean (Phaseolus vulgaris) seed, 
representing about 50% of the total protein in mature seeds (Ma and Bliss, 1978). It 
comprises of three polypeptide variants: a (51-53kDa), p (47-48kDa) and y (43-46kDa) 
(McLeester et al, 1973). 
The complete nucleotide sequence of P-phaseolin was determined (Sun et al., 
1981; Slightom et al,, 1983) and its promoter was also well-characterized (Sengupta-
Gopalan et al, 1985; Bustos et al., 1989). Phaseolin promoter was reported to driven 
strong expression of transgenes in plants, for example, the expression of the Brazil nut 
2S albumin in transgenic tobacco and canola seeds (Altenbach et al, 1989; Altenbach et 
al, 1992) and maize zein protein in transgenic tobacco seeds (Hoffman et al., 1987). 
The strong and seed-specific expression of this promoter makes it an important tool for 
expressing transgenes in different plant expression system. 
(b) Lysine-rich protein (LRP) as fusion partner 
The lysine-rich protein (LRP) is a seed protein with high lysine content ( � 1 1 
moP/o), it was first characterized from winged bean {Psophocarpus tetragonolobus) and 
was hypothesized to be involved in pathogenesis in plant (Wong, 2002). LRP was 
demonstrated to be able to be express and stably accumulated in transgenic plant; in 
Arabisopsis, LRP was found to express at a very high level (8-10% as total protein) 
when driven by the seed-specific phaseolin promoter (Cheung 1999) while in transgenic 
rice, high expression level (-12%) of LRP was observed under the control of a glutelin 
(Gtl) promoter (Liu, 2002). With an aim to make use of the stability of LRP in 
transgenic plants, LRP fusion constructs were constructed (Lo, Dept. of Biology, 
CUHK). The fusion construct allows the expression of LRP as a fusion partner to a 
foreign protein, stabilizing the foreign protein for its accumulation. There are two 
modifications, one with the recombinant protein fused with C-terminal of while the other 
modification with the recombinant protein inserted in the middle of LRP protein. 
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(c) Fusion protein with membrane anchor for targeting to specific vesicle 
compartments 
There are many plant expression systems that target the recombinant proteins to 
various compartments of the cell. Although with some degree of success, level of 
expression or accumulation of the recombinant proteins is extremely low. These might 
due to the low expression or high turn over rate of the recombinant proteins. Proteins 
that expressed might be targeted for degradation by the proteolytic systems in various 
compartments of the plant cell. 
Unlike mammalian and yeast cells which have a single vacuole serving for 
degradative purposes, plant cells contains two distinct vacuoles, PSV and LV, with 
distinct functions (Neuhaus and Rogers 1998). During plant seed development and 
maturation, storage proteins are deposited into PSV in which the storage proteins can be 
stably accumulated to high levels, and it serves as a nutrient store for use by the embryo 
during germination. The high stability and accumulation level of the seed proteins make 
the PSV an attractive compartments for high level expression and stable storage of 
various recombinant proteins (Jiang and Sun, 2002). 
PSV is a compound organelle with distinct compartments, including the matrix, 
globoid and crystalloid, which provide distinct and separated environments for different 
functions (Jiang et al,, 2001; Jiang and Rogers 2001). There are active proteases present 
in the PSV globoid which may function as a LV for processing storage within the PSV. 
Targeting recombinant proteins to specific sub-compartments/ environments within the 
seed PSV may allow the accumulation of the proteins at the most optimal manner. 
Various vacuolar sorting determinants, for example, the N-terminal, internal and C-
terminal sorting determinants, were described in plant proteins (Neuhaus and Rogers 
1998). For sorting of integral membrane proteins, sorting signals to each of the three 
vesicular pathways are derived from specific transmembrane domain (TMD) and 
cytoplasmic tail (CT) sequences (Jiang and Rogers 1998; Jiang and Rogers 1999a; Jiang 
and Rogers 1999b; Jiang et al., 2000). Moreover, these sequences were demonstrated to 
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have the ability to direct reportor proteins to specific vacuolar compartments via 
different vesicular pathways in plant cells (Jiang and Rogers 1998). 
In this experiment, unique TMD and CT sequences are used as anchors for 
delivering recombinant proteins via distinct vesicular transport pathways to specific 
vacuolar compartments where stable accumulation can occur. Under the control of 
phaseolin promoter, fusion containing BP-80 TMD/CT sequences would be directed to 
PSV globoid in transgenic seeds via Golgi (Jiang and Rogers 1998; Jiang and Rogers 
2000) while fusion containing the BP-80 TMD and a-TIP (tonoplast intrinsic protein) 
CT would be targeted to the PSV crystalloid via a direct ER to PSV pathway (Jiang and 
Rogers 1998; Jiang and Rogers 2000). Targeting proteins to PSV via a direct ER to PSV 
pathway bypassing Golgi will have an additional advantage for expression of 
pharmaceutical proteins as the plant specific complex N-glycans which are highly 
immunogenic in human can be eliminated (Jiang and Sun 2002). 
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4.2 MATERIALS 
4.2.1 Bacterial Strains 
1. Agrobacterium tumefacien, GV310 l/pMP90 
4.2.2 Arabidopsis strain 
Arabidopsis thaliana ecotype Columbia-0 
4.2.3 Chemicals 
1. Benzylaminopurine Sigma B3408 
2. Metro-mix soil Hummert 10-0325 
3. 4-morpholineethanesulfonic acid (MES) Boehringer Mannheim 223749 
4. Murashige and Skoog (MS) salts and vitamin mixture Gibco BRL 10632-016 
5. Phenylmethylsulfonyl fluoride (PMSF) Sigma P7626 
6. Potassium hydroxide Sigma P5958 
7. S i l w e t T M L-77 Lehle seeds VIS-01 
8. Sucrose Sigma SI888 
9. Leupeptin 
4.2.4 Antibiotics 
1. Rifampicin Sigma R3501 
2. Gentamycin Sigma 1264 
4.2.5 Nucleic acids 
1. pBluescript II KS (+) Stratagene 212207 
2. pBI 121 vector From Dr. Lam 
3. pBI221 -491 From Dr. Jiang 
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4. pBI221-526 From Dr. Jiang 
5. pET32a+MIH From Prof. Sun 
6. pBluescript/LRPI/P30 Constructed by Lo CS. 
4.2.6 Solutions 
1. Infiltration medium/ Dissolve 2.2g MS salts, 50g sucrose and 0.5g MES in Milli-
IL Q. Adjust to pH 5.7 with KOH and sterilize by autoclaved. 
Add 0.044|iM benzylaminopurine and 200jil Silwet L-77 
before use. 
2.Membrane protein 50mM Tris-HCl, pH 7.4, ISOmM NaCl, ImM EDTA, 
extraction buffer 0. ImM PMSF, 5pig/ml Leupeptin and 1% SDS 
3. MS agar (IL) 4.4g MS salt, 30g sucrose and 0.5g MES, dissolved in Milli-
Q and adjust pH to 5.7 with IN KOH. Add 9g/L agar and 
sterilize by autoclaved. 
4. MS+Kan agar MS agar was prepared and added with filter-sterilized 
kanamycin to final concentration of 50jig/ml 
5. Total seed protein 0.25M NaCl, 0.05M NaP04, pH 7.0, with the addition of IX 
extraction buffer Complete protease inhibitor cocktail before use 
6. YEP medium lOg tryptone, lOg yeast extract and 5g NaCl. Fill up to IL 
with distilled water. Autoclave. 
4.2.7 Enzymes 
Xhol Promega R616 A 
Ndel New England Biolab 111S 
EcoRI Promega R601A 
Xbal Promega R618G 
Apal Amersham 
Sspl New England Biolab 132S 
Sad Promega R606A 
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4.2.8 Primers 
(a) Primers for subcloning 
Name of primer Sequence (5，to 3，） Tm/ 
MF 759 TCA CTC CAG GTG GGA GC GGA C 7 ^ 
MF 760 GGC TCG AGT TCT CCA GGT GGG AGG CGG ^ 
ACAC 
MF770 CGA ATA GCA TAT GCA ATG GGA AAC AAC W 
GTG GCC AG 
MF771 CGG AAT TCT GTC TCC AGG TGG GAG GCG ^ 
GAC AC 
MF 772 CAA GCT TCC GAT CTA GTA ACA TAG ATG 70 
ACA CC 
MF 773 GGA ATT CGA CTA CAA GGA CGA CGA TG W 
MF620 GAG CGT CTA CAT GGG TGT TTT ^ 
* Tm was calculated as (A+T) x2 + (C+G) x 4 
(b) Sequencing primers 
Name of primer Sequence (5，to 3，） Tm / ®C 
MF 761 CCA TCC ATC CAG AGT ACT ACT ^ 
MF 762 ATT ATA CTG TTA CAT GGT CGG ^ 
MF 839 TTA CAT GCG AGA CGC ATC TTC TA ^ 
MF 840 GCC ACG TTG TTT CCC ATT GC ^ 
NOS CAT CGC AAG ACC GGC AAC AGG ^ 
* Tm was calculated as (A+T) x2 + (C+G) x 4 
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4.3 METHODS 
4.3.1 Construction of plant expression vectors 
4.3.1.1 Strategy 1: Lysine-rich protein (LRP) fusion 
Based on previous study (Cheung, 1999), lysine-rich protein was successfully 
expressed in transgenic Arhidopsis thaliana. So, for strategy 1, the lysine-rich protein 
was used as a fusion partner with the transgene (MEA). There are two modifications, 
one with the recombinant protein fused with C-terminal of LRP and with a His-tag 
behind it. The other modification with the recombinant protein inserted in the middle of 
LRP protein. The secondary structure of LRP was predicted from the coding sequence in 
which the loose random coil in the middle of LRP was chosen as site for insertion since 
it may affect the overall conformation with minimal effect. 
For the construction of the LRP-MEA-his-tag fusion protein, The plasmid 
pCRII-TOPO-MEA and pBluescript/LRPI/P30 (constructed by Lo, Chi-sing, Jack) were 
used as the starting materials. The P30 in the recombinant plasmid was replaced with the 
MEA which was amplified by PGR from the plasmid pCRII-TOPO-MEA. This fusion 
product was then subcloned into a plant expression vector pBI121 under the control of a 
seed-specific phaseolin promoter for high level expression of recombinant MEA in plant 
seeds. The procedures were outlined in Figure 4.1A and 4. IB 
For the modification 2，pBI121/Phaseolin Promoter/ LRPIIA/ MEA/ Phaseolin 
terminator, the transgene (MEA) was inserted in the middle of the lysine-rich protein. 
The plasmid pCRII-TOPO-MEA and pBluescript/LRPIIA (constructed by Lo, Chi-sing, 
Jack) were used as the starting materials. The MEA gene was amplified from the pCRII-
TOPO-MEA and then subcloned in the pBluescript/LRAIIA vector. Then, the LRP-
MEA fusion was cloned into a plant expression vector pBI121 under the control of a 
seed-specific phaseolin promoter for high level expression of recombinant MEA in plant 
seeds. The procedures were outlined in Figure 4.2A and 4.2B. 
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Figure 4.1A Construction of pBI121/phaseolin promoter/ LRPI/ MEA/ Phaseolin 
terminator. 
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Figure 4.2A Construction of pBI121/phaseolin promoter/ LRPIIA/ MEA/ Phaseolin 
terminator. 
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Figure 4.2B Construction of pBI121/phaseolin promoter/ LRPIIA/ MEA/ Phaseolin 
terminator. 
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a) Construction of pBI121/ Phaseolin Promoter/ LRPl/ MEA/ his-tag/ 
Phaseolin Terminator 
Plasmid pCRII-TOPO-MEA and pBluescript/ LRPI/P30 were used as the starting 
materials and were purified as described in 2.3.1.a. MEA fragment was amplified from 
pCRII-TOPO-MEA by PGR (as in 2.3.Lb) using gene specific primers (MF734 and 
MF760) with a Xhol site introduced in the 3'-terminal of the fragment and the stop 
codon was removed. This fragment was purified and was restriction digested with Xhol 
(as in 2.3.1c). Similarly, recombinant plasmid, pBluescript/ LRPl/ P30, was restriction 
digested with Ncol, followed by subjecting to fill-in reaction (as described in 2.3.Ld). 
The fill-in vector was further digested with Xhol. After purification, it was ligated with 
the MEA DNA fragment and transformed into DH5a competent cells (as in 2.3.1.h) for 
constructing recombinant plasmid pBluescript/ LRPl/ MEA. 
A vector (pBK/ PP/ PT) containing the phaseolin promoter and the phaseolin 
terminator was obtained from Prof. Sun and thr recombinant plasmid, pBluescript/ 
LRPl/ MEA were restriction digested with AccI (as in 2.3.1c). The LPRI/ MEA 
fragment was released from pBluescript/ LRPl/ MEA and the AccI cut vector were 
resolved by agarose gel electrophoresis and then purified (as in 2.3.1.e). They were 
ligated and was transformed into DH5a competent cells (as in 2.3.1.h) for the 
construction of recombinant plasmid of pBluescript/ PP/ LRPl /MEA/ PT. 
The expression cassette was finally sub-cloned into the binary vector, pBI121. 
The expression cassette (-PP/ LRPl/ MEA/ PT-) was retrieved by restriction digestion of 
pBluescript/PP/ LRPl /MEA/ PT with Hindlll (as in 2.3.1c) and then resolved by 
electrophoresis in 0.8% agarose gel. The expression cassette was purified, then 
subcloned into Hindlll cut pBI121 as described in 2.3.1.f. and transformed into DH5a 
competent cells (as in 2.3.l.h) for constructing the recombinant plasmid of pBI121/ PP/ 
LRPl/ MEA /PT. Sequences of the putative plasmid was confirmed by cycle sequencing 
(as described in 2.3.l.j) and this recombinant plasmid were ready for transforming plants 
via agrobacterium-mediated transformation. 
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b) Construction of pBI121/ Phaseolin Promoter/ LRPIIA/ MEA/ Phaseolin 
Terminator 
Plasmid pCRII-TOPO-MEA and pBluescript/ LRPIIA were used as the starting 
materials and were purified as described in 2.3.La. MEA fragment was amplified from 
pCRII-TOPO-MEA by PCR (as in 2.3.l.b) using gene specific primers (MF734 and 
MF735) and was purified (as described in 2.3.l.e). Recombinant plasmid, pBluescript/ 
LRPIIA, was restriction digested with Ncol (as in 2.3.1c), followed by subjecteing to 
fill-in reaction as described in 2.3.l.d. The fill-in vector was ligated with the LRPIIA/ 
MEA fragment as described in 2.3.l.f and was transformed into DH5a competent cells 
(as in 2.3. l.h) for the construction of recombinant plasmid pBluescript/ LRPIIA/ MEA. 
Recombinant plasmid, pBK/ LRPIIA/ MEA, was restriction digested with AccI 
(as in 2.3.1c and was resolved in 1% agarose gel. The LPRI/ LRPIIA/ MEA fragment 
released from pBluescript/ LRPIIA/ MEA was purified (as in 2.3.l.e) and then 
cubcloned into AccI cut pBluescript/ PP/PT (prepared in 4.3.1.1.a) as described in 
2.3. l.f. for constructing recombinant plasmid of pBluescript/ PP/ LRPIIA / MEA/ PT. 
The expression cassette was finally sub-cloned into the binary vector, pBI121. 
The expression cassette (-PP/ LRPIIA/ MEA/ PT-) was retrieved by restriction digestion 
of p B l u e s c r i p t / P P / L R P I I A /MEA/ PT with Hindlll as described in 2.3.1c., then resolved 
by electrophoresis in 0.5% agarose gel and was purified (as in 2.3. Le). It was subcloned 
into Hindlll cut pBI121 as described in 2.3.l.f. for the construction of recombinant 
plasmid of pBI121/ PP/ LRPIIA/ MEA /PT. Sequences of the putative plasmid was 
confirmed by cycle sequencing (as described in 2.3.1.j) and it was ready for 
transforming plants via agrobacterium-mediated transformation. 
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4.3.1.2 Strategy 2: Fusion proteins with membrane anchor for vesicle targeting to 
specific vesicle compartments 
Strategy 2 is to target the recombinant fusion protein to specific vesicle 
compartment to the plant cell. Till now, there are many plant expression systems that the 
expression level of the recombinant proteins is extremely low. This may due to low 
expression level or more likely, because the protein that expressed are targeted for 
degradation by proteolytic systems of plants and consequently unstable and have a high 
turn over rate. In this experiment, unique transmembrane domain and cytoplasmic tail 
sequences are used as anchors for delivering recombinant proteins via distinct vesicle 
transport pathways to specific vesicular compartments where stable accumulation can 
occur. Constructs derived from 491 direct recombinant protein to lytic vesicle via golgi 
while constructs derived from 526 direct recombinant protein from the endoplasmic 
reticulum directly to the protein storage vesicle bypassing the golgi, which would avoid 
plant golgi-specific modification including N-linked glycosylation�These constructs 
were under the control of either the seed-specific phaseolin promoter. 
The plasmid pCRII-TOPO-MEA was used as the starting material in this 
experiment. The MEA gene was amplified from the plasmid and then subcloned together 
with the vesicle-targeting sequence and the signal peptide into a plant expression vector 
pBI121 under the control of a seed-specific phaseolin promoter for high level expression 
of recombinant MEA in the lytic or plant storage vesicle of the plant cells. The 
procedures were outlined in Figure 4.3A-D. 
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Figure 4.3A Construction of pBI121/phaseolin promoter/ SP/ MEA(J)/ 491 or 526/ 
NOS. 
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Figure 4.3B Construction of pBI121/phaseolin promoter/ SP/ MEA(J)/ 491 or 
526/NOS. 
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Figure 4.3C Outline of the construction of pBI121/phaseolin promoter/ SP/ MEA(J)/ 
491 or 526/ NOS. 
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Figure 4.3D Construction of pBI121/phaseolin promoter/ SP/ MEA(J)/ 491 or 526/ 
N O S . 
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a) Construction of pBI121/Phaseolin Promoter/ SP/ MEA(J)/ 491/ NOS 
terminator 
Plasmid pCRII-TOPO-MEA and pBluescript II SK (-) was purified as described 
in 2.3.La. MEA(J) fragment was amplified from pCRII-TOPO-MEA by PCR (as in 
2.3.Lb) using gene specific primers (MF770 and MF771) with a Ndel site introduced in 
the 5'-terminal and a EcoRI site introduced in the 3'-terminal with the stop codon 
removed. The MEA DNA fragment was then ligated with Sma I cut pBluescript as 
described in 2.3.Lf. for construction of recombinant plasmid pBluescript/ MEA(J). 
Plasmid pBI221-491 was obtained from Dr. Jiang. The 491 fragments was 
amplified from the pBI221-491 by PCR (as in 2.3.l.b) using gene specific upper primer 
and NOS terminator primer (MF773 and MF772) and was then subcloned into the 
EcoVI cut pBluescript II SK (-) for constructing recombinant plasmid, pBluescript/49L 
Recombinant plasmids, pBluescript/ MEA(J) and pBluescript/ 491, were 
restriction digested with EcoRI (as in 2.3.1c). The 491 fragment released from the EcoRI 
cut pBluescript/491 and the EcoRI cut pBluescript/ MEA(J) were purified from agarose 
gel after electrophoresis (as in 2.3.Le). They were then ligated and transformed into 
DH5a competent cells (as in 2.3.l.h) for the construction of recombinant plasmid, 
pBluescript/ MEA(J)/ 491. 
A vector (pBK/PP/SP/PT) containing the phaseolin promoter, signal peptide and 
the phaseolin terminator was obtained from Sun, CUHK, and pBluescript/ MEA(J) were 
restriction digested with Ndel and Hindlll (as in 2.3.1c). and were resolved by gel 
electrophoresis on 0.8% agarose gel. The MEA(J) fragment (~400bp) released from 
pBluescript/MEA(J) and the DNA fragment carrying the phaseolin promoter and signal 
peptide (~1.3kb) released from pBK/PP/SP/PT were purified (as in 2.3.Le) and then co-
ligated with Hindlll cut pBluescript as described in 2.3.l.f. for constructing the 
recombinant plasmid,pBluescript/ PP/SP/MEA(J). 
For construction of the pBluescript/PP/SP/MEA(J)/491/NOS, pBluescript 
/PP/SP/MEA(J) and pBluescript/ MEA(J)/491 were restriction digested with Apal and 
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Hindlll (as in 2.3.1c). The MEA(J)/491 fragment released from pBluescript/ MEA(J) 
/491 and the DNA fragment carrying the phaseolin promoter, signal peptide and MEA(J) 
(�1.4kb) released from pBK/PP/SP/MEA(J) were purifed from the agarose gel as in 
2.3.I.e. and then co-ligated with Hindlll cut pBluescript as described in 2.3.1.f. for 
construction of recombinant plasmid, pBluescript/ PP/ SP/ MEA(J)/ 491/NOS. 
The expression cassette was finally sub-cloned into the binary vector, pBI121. 
The expression cassette (-PP/SP/MEA(J)/491/NOS-) was retrieved by restriction 
digestion of pBluescript/PP/SP/MEA(J)/NOS with Hindlll (as in 2.3.1c) and then 
subcloned into Hindlll cut pBI121 as described in 2.3.l.f. for construction of 
recombinant plasmid ofpBI121/ PP/ SP/ MEA(J)/ 491/ NOS. Sequences of the putative 
plasmid was confirmed by cycle sequencing (as described in 2.3.l.j) and this 
recombinant plasmid were ready for transforming plants via agrobacterium-mediated 
transformation. 
b) Construction of pBI121/Pliaseolm Promoter/ SP/ MEA(J)/ 526/ NOS 
terminator 
Procedures for the cloning of the pBI121/Phaseolin Promoter/ SP/ MEA(J)/ 526/ 
NOS was the same as described in 4.3.L2.ai, except one of the starting material 
(pBI221-491) was replaced by pBI221-526. 
4.3.1.3 Construction of transgenic control pBI121/phaseolin promoter/ MEA/ 
phaseolin terminator 
For the construction of recombinant plasmid pBI121/ PP/ MEA/ PT, the plasmid 
pBluescript/ phaseolin promoter/ phaseolin terminator and pCRII-TOPO-MEA were 
used as the starting material. The MEA gene was amplified from pCRII-TOPO-MEA, 
and then subcloned into AccI cut, fill-in pBluescript/ phaseolin promoter/ phaseolin 
terminator. This expression cassette was finally transformed into the Hindlll cut binary 
vector, pBI121. The procedures were outlined in Figure 4.4. 
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Plasmid pBluescript/PP/PT and pCRII-TOPO-MEA were purified as described in 
2.3.1.a. MEA fragment was amplified from pCRII-TOPO-MEA by PCR (as in 2.3.l.b) 
using gene specific primers (MF734 and MF759) and then suncloned into the AccI cut, 
fill-in pBluescript/ PP/ PT for construction of recombinant plasmid pBluescript/ PP/ 
MEA/ PT. Sequences of the putative plasmid was confirmed by cycle sequencing (as 
described in 2.3.l.j). 
The expression cassette was finally sub-cloned into the binary vector, pBI121. 
The expression cassette (-PP/ MEA/ PT-) was obtained by restriction digestion of 
pBluescript/ PP/ MEA/ PT with Hindlll (as in 2.3.1c)�The xpression cassette was 
resolved by agarose gel electrophoresis and was purified (as in 2.3.l.e). It was ligated 
with Hindlll cut pBI121 as described in 2.3.l.f. and was transformed into DH5a 
competent cells (as in 2.3.l.h). Recombinant plasmid of pBI121/ PP/ MEA/ PT was 
purified from positive transformants as described in 2.3.1.i and the sequences of the 
putative plasmid was confirmed by cycle sequencing (as described in 2.3.1.j) and this 
recombinant plasmid were ready for transforming plants via agrobacterium-mediated 
transformation. 
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Figure 4.4. Construction of pBI121/ Phaseolin promoter/ MEA/ PT 
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4.3.2 Agrobacterium-mediated transformation oi Arabidopsis thaliana by vaccum 
infiltration 
a) Preparation of competent cell for Agrobacterium GV3101 
Starter culture was prepared by inoculating colony from a freshly streaked YEP 
Genta25 agar plate and shaked at 250rpm, 28°C for 2 days until a dense culture with 
the optical density at 600nm over 2.0. 8ml of the starter culture was seeded into 400ml 
pre-warmed YEP Rif^^ Genta^^ broth. The culture was shaken vigorously at 28°C until 
the ODeoo was between 0.5-1.0. The culture was then chilled on ice for 15 minutes. The 
cells were harvested by centrifugation at 4000xg for 15 minutes at 4°C. The pellet was 
washed twice with 400ml and 200ml ice-cold sterile milli-Q water with the same 
centrifugation conditions. The washed pellet was resuspended in 4ml pre-chilled 10% 
glycerol, transferred to a 15ml falcon tube and the spun again with the same 
centrifugation conditions. Finally the pellet was resuspended in 0.4ml pre-chilled 10% 
glycerol. It was divided into 4 0 j L i l aliquots and stored at 一70°C as stock for electro-
competent cells. 
b) Transformation of electro-competent agrobacterium with plant expression 
vector by electroporation 
An aliquots of electro-competent agrobacteria was thawed on ice with the 
addition of 0.1|Lig of recombinant plasmid. It was incubated on ice for 1 minute. It was 
then transferred to a pre-chilled 0.2cm electroporation cuvette carefully and the 
suspension was shaken to the bottom of the cuvette without introducing any bubbles� 
The cuvette was wrapped with absorbent paper to ensure no water condensed in its 
surface. It was then inserted into sample position of gene pulser apparatus (BioRad) 
which the conditions were set as 25^iF, 2.5kV and 600ohms. An electrical pulse was 
applied. 
1ml SOC medium was added to resuspend the cells in the cuvette. The cell 
suspension was transferred into a 15ml falcon tube and was shaked at 28°C for 2 hours. 
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Cells were harvested by short spin at high speed and finally resuspended with 200)il SOC 
medium, afterwards spreaded on three YEP Genta^^ plates. The plates were 
allowed to incubate at dark at 28°C for 2 days to develop transformed agrobacterium 
colonies. 
c) PCR screening for agrobacterium carrying the desirable plant expression 
vector 
Transformed agrobacteria are able to form colonies on YEP plates under 
kanamycin selection. Cells were picked from individual colonies and resuspended into 
10]Lil milli-Q water in a PCR tube as template for PCR reactions. 40^1 PCR master mix, in 
which specific primers were included, was added to each PCR reaction (as described in 
2.3.1.b). The PCR products were subjected to agarose gel electrophoresis and the size of 
the EtBr-stained PCR products was visualized under UV illumination. Gel photos were 
taken as record. 
d) Vacuum infiltration 
Arabidopsis thaliana ecotype Columbia-0 seeds were kept at 4°C for at least 2 
days as imbition period to synchronize germination. It was then sowed on wet Metro-
Mix soil and was allowed to grow on plastic pot. They were placed in walk-in chamber 
of the department of Biology, CUHK, in which the conditions was set as 22�C and 16-
hour light (daylight, 4000k lux) and 8-hour dark. After 4 to 6 weeks, plants at flowering 
stage were ready for agrobacterium-mediated transformation. 
A single colony of transformed agrobacterium was picked and inoculated into 
15ml YEP Rif50 Genta^^ Kan^ ® medium. It was shaked overnight at 28�C. 5ml of the 
overnight culture was seeded as starter culture to 500ml pre-warmed YEP Genta^^ 
medium and shaken at 28�C for overnight. Cells from overnight culture were 
harvested by centrifligation at 6000rpm at 4°C for 20 minutes (JA-20 rotor, Beckman). 
The bacterial pellet was resuspended in IL of infiltration medium. The suspended 
culture was transferred into a beaker inside a vacuum desiccator. 
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Plants in the plastic pots (4 plants per pot) were inverted and immersed into the 
agrobacterium suspension. The entire plants should be coved with medium to ensure 
successful transformation. Vacuum was applied for 10 minutes. These infiltrated plants 
were then taken out and dried. It was set upright by plastic roll and put back to the walk-
in chamber under the same conditions as described before. Watering to the infiltrated 
mature plants was stopped and seeds were harvested individually and designated as the 
number of plants. 
4.3.3 Screening of homozygous transgenic plants with single insertion of 
transgene 
Around lOO^ il of seeds from individual plant (TO) was transferred to a 1.5ml 
sterile eppendorf tube and sterilized under laminar hood. 1ml Chlorox was added and 
then vortexed for 3-5 minutes. Seeds were spun down by brief centrifugation and were 
further washed with 1ml sterile water for 5 times. The sterilized seeds were then spread 
onto M S Kan5o ^ g^^ plates. These plates were incubated in 4。C for 2 days as imbition 
period to synchronize germination, and then placed in growth chamber at defined 
conditions. Green transformants (Tl) were selected and were allowed to grow and self-
cross. 
Seeds from mature Tl plants were harvested individually and sterilized. They 
were plated on new M S Kan^^ plates in array order and placed under growth chamber at 
defined conditions to select for single insertion of the transgene in the plant genome. The 
number of green transformants and yellow seedlings was counted and chi-square test 
was performed to select for 3: 1 ratio of green to yellow seedlings. Significance level 
was set at 0.05 and the critical value was calculated as 3.841. Green transformants (T2) 
with acceptable chi-square values were selected and were transferred to plastic pots with 
wet Metro-Mix soil for allowing grow and self-cross. Seeds from T2 plants were 
harvested and allowed to development into homozygous transgenic plants (T3) showed 
by 100% kanamycin-resistant phenotype on M S agar plates under antibiotic selection. 
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4.3.4 Detection of MEA or MEA fusion protein in transgenic plants 
As all of the plant expression cassettes transformed were driven by the seed-
specific promoter, for the detection of the accumulation of the recombinant M E A 
antigen in transgenic plants, seed proteins were extracted from mature seeds from A. 
thaliana of homozygous lines and was subjected to western blot analysis with anti-MEA 
antibodies. 
a) Extraction of seed protein (Soluble and membrane fractions) 
Mature Arabidopsis seeds of around 0.05g were grinded with a little bit broken 
glass and total seed protein was extracted with 0.5ml total seed protein extraction buffer. 
The homogenate was then centrifiiged at 14,000 rpm for 15 minutes at 4°C. After 
removal of the top lipid layer, the clear supernatant was transferred to a new Eppendorf 
tube (soluble fractions of seed proteins). The pellet was then mixed with 150)il 
membrane protein extraction buffer, after boiling for 10 minutes, the homogenate was 
centrifuged at 14,000 rpm for 15 minutes and the supernatant was transferred to another 
new Eppendorf tube (seed proteins of membrane fraction). Protein concentration was 
then determined by Bio-rad protein assay (Braford) using bovine serum albumin (BSA) 
as standard. 
b) Western blot of seed protein by anti-serum against HisMEA 
50|Lig of seed protein was mixed with ！4 volume of 5x sample loading buffer and 
were boiled for 8 minutes. After cooling, samples were loaded on 12.5% SDS-
polyacrylamide gel for electrophoresis (as in 2.3.3.b), then transblotted onto PVDF 
membrane and then probed with anti-serum against HisMEA prepared in Chapter 2 (pre-
absorbed with lOX total seed protein of wild-type (Col-0) A. thaliana) at the titre 
of. 1:1000. After incubation for overnight, the membranes were washed and hybridized 
with 1:2000 titer of secondary antibody conjugated with HRP (goat anti-mouse IgG 
antibody). Signals were detected with ECL detection system as described in 2.3.3 .a. 
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4.4 Results 
4.4.1 Construction of plant expression vectors and transgenic A, thaliana 
(a) Construction of pBI121/ phaseolin promoter/ LRPI or LRP II/ MEA/ 
Phaseolin terminator 
For construction of pBI121/ phaseolin promoter (PP)/ LRPI/ MEA/ Phaseolin 
terminator (PT), the M E A gene was amplified from the pCRII-TOPO-MEA by PCR using 
specific primers (MF 734/ 760) with the introduction of a Xhol site at the 3' end。It was 
then purified and subjected to restriction digestion with Xhol. The recombinant plasmid 
pBluescript/ LRPI/ P30 was digested by Ncol, followed by fill-in reaction. After desalted 
by ethanol precipitation, it was further digested with Xhol for releasing the P30 gene 
fragment (~700bp). The Xhol cut M E A D N A fragment was then subcloned the Ncol cut, 
fill-in and Xhol cut pBluescript/ LRPI (i.e. P30 in the pBluescript/ LRPT/ P30 was 
replaced by MEA). The M E A gene was in-frame fused with the C-terminal LRP with an 
enterokinase cleavage site inbetween. The LRP-MEA fusion (〜950bp) was released from 
pBluescript/ LRPI/ MEA-1 by AccI digestion and then sub-cloned into AccI cut 
pBluescript/ PP/ PT for the construction of pBluescript/ PP/LRPI/ MEA/ PT. The 
expression cassette ( ~PP/LRPI/MEA/PT~; of around 3kb) was retrieved from pBluescript/ 
PP/ LRPI/ MEA/ PT-1 by restriction digestion with Hindlll and subcloned into Hindlll cut 
binary vector, pBI121 for construction ofpBI121/PP/ LRPI/ M E A / PT. 
For construction ofpBI121/ PP/ LRPIIA/ MEA/ PT, the M E A gene was amplified 
from the pCRII-TOPO-MEA by PCR using gene specific primers (MF 734/ 735) 
(Figure4.9) and was ligated into the Ncol cut, fill-in the pBluescript/ LRPIIA. The M E A 
gene was in-frame inserted into the middle of the LRP. The recombinant plasmid, 
pBluescript/ LRPIIA/ MEA-18, was restriction digested with AccI for releasing the LRP-
M E A fusion (~850bp) (Figure 4.10) which was then subcloned into AccI cut pBluescript/ 
P P / PT f o r c o n s t r u c t i o n o f pBluescript/ PP/ LRPIIA/ M E A / PT. The e x p r e s s i o n c a s s e t t e 
(~PP/LRPIIA/MEA/PT~; of around 3.2kb) was retrieved from pBluescript/ PP/ LRPIIA/ 
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M E A / PT-4 by restriction digestion with Hindlll and subcloned into Hindlll cut binary 
vector, pBI121 for construction ofpBI121/PP/ LRPIIA/ M E A / PT. 
The nucleotide sequence ofpBI121/PP/ LRPI/ M E A / PT and pBI121/PP/ LRPIIA； 
M E A / PT was read and confirmed by cycle sequencing with sequencing primers. The 
nucleotide sequences were edited by DNasis's Contig Manger program and shown in 
Figure 4.5 and 4.6. 
(b) Construction of pBI121/ PP/ SP/ MEA(J)/ 491 or 526/ PT 
For construction ofpBI121/ PP/ SP/ MEA(J)/ 491 or 526/ PT, the M E A gene was 
firstly amplified from the pCRII-TOPO-MEA by PGR using specific primers (MF 770/771) 
with the introduction of a Ndel site at the 5 ’ end and an EcoRI site at the 3 ’ end and was 
then subcloned into Smal cut pBluescript II SK (-) for the construction of pBluescript/ 
MEA(J). The 491 or 526 fragment together with the N O S terminator (~500bp and 〜400bp, 
respectively) was amplified by PGR using specific primers (MF 772/773) with the 
introduction of a EcoRI site at the 5' end and an Hindlll site at the 3' end , just beyond the 
N O S terminator and was then subcloned into EcoRV cut pBluescript II KS(+). The 
recombinant plasmid pBluescript/ 491-5 or pBluescript/ 526-5 was digested by EcoRI for 
retrieving the 491 or 526 fragment together with the N O S terminator (〜600bp) and was 
then subcloned into EcoRI cut pBluescript/ M E A (J)-l for the construction of pBluescript/ 
M E A (J)/ 491 or 526/NOS. 
On the other hand, the phaseolin promoter and its signal peptide (〜1400bp) and the 
MEA(J) D N A fragment (〜500bp) were retrieved pBluescript/ PP/ SP/PT and pBluescript/ 
MEA(J)-1 respectively by restriction digestion with Ndel and Hindlll. These fragments 
were then co-ligated into Hindlll digested pBluescript II SK (-) for construction of 
pBluescript/ PP/ SP/ MEA(J). 
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The expression cassette (〜PP/ SP/ MEA(J)/ 49lor 526/ NOS〜)was constructed by 
co-ligation of Apal and Hindlll retrieved D N A fragments from pBluescript/ PP/ SP/ 
MEA(J)-2 (~350bp) and pBluescript/ MEA(J)/ 491/ NOS-2 (〜850bp) or pBluescript/ 
MEA(J)/ 526/ NOS-2 (〜800bp) into Hindlll cut pBluescript. After confirming the D N A 
sequences by cycle sequencing , the expression cassette (〜PP/ SP/ MEA(J)/ 491 or 526/ 
NOS; of around 2.2kb) was retrieved from pBluescript/ PP/ SP/ MEA(J)/ 491/ NOS-1 or 
pBluescript/ PP/ SP/ MEA(J)/ 526/ NOS-1 by restriction digestion with Hindlll (Figure 
4.17 and 4.18) and subcloned into Hindlll cut binary vector, pBI121 for construction of 
pBI121/PP/ SP/ MEA(J)/ 491 or 526/NOS. 
The nucleotide sequence of these recombinant plasmids, pBI121/PP/ SP/ MEA(J)/ 
491 or 526/ NOS, was read and confirmed by cycle sequencing with sequencing primers. 
The nucleotide sequences were edited by DNasis's Contig Manger program and shown in 
Figure 4.7 and 4.8. 
(c) Construction of transgenic control pBI121/ PP/ MEA/ PT 
For construction of transgenic control pBI121/ PP/ MEA/ PT, the full-length 
sequence of M E A gene was amplified from the pCRII-TOPO-MEA by PCR using gene 
specific primers (MF 734/ 759) and was ligated into AccI cut, fill-in pBluescript/ PP/PT 
vector . The expression cassette (〜PP/MEA/PT〜；of around 3kb) was retrieved from the 
recombinant plasmid pBluescript/ PP/ M E A / PT-3 by restriction digestion with Hindlll 
and subcloned into Hindlll cut binary vector, pBI121 for construction of pBI121/ PP/ 
M E A / PT. The nucleotide sequence of pBI121/PP/ MEA/ PT, was read and confirmed by 
cycle sequencing with sequencing primers. 
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(d) Agrobacterium-mt{!i\2dQd. transformation of A thaliana 
For construction of transgenic A. thaliana, different plant expression vectors 
(prepared in 4.4.1a-c) were transformed into Agrobacterium by electroporation so that 
the binary system of Agrobacterium could be utilized for plant transformation. 
SuccessfUlness of the transformation of the plant expression vector into the 
Agrobacterium was confirmed by the positive selection on selection media and 
also by PCR screening with the total lysate of transformed Agrobacterium using gene 
specific primers. 
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A c c I 
1 GTC TAC I3 !g GGT GTT TTC ACA TAT GAG GAT GAA ACC ACT 39 
M G V F T Y E D E T T 
4 0 TCA CCA GTG GCT CCT GCT ATC CTT TAC AAA GCA ATA GTT 79 
S P V A P A I L Y K A I V 
8 0 AAA GAT GCT GAT AAC ATC TTT CCA AAG GCT GTT GAT TCC 1 1 9 
K D A D N I F P K A V D S 
12 0 TTT AAG AGT GTT GAA ATT GTT GAG GGA AAT GGT GGT CCT 1 5 9 
F K S V E I V E G N G G P 
160 GGA ACC ATC AAG AAG ATC TCT TTT GTT GAG GAT GGG GAA 1 9 9 
G T I K K I S F V E D G E 
2 0 0 AGC AAG TTT GTG TTG CAC AAG ATT GAG TCA ATT GAT GAG 2 3 9 
S K F V L H K I E S 工 D E 
2 4 0 GCT AAT TTG GGA TAC AGC TAC AGC ATA GTT GGT GGT GCT 2 7 9 
A N L G Y S Y S I V G G A 
2 8 0 GCT TTG CCA GAC ACA GTG GAG AAG ATT ACA TTT GAG TCC 3 1 9 
A L P D T V E K I T F E S 
3 2 0 AAA TTG AGT GCT GGA CCT TCT GGA GGC TCT GTT GGG AAA 3 5 9 
K L S A G P S G G S V G K 
3 6 0 CTC ACT GTG AAA TAC CAA ACC AAA GGA GAT GCT GAG CCC 3 9 9 
L T V K Y Q T K G D A E P 
4 0 0 AAT GAA GAG GAA CTC AAA GTT GGC AAA GCC AAG GGT GAT 4 3 9 
N E E E L K V G K A K G D 
4 4 0 GCT CTC TTC AAG GCT GTT GAG GCT TAC CTT TTG GCC CAT 4 7 9 
A L F K A V E A Y L L A H 
EK c l e a v a g e s i t e f i l l i n - N c o i 
4 8 0 CCT GAA TAC AAT Q X ^ l S ^ G ^ I S c O a GCC ATG GCA ATG 5 1 9 
P E Y N D D D D K H A M 
52 0 GGA AAC AAC GTG GCC AGG TGC TCC TAC GGC GCC GAC AGC 5 5 9 
G N N V A R C S Y G A D S 
560 ACC CTG GGC CCA GTG CCT GGT GGT GGA CCA CCT CAG CAG 5 9 9 
T L G P V P G G G P P Q Q 
600 CGC GCC GCC CAC GTG CCT GTG CCC GAC TTC AGC CAG CCT 6 3 9 
R A A H V P V P D F S Q P 
640 GGT GGT GGT CCA TGC AAC GAG AAG TCC TTC AAG GAC ATC 6 7 9 
G G G P C N E K S F K D I 
6 8 0 CTG CCC AAG CTG ACC GAG AAC CCA TGG CAG CCA GGT GGA 7 1 9 
L P K L T E N P W Q P G G 
7 2 0 GGT CCA ACC GAC CCT GGT GAC GTG GTC ATC GAA GAG CTG 7 5 9 
G P T D P G D V V I E E L 
760 TTC AAC CGC ATC CCC GAG ACC AGC GTC CCA GGA GGA GGT 7 9 9 
F N R I P E T S V P G G G 
800 CCT TTC AAC AAC TTC ACC GTG TCC TTC TGG CTG CGC GTG 8 3 9 
P F N N F T V S F W L R V 
X h o l 
840 CCT AAG GTG TCC GCC TCC CAC CTG GAG AAC TCG AGC CAC 8 7 9 
P K V S A S H L E N S S " T T 
H i s - t a a A c c I 
880 CAT CAT CAT CAT CAT TGA GTA TAC 
— H ~ H H H r r ~ 5 t � p  
Figure 4.5 Nucleotide sequence of pBI121/Phaseolin Promoter /LRPl/ MEA /Phaseolin 
Terminator. The sequence read by primers on phaseolin promoter and terminatot were edited and 
manipulated by Contig Manger Program of DNasis. The shaded letters represented the enterokinase 
cleavage site while the shaded and underlined letters represented the 6X histidine tagged (his-tag). The 
cloning sites within the construct were specified. The complete coding sequence of this gene was flanked 
by start (ATG) and stop codon (TGA). The fill-in Ncol site was underlined and bolded. 
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A c c I 
1 GTC TAG GGT GTT TTC ACA TAT GAG GAT GAA ACC ACT 39 
M G V F T Y E D E T T 
40 TCA CCA GTG GCT CCT GCT ATC CTT TAG AAA GCA ATA GTT 79 
S P V A P A I L Y K A I V 
80 AAA GAT GCT GAT AAC ATC TTT CCA AAG GCT GTT GAT TCC 1 1 9 
K D A D N I F P K A V D S 
—EK c 1 eavag_e_ s i t e ^ — 
120 TTT AAG AGT GTT GAA ATT GTT 彌 S S g g S M S a ^ S S ^ M O ^ 15 9 
F K S V E I V E D D D D K 
f i l l i n - N c o I 
.160 GCC ATG GCA CTC GAG GCA ATG GGA AAC AAC GTG GCC AGG 199 
S M A L E A "M~G B H V S ~ 
200 TGC TCC TAG GGC GCC GAC AGC ACC CTG GGC CCA GTG CCT 2 3 9 
"C~~S~？ G S D S T L 5 P V P ~ 
240 GGT GGT GGA CCA CCT CAG CAG CGC GCC GCC CAC GTG CCT 2 7 9 
G~G P P S 0~K S XH V 
2 8 0 GTG CCC GAC TTC AGC CAG CCT GGT GGT GGT CCA TGC AAC 3 1 9 
~ V ~ ~ P ~ D P S~~~a P ~ G 5 S ~ P C~！T" 
320 GAG AAG TCC TTC AAG GAC ATC CTG CCC AAG CTG ACC GAG 3 5 9 
~ ~ E ~ ~ K S F K D 1 L ~ P K ~ L T E T " 
360 AAC CCA TGG CAG CCA GGT GGA GGT CCA ACC GAC CCT GGT 3 9 9 / 
P W a P 5 5 5 ~ P T D V ~ 
4 0 0 GAC GTG GTC ATC GAA GAG CTG TTC AAC CGC ATC CCC GAG 4 3 9 “ 
T V V 1 E E L ~ F n E I F ~ E ^ 
4 4 0 ACC AGC GTC CCA GGA GGA GGT CCT TTC AAC AAC TTC ACC 4 7 9 
S ~ 1 P 5 5 G P ~ P R F T ~ 
480 GTG TCC TTC TGG CTG CGC GTG CCT AAG GTG TCC GCC TCC 5 1 9 
— V S P W E~K V~P K V~S S S ~ 
520 CAC CTG GAG G'Gl AAT GGT GGT CCT GGA ACC ATC AAG AAG 5 5 9 
H L W~ G N G G P G T I K K 
560 ATC TCT TTT GTT GAG GAT GGG GAA AGC AAG TTT GTG TTG 599 
工 S F V E D G E S K F V L 
600 CAC AAG ATT GAG TCA ATT GAT GAG GCT AAT TTG GGA TAG 639 
H K I E S I D E A N L G Y 
640 AGC TAG AGC ATA GTT GGT GGT GCT GCT TTG CCA GAC ACA 679 
S Y S I V G G A A L P D T 
680 GTG GAG AAG ATT ACA TTT GAG TCC AAA TTG AGT GCT GGA 7 1 9 
V E K I T F E S K L S A G 
720 CCT TCT GGA GGC TCT GTT GGG AAA CTC ACT GTG AAA TAG 759 
P S G G S V G K L T V K Y 
760 CAA ACC AAA GGA GAT GCT GAG CCC AAT GAA GAG GAA CTC 7 9 9 
Q T K G D A E P N E E E L -
800 AAA GTT GGC AAA GCC AAG GGT GAT GCT CTC TTC AAG GCT 839 
K V G K A K G D A L F K A 
840 GTT GAG GCT TAG CTT TTG GCC CAT CCT GAA TAG AAT 879 
V E A Y L L A H P E Y N S t o p 
A c c I 
880 GTA TAG 
\ 
Figure 4.6 Nucleotide sequence of pBI121/Phaseolin Promoter /LRPIIA/ MEA /Phaseolin 
Terminator. The sequence read by primers on phaseolin promoter and terminatot were edited and 
manipulated by Contig Manger Program of DNasis. The shaded letters represented the enterokinase 
cleavage site while the underlined letters represented the sequence of MEA gene. The cloning sites within 
the construct were specified. The complete coding sequence of this gene was flanked by start (ATG) and 
stop codon (TGA). The fill-in Ncol site was underlined and bolded. 
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1 ATG ATG AGA GCA AGG GTT CCA CTC CTG TTG CTG GGA A T T 3 9 
M M R A R V P L L L L G I 
F i l l i n N d e l 
4 0 C T T T T C CTG GCA TCA C T T T C T GCC TCA TAT GCA ATG GGA 7 9 
L F L A S L S A S T ~ A "M G 
8 0 AAC AAC GTG GCC AGG TGC TCC TAC GGC GCC GAC AGC ACC 1 1 9 
"N N V A R C S Y G A D S T ~ 
1 2 0 CTG GGC CCA GTG CCT GGT GGT GGA CCA CCT CAG CAG CGC 1 5 9 
T G P V P G G G P P Q Q ^ 
1 6 0 GCC GCC CAC GTG CCT GTG CCC GAC T T C AGC CAG CCT GGT 1 9 9 
A H V P V P D F S Q P ~ 
2 0 0 GGT GGT CCA TGC AAC GAG AAG TCC T T C AAG GAC A T C CTG 2 3 9 
~ G G P C N E iC S F K D I L " 
2 4 0 CCC AAG CTG ACC GAG AAC CCA TGG CAG CCA GGT GGA GGT 2 7 9 
~ K L f E N P W Q P G G ~ 
2 8 0 CCA ACC GAC CCT GGT GAC GTG GTC ATC GAA GAG CTG T T C 3 1 9 
~ T D P G D V V i E E L F ~ 
3 2 0 AAC CGC ATC CCC GAG ACC AGC GTC CCA GGA GGA GGT CCT 3 5 9 
~ N R I P E T S V P G G G P~" 
3 6 0 T T C AAC AAC T T C ACC GTG TCC T T C TGG CTG CGC GTG CCT 3 9 9 
~ F N N F T V S F W L R V W~ 
E c o R I 
4 0 0 AAG GTG TCC GCC TCC CAC CTG GAG GAA TTC GAC TAC AAG 4 3 9 
"IC V S A S H L E ~ E F D Y K 
4 4 0 GAC GAC GAT GAC AAG AGT AAA ACT GCC AGT CAG GCA AAA 4 7 9 
D D D D K S K T A S Q A K 
4 8 0 TCC ACT TGG GCT GCT T T T TGG GTC GTT TTG A T T GCC T T A 5 1 9 
S T W A A F . W V V L I A L 
5 2 0 GCT ATG A T T GCA GGA GGG GGA T T C CTT GTG TAT AAA T A T 5 5 9 
A M I A G G G F L V Y K Y 
5 6 0 AGA A T T AGG CAA TAC ATG GAT T C T GAA ATC AGA GCA ATC 5 9 9 
R I R Q Y M D S E I R A I 
6 0 0 ATG GCA CAA TAT ATG CCC TTG GAC AGC CAA GAA GAA GGT 6 3 9 
M A Q Y M P L D S Q E E G 
6 4 0 CCA AAT CAC GTC AAT CAT CAA AGA GGT TGA 
P N H V N H Q R G S t o p 
Figure 4.7 Nucleotide sequence of pBI121/Phaseolin Promoter / SP/ MEA(J)/ 
491 /Phaseolin Terminator. The sequence read by primers on phaseolin promoter and 
terminatot were edited and manipulated by Contig Manger Program of DNasis. The 
bolded letters represented the signal peptide, underlined letters represented M E A gene 
and the shaded sequences represented the linker sequences within MEA. The complete 
coding sequence of this gene was flanked by start (ATG) and stop codon (TGA). The 
fill-in Ndel site was underlined and bolded. 
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1 ATG ATG AGA GCA AGG GTT CCA CTC CTG TTG CTG GGA ATT 3 9 
M M R A R V P L L L L G I 
F i l l - i n N d e l 
4 0 C T T T T C C T G GCA T C A C T T T C T GCC T C A T A T GCA A T G GGA 7 9 
L F L A S L S A S Y~ A ~M 
80 AAC AAC GTG GCC AGG TGC TCC TAG GGC GCC GAC AGC ACC 119 
N N V A R C S Y G A D S T ~ 
120 CTG GGC CCA GTG CCT GGT GGT GGA CCA CCT CAG CAG CGC 159 
L G P V P G G G P P Q Q ~ 
160 CGC GCC CAC GTG CCT GTG CCC GAC TTC AGC CAG CCT GGT 199 
~A A E V P V P D F S Q P ^ 
200 GGT GGT CCA TGC AAC GAG AAG TCC TTC AAG GAC ATC CTG 239 
~G G P C N E K S F K D I IT 
240 CCC AAG CTG ACC GAG AAC CCA TGG CAG CCA GGT GGA GGT 279 
~P K L T E N P W Q P G G G" 
280 CCA ACC GAC CCT GGT GAC GTG GTC ATC GAA GAG CTG TTC 319 
"P T D P G D V V i 1 E L F~ 
320 AAC CGC ATC CCC GAG ACC AGC GTC CCA GGA GGA GGT CCT 359 
~N R I P E T S V P G G G W~ 
360 TTC AAC AAC TTC ACC GTG TCC TTC TGG CTG CGC GTG CCT 399 
T N N F T V S F W L R V P~ 
EcoRI 
400 AAG GTG TCC GCC TCC CAC CTG GAG GAA TTC GAC TAG AAG 439 
"IC V S A S H L 1" E F D Y K 
440 GAC GAC GAT GAC AAG AGT AAA ACT GCC AGT CAG GCA AAA 479 
D D D D K S K T A S Q A K 
480 TCC ACT TGG GCT GCT TTT TGG GTC GTT TTG ATT GCC TTA 519 
S T W A A F W V V L I A L 
520 GCT ATG ATT GCA GGA GGG GGA TTC CTT GTG TAT AAA TAT 559 
A M I A G G G F L V Y K Y 
560 AGA ATT AGG CCA ATT GAA CCA CCC CCA CAC CAC CAC CAA 599 
R I R P I E P P P H H H Q 
6 0 0 CCT T T G GCA A C T GAA GAT TAG TGA 
P L A T E D Y Stop 
Figure 4.8 Nucleotide sequence of pBI121/Phaseolin Promoter / SP/ MEA(J)/ 
526 /Phaseolin Terminator. The sequence read by primers on phaseolin promoter and 
terminatot were edited and manipulated by Contig Manger Program of DNasis. The 
bolded letters represented the signal peptide, underlined letters represented M E A gene 
and the shaded sequences represented the linker sequences within MEA.. The complete 
coding sequence of this gene was flanked by start (ATG) and stop codon (TGA). The 
fill-in Ndel site was underlined and bolded. 
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4.4.2 Screening of homozygous transgenic plant with single insertion of transgene 
16 wild-type A. thaliana Columbia-) ectype (FO) were grown to flowering stage, 
numbered (no. A to no. P) and were subjected to vacuum infiltration. After vacuum 
infiltration, as the selection marker (NPTII) conferred a dominant phenotype of 
kanamycin resistance, the positive transformants (Fl) carrying the plant expression 
vector could be easily screened as they could develop to green seedlings with true leaves 
(Figure 4.23). Although the non-transformed seeds could also germinate, they would 
then exhibit yellow leaves and eventually died (Figure 4.9). For most of the six 
constructs, over 80% of the 16 plants (FO) produced transgenic offsprings (Table 4.2). 
In most of the cases, only one copy of transgene was expected to integrate into 
the plant genome, i.e. most of the transgenic offsprings were expected to be hemizygous. 
For screening of homozygous transgenic lines with single insertion, the hemizyous (Fl) 
plants were allowed to self-crossed, resulted in both heterozygous and homozygous 
offsprings. According to mendelian law of independent segregation, if the plant carried 
only one copy of transgene, the F2 offsprings would exhibit a ratio of 3:1 of antibiotic-
resistance seedlings (green appearance in selection medium) to antibiotic-sensitive 
seedlings (yellow appearance in selection medium) (Figure 4.10). Green transformants 
(F2) with acceptable chi-squares values were selected and was allowed to propagate 
(Table 4.3). 
The green transformants (F2) could be either heterozygous or homozygous and 
they could not be distinguished by their antibiotic-resistance phenotype. For screening of 
homozygous lines, they were allowed to self-cross. If the F2 plant was heterozygous, 
again a 3:1 ratio of green to yellow seedlings would be displayed in the F3 generation. 
On the other hand, if the F2 plant was homozygous, all the offsprings would appear 
green and they would be regarded as homozygous plants carrying a single copy of 
transgene in their genome (Figure 4.11). Different homozygous lines of A. thaliana 
carrying different plant expression constructs were obtained and were summarized in 
Table 4.4. 
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Table 4.2 Positive transformants obtained (F1 generation) in different 
transgenic constructs. 
I.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ LRPI/ MEA/ PT 
FO plant Positive transformant FO plant Positive transformant  
Number Naming Number Naming  
LIA 4 L1A3,4,6, 1.2 Ll l 3 L1I2,9, 10 
LIB 5 L1B1,2,9,12,15 LIJ 2 L1J6, 14 . 
L i e 1 L1C9 U K 2 L1K5, 15 
LID 2 L1D1,6 LIL 3 L1L2,7,8 
LIE 2 L1E2,20 LIM (1) (L1M3) 
LIF 4 L1F5,7, 18, 19 LIN 3 LlNl, 7，17 
LIG 3 L1G1,4, 16 LIO 2 L105, x9 
LIH (1) (L1H3) LIP 2 L1P5, 10 
II.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ LRPI/ MEA/ PT 
FO plant Positive transformant FO plant Positive transformant 
Number Naming Number Naming  
L2A 7 L2A1,3,8,9 14, 16, 17 L2I 3 L2I1,2,3 
L2B 3 L2B1,2,3 L2J 1 (L2J4) 
L2C (1) (L2C1,2) L2K 1 L2K1 
L2D 0 - L2L (1) (L2L1) 
L2E 4 L2E9, 10, 11, 12 L2M 5 L2M1,2,3,4, 11 
L2F 0 - L2N 0 -
L2G 3 L2G8, 11, 13 L20 (1) (L201) 
L2H 3 L2H1,3,6 L2P (2) (L2P2,3) 
III.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ SP/ MEA(J)/ 491/ NOS 
FO plant Positive transformant FO plant Positive transformant  
Number Naming Number Naming 
PJIA 3 PJ1A7,32,34 ？Ju 2 PJ1I7,9 
PJIB 1 PJ1B15 PJIJ 1 PJ1J5 
PJIC 3 PJ1C3，6, 18 PJIK 1 PJ1K2 
PJID 2 PJ1D5,9 PJIL 1 PJ1L13 
PJIE 1 PJlEl PJIM 2 PJ1M4, 19 
PJIF (3) (PJ1F5, 14, 19) PJIN 2 PJ1N3, 10 
PJIG 3 PJ1G1,6, 10 PJIO 4 PJ106,27,30,34 
PJIH (2) (PJlHxl4,31) PJIP 2 PJ1P2,4 
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IV.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ LRPI/ MEA/ PT 
FO plant Positive transformant FO plant Positive transformant  
Number Naming Number Naming  
PJ2A 2 PJ2Axl, x2 PJ2I 1 PJ2Ixl 
PJ2B 1 PJ2Bxl PJ2J 0 -
PJ2C 0 - PJ2K 5 PJ2K3,5,6, 12, 13 
PJ2D (1) (PJ2Dxl) PJ2L . 2 PJ2Lx9,xl8 
PJ2E 0 - PJ2M 2 PJ2Ml,xl 
PJ2F (1) (PJ2Fxl) PJ2N 0 -
PJ2G 0 - PJ20 0 -
PJ2H 5 PJ2Hl,xl,x3,x6, x8 PJ2P 0 -
V.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ LRPI/ MEA/ PT 
FO plant Positive transformant FO plant Positive transformant 
Number Naming Number Naming  
MEAA (1) (MEAAl) MEAI 0 -
MEAB 3 MEAB 1,5,7 MEAJ 3 MEAJ1,2,6 
MEAC (3) (MEAC1,3,9) MEAK 3 MEAK5,6, 10 
MEAD (2) (MEAD2,6) MEAL (3) (MEAL2,5,8) 
MEAE 3 MEAE3,4,6 MEAM (1) (MEAMl) 
MEAF 2 MEAI, 6 MEAN (1) (MEAN2) 
MEAG (1) (MEAGl) MEAO 4 MEA01,2,6,8 
MEAH 1 MEAH2 MEAP 1 MEAP2 
VI.Transgenic A. thaliana (Fl) carrying pBI121/ PP/ SP/ MEA(J)/ 491/ NOS 
FO plant Positive transformant . FO plant Positive transformant … 
Number Naming Number Naming 
T I I A 3 121A3，4,5 1211 2 121113, 15 
121B (1) (121B2) 121J 2 121J6,7 
121C 2 121C1, 19 121K 1 121K2 
121D 2 121D1,6 121L 2 121L13,20 
121E (2) 121E3,5 121M 4 121M6, 10, 16,23 
121F 1 121F6 121N (1) (121N3) 
121G 1 121G1 1210 3 12104, 11, 17 
121H 3 121H1,7, 11 121P (1) (121P1) 
Remarks: lines in ( ) had not been processed into F2 generation. 
174 
；“’ 「-； J, ； 
漆 ， V : . ? 錢 
II •、竭，、‘ • • ‘ 
* A ‘ <-V ！J- £ -i 
Cr 4 博 私 y Si ，二} • , Y 
； 歡 岸 - ^ V . , - ‘ 
； k “ -f •  ^^ ‘ , 贫•'、〜'.， 
‘ \ ； ’ ， 身 洲 
Figure 4.9 Screening of positive transformants (Fl) on kanamycin selection 
medium. Mature seeds were collected from transformed TO plants and were plated on 
kan50 selection medium. Positive candidates were kanamycin resistance and appeared as 
green seedlings with true leaves while untransformed individuals ceased growth and 
appeared yellow. 
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Figure 4.10 Screening of a single insertion locus of the transgenic plants showed 
by 3:1 ratio (green: yellow) in F2 (selfed progenies of successful transformants) 
generation. Transformed Fl plants were allowed to self-crossed to propagate to F2 
generation and were screened on selection media for selection of F2 transgenic 
plants with single insertion of transgene in which a 3:1 ratio of green to yellow seedling 
would be observed according to the Mendel's law of monohybrid inheritance. The 
number of green transformants versus yellow seedlings was recorded and chi square test 




Figure 4.11 Screening of homozygous transgenic plants with single insertion of 
transgene in F3 generation. F2 plants with single insertion of transgene in their 
genome were allowed to self-cross and to propagate to F3 generation. Homozygous F3 
plants would all display a kanamycin resistance phenotype on selection media (Figure 
on left) while for untransformed plants, they would appear yellow with ceased growth 
(Figure on right). 
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Table 4.3 Chi-square analysis of transgenic plants of F3 generation 
I. Transgenic A. thaliana carrying pBI121/ PP/ LRPI/ M E A / PT 
Lines Green: value Accept or Lines Green: value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
L1A4 127:42 0.002 Accept LIIIO 68:26 Accept 
L1A3 122:15 14.425 Reject L1I9 60:4 12.001 Reject 
LlBl 67:15 1.967 Accept L1J6 60:17 0.351 Accept 
L1B15 92:24 1.149 Accept L1J14 107:36 0.002 Accept 
LIC9 84:34 0.914 Accept L1K5 55:18 0.005 Accept 
L1D6 60:23 0.325 Accept L1K15 55:18 0.005 Accept 
LlDl 50:4 7.892 Reject L1L7 96:27 0.610 Accept 
L1E2 70:27 0.416 Accept L1L8 56:23 0.713 Accept ^ 
L1E20 91:34 0.323 Accept U N I 76:25 0.003 Accept 
L1F5 92:8 15.413 Reject L1N17 123:43 0.072 Accept 
L1F19 58:18 0.071 Accept L105 108:41 0.503 Accept 
L1F18 104:31 0.299 Accept LI 0x9 80:30 0.303 Accept 
LlGl 67:18 0.663 Accept L1P5 90:7 14.841 Reject 
L1G4 101:9 16.297 Reject LIP 10 141:44 0.146 Accept 
II. Transgenic A. thaliana carrying pBI 121/ PP/ LRPIIA/ MEA； PT 
Lines Green: y^ value Accept or Lines Green: y^ value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
L2A3 82:28 0.012 Accept L2H1 39:14 0.057 Accept 
L2A14 52:15 0.243 Accept L2H3 91:5 20.056 Reject 
L2B1 158:47 0.470 Accept L2I1 130:41 0.096 Accept 
L2B3 57:18 0.040 Accept L2I3 63:20 0.036 Accept 
L2C2 67:17 1.016 Accept L2I1 130:41 0.096 Accept 
L2E9 70:25 0.088 Accept L2J4 66:5 12.211 Reject 
L2E10 50:16 0.020 Accept L2K1 70:22 0.058 Accept 
L2E11 101:14 9.836 Reject L2M1 56:18 0.018 Accept 
L2G8 83:1 25.397 Reject L2M2 69:26 0.284 Accept 
L2G13 55:17 0.074 Accept L2M11 97:11 12.642 Reject 
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in. Transgenic A. thaliana carrying pBI121/PP/ SP/ MEA(J)/ 491/N〇S 
Lines Green: y^ value Accept or Lines Green: value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
PJ1A7 140:43 0.220 A c c e p t P J 1 I 9 82:27 Accept 
PJ1A32 86:34 0.711 Accept PJ1J5 142:40 0.886 Accept 
PJ1A34 90:39 1.884 Accept PJ1K2 145:33 0.330 Accept 
PJ1B15 106:37 0.058 Accept PJ1L13 101:10 14.848 Reject 
PJ1C3 72:26 0.122 Accept PJ1M4 112:8 19.828 Reject 
PJ1C6 64:22 0.016 Accept PJ1M19 108:47 2.342 Accept 
PJ1C18 96:66 21.407 Reject PJ1N3 141:8 30.624 Reject 
PJ1D5 144:7 33.397 Reject PJINIO 60:17 0.351 Accept 
PJ1D9 102:40 0.761 Accept PJ107 246:37 21.466 Reject 
PJlEl 115:51 2.900 Accept PJ1027 126:47 0.052 Accept 
PJIGI 117:43 0.300 Accept PJ1030 116:34 0.267 Accept 
PJIGIO 89:27 0.184 Accept PJ1034 133:21 2.766 Accept 
PJ1I7 95:35 0.256 Accept PJ1P4 168:50 0.495 Accept 
IV. Transgenic A. thaliana carrying pBI121/ PP/ PP/ SP/ MEA(J)/ 526/ N O S 
Lines Green: y^  value Accept or Lines Green: value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
PJ2Axl 161:58 0.257 Accept PJ2K3 121:30 2.121 Accept 
PJ2Ax2 95:29 0.172 Accept PJ2K6 147:24 10.945 Reject 
PJ2Bxl 60:21 0.037 Accept PJ2K12 121:52 1.639 Accept 
PJ2H1 122:37 0.254 Accept PJ2K13 103:41 0.926 Accept 
PJ2Hxl 59:19 0.017 Accept PJ2Lxl8 49:16 0.005 Accept 
PJ2Hx6 55:13 1.255 Accept PJ2Lx9 48:15 0.048 Accept 
PJ2Ixl 108:31 0.539 Accept PJ2M1 82:26 0.003 Accept 
PJ2K5 100:12 12.190 Reject PJ2Mxl 100:8 17.825 Reject 
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V. Transgenic A. thaliana carrying transgenic control, pBI121/ PP/ M E A / PT 
Lines Green: y^ value Accept or Lines Green: y^ value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
MEABl 111:44 0948 Accept MEAJ6 85:34 0.810 Accept 
MEAB5 100:33 0.003 Accept MEAJ2 142:35 2.578 Accept 
MEAB7 57:53 31.527 Reject MEAK5 160:55 0.039 Accept 
MEAE4 138:37 1.389 Accept MEAKIO 130:44 0.008 Accept 
MEAE3 68:20 0.242 Accept MEAK6 120:13 6.458 Reject 
MEAE6 154:17 20.680 Reject MEAOl 77:24 0.051 Accept 
MEAFl 103:37 0.152 Accept MEA02 100:12 12.190 Reject 
MEAF6 68:3 16.343 Reject MEA06 150:46 0.245 Accept 
MEAH2 93:30 0.024 Accept MEA08 100:2 28.876 Reject 
MEAJl 95:30 0.067 Accept MEAP2 37:17 1.200 Accept 
VI. Transgenic A. thaliana carrying transgenic control, pBI121 
Lines Green: y^ value Accept or Lines Green: y^ value Accept or 
yellow Reject yellow Reject 
plantlets plantlets 
121A3 135:50 Accept 121113 90:32 Accept 
121A4 146:45 0.211 Accept 121J6 66:20 0.140 Accept 
121A5 111:9 19.600 Reject 121J7 121:31 1.719 Accept 
121C1 92:23 1.533 Accept 121K2 95:31 0.011 Accept 
121C19 .�96:27 0.610 Accept 121L13 154:52 0.006 Accept 
121D1 155:60 0.969 Accept 121L20 110:42 0.561 Accept 
121D6 120:30 2.000 Accept 121M23 103:5 23.901 Reject 
121F6 86:36 1.322 Accept 121M10 94:36 0.502 Accept 
121G1 79:25 0.051 Accept 121M16 190:65 0.033 Accept 
121H1 135:36 1.421 Accept 12104 100:12 12.190 Reject 
121H7 102:31 0.203 Accept 121011 110:35 0.057 Accept 
121H14 98:38 0.627 Accept 121017 98:34 0.040 Accept 
* Significance level was set at 0.05 and the critical value was calculated as 3.841. 
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Table 4.4 Homozygous lines obtained (F3 generation) in different transgenic 
constructs. 
I. Transgenic A. thaliana carrying pBI121/ PP/ LRPI/ MEA/ PT 
L1A4-6 LlBl-8 L1B15-10 L1C9-2 L1D6-5 L1E20-3 
L1F18-4 L1F19-7 L1E2-1 LlGl-4 LlIlO-6 L1J6-5 
L1J14-6 L1K15-10 L1L8-4 LlNl-3 L105-6 LlPlO-3 
II. Transgenic A. thaliana carrying pBI121/ PP/ LRPI/ MEA/ PT 
L2C2-12 L2E10-8 L2I1-5 L2K1-8 L2M2-10 
III. Transgenic A, thaliana carrying pBI121/ PP/ SP/ MEA(J)/ 491/ NOS 
PJ1A7-7 PJ1A32-9 PJ1B15-3 PJ1C6-5 PJlGl-3 PJlGlO-7 
PJ1I9-4 PJlIlO-10 PJ1J7-4 PJ1K2-9 PJ1C3-5 PJ1A34-2 
PJ1M19-1 PJlNlO-8 PJ1034-6 PJ1027-3 PJ1P2-6 PJ1P4-7 
rV. Transgenic A. thaliana carrying pBI121/ PP/ SP/ MEA(J)/ 526/ NOS 
PJ2Axl-2 PJ2Bxl-7 PJ2H1-6 PJ2x6-l PJ2Ixl-4 
PJ2K3-5 PJ2K12-7 PJ2K13-5 PJ2M1-7 
V. Transgenic A. thaliana carrying pBI121/ PP/ MEA/ PT 
M E A B 1-7 MEAE4-2 M E A P 1-5 MEAH2-4 MEAJl-8 
MEAK5-1 MEAJ6-2 M E A O 1-9 MEA06-9 MEAP2-3 
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4.4.3 Molecular analysis of the MEA/ MEA fusion in transgenic plants 
Transgenic A. thaliana carrying single insert of either one of the six constructs 
was propagated into homozygous lines (F3 generation). In order to investigate the 
possibility of using transgenic plants as bioreactor to produce the multi-epitopic antigen, 
. the presence of the recombinant M E A proteins (either with or without fusion partners) in 
transgenic plants was detected by Western blot, using the anti-serum against His-tag 
M E A (for results summary, see Table 4.5). 
Seed proteins of soluble fraction were extracted from mature seeds from 
transgenic plants carrying either pBI 121 /PP/LRPI/MEA/PT, pBI 121 /PP/LRPIIA/MEA/ 
PT or pBI121/PP/ MEA/PT while seed proteins of membrane fraction was extracted for 
transgenic plants transformed with pBI121/PP/SP/MEA(J)/491/NOS or pBI121/PP/SP/ 
MEA(J)/526/NOS. Extracted seed proteins were quantified by Bio-rad Protein Assay as 
described in 2.3.3.fusing BSA as standard. 
For expression strategy 1, in which the M E A protein was fused with the LRP, 
recombinant LRPI-MEA fusion protein could be detected in the soluble fraction of the 
seed protein extracted from transgenic plants transformed with pBI121/PP/LRPI/ 
MEA/PT (Figure 4.12)，however, the other LRPII-MEA fusion protein could not be 
detected in transgenic plants carrying pBI121/ PP/ LRPIIA/ M E A / PT (data not shown) 
and the expression of M E A protein (without any fusion partner) in transgenic A. 
thaliana transformed with pBI121/PP/MEAyPT could not be detected also (Figure 4.13). 
For expression strategy 2, in which the M E A protein would be targeted to 
different sub-compartments of the PSV through distinct pathways by the fusion with 
unique membrane anchors, recombinant M E A proteins could not be detected by western 
blot using anti-serum against His-tag M E A in either the soluble fraction (Figure 4.14) or 
membrane fraction (Figure 4.15) of seed proteins extracted from transgenic A. thaliana 
carrying either pBI121/ PP/ SP/ MEA(J)/ 491/ N O S or pBI121/ PP/ SP/ MEA(J)/ 526/ 
NOS. 
182 
Control . LRPI-MEA (pBI121/PP/LRPi/MEA/PT). 
WT vector A C D E F G I 





Control • LRPI-MEA (pBI121/PP/LRPI/MEA/PT) 
W T vector j K L N 〇 P 





Figure 4.12 Western blot of soluble seed proteins extracted from transgenic A. 
thaliana transformed with pBI121/PP/LRPI/MEA/PT with anti-serum against 
HisMEA. 50)ig seed proteins of soluble fraction were loaded on 12.5 % SDS-
polyacrylamide gel for electrophoresis. The resolved proteins were then transferred to 
PVDF membrane and hybridized with 1:1000 pre-absorbed antiserum against HisMEA. 
The arrow indicated the positive signal corresponding size of the putative recombinant 
LRP-MEA fusion protein (-31 KDa) the size of the protein marker was indicated as kDa 
and shown on the left. A to P represents different transgenic lines. 
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Figure 4.13 Western blot of soluble seed proteins extracted from transgenic A 
thaliana transformed pBI121/PP/MEA/PT with anti-serum against HisMEA. 50^g 
s e e d p r o t e i n s o f s o l u b l e f r a c t i o n w e r e l o a d e d o n 1 2 . 5 % S D S - p o l y a c r y l a m i d e g e l f o r 
electrophoresis. The resolved proteins were then transferred to PVDF membrane and 
hybridized with 1:1000 pre-absorbed antiserum against HisMEA. The size of the protein 
marker was indicated as kDa and shown on the left. B to P represents different transgenic 
lines. 
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Figure 4.14 Western blot of soluble seed proteins extracted from transgenic A 
thaliana transformed pBI121/PP/SP/MEA(J)/491 or 526/NOS with anti-serum against 
HisMEA. 50|ig seed proteins of soluble fraction were loaded on 12.5 % SDS-
polyacrylamide gel for electrophoresis. The resolved proteins were then transferred to 
PVDF membrane and hybridized with 1:1000 pre-absorbed antiserum against HisMEA. 
The size of the protein marker was indicated as kDa and shown on the left. A to N 
represents different transgenic lines. 
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Figure 4.15 Western blot of membranous seed proteins extracted from transgenic A. 
thaliana transformed pBI121/PP/SP/MEA(J)/491 or 526/NOS with anti-serum against 
HisMEA. 50|Lig seed proteins of membrane fraction were loaded on 12.5 % SDS-
polyacrylamide gel for electrophoresis. The resolved proteins were then transferred to 
PVDF membrane and hybridized with 1:1000 pre-absorbed antiserum against HisMEA. 
The size of the protein marker was indicated as kDa and shown on the left. A to N 













































































































































































































































































































































































































































































































































































































































































4.5.1 Construction of plant expression vector 
All of the expression cassettes were driven by the phaseolin promoter (PP), 
which had been reported to drive high-level expression of maize zein protein (Hoffman 
et al., 1987) and Brazil nut 2S albumin (Altenbach et al., 1989; Altenbach et al, 1992) 
in seeds of transgenic tobacco or canola, for expression of the heterologous proteins in 
transgeninc plants. Either the phaseolin terminator (PT) or the nospaline (NOS) 
terminator was used for efficient termination and polyadenylation of the transgene 
transcripts. All the expression cassettes were subcloned into the binary vector, pBI121, 
in which the neomycin phosphotransferase (NPTII) gene was driven by the constitutive 
Cauliflower mosaic virus (CaMV) promoter (Odell et al” 1985) which could act as a 
selectable marker during the screening procedures (Reiss et al., 1984). 
For the construction of plant expression vectors, pBI 121 /PP/LRPI/MEA/PT and 
pBI 121 /PP/LRPIIA/MEA/PT, lysine-rich protein was used as the fusion partner for the 
enhancement of the stability of the recombinant proteins. The M E A protein was either 
fused with the C-terminal of the LRP (Modification I) or inserted into the middle of the 
LRP (Modification II) (Lo, Dept of Biology, CUHK). For modification I, it was 
modified by adding an enterokinase (EK) site, the flill-length of M E A gene (with stop 
codon removed) followed by a polyhistidine tag in frame at the 3, end just before the 
stop codon of the LRP gene while for modification II，an enterokinase site and the full-
length of the M E A gene (without stop codon) was inserted in the loose random coil in 
the middle of LRP as predicted from its coding sequences since it was believed that this 
insertion might affect the overall conformation with the minimum extent. 
For the construction of plant expression vectors, pBI 121/PP/SP/MEA(J)/491 / 
N O S and pBI121/PP/MEA(J)/526/NOS, the recombinant proteins were directed into the 
secretory pathway of the cells and were targeted to different sub-compartments of the 
PSV. As the recombinant antigen M E A does not contain any signal peptide sequences, it 
was fused with a signal peptide sequence from seed protein, phaseolin (Sun et al., 1981; 
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Slightom et al, 1983) and specific TMD/CT sequences from either BP-80 or a-TIP was 
fused at C-terminal (Jiang and Rogers 1998; Jiang and Rogers 1999a; Jiang and Rogers 
1999b; Jiang et al, 2000) for targeting the recombinant proteins to the globoid or 
crystalloid of PSV. A spacer sequence was included between the M E A and sorting 
signals for providing flexibility and thus allowed proper folding of the recombinant 
proteins. 
4.5.2 Screening of homozygous transgenic plant with single insertion of transgene 
As demonstrated by previous studies, ecotype Columbia-0 of A. thaliana had 
good transformation efficiency with standard agrobacterium-mediated transformation 
procedures (Bechtold and Bouchez, 1995; Koncz and Schell, 1986). In this experiment, 
A. thaliana were transformed by agrobacterium-mediated transformation via vaccum 
infiltration following the procedures modified in Dr. Lam's laboratory. Silwet L-77 
which is a surfactant, was added in the infiltration medium for effective transformation 
(Clough and Bent, 1998). 
After infiltration, most transgenic plants were expected to be independent and 
hemizygous (Feldmann, 1987) with majority of transgene inserted segregated as one 
locus (Bectold et al” 1993). Transgenic A. thaliana (Fl) could be identified under 
kanamycin selection (as shown in Figure 4.23) and were then allowed to self-pollinate to 
generation F2 generation. According to the Mendel's law of monohybrid inheritance, if 
F2 plant contained only a copy of transgene (A), % of them would exhibit a kanamycin 
resistance phenotype (green plantlet) in which they were either homozygous (AA) or 
heterozygous (Aa) while the rests would be homozygous recessive (aa) and became to 
yellow plantlet upon selection (Figure 4.24). After chi-square analysis, F2 transformants 
were allowed to grow and self-cross to produce homozygous F3 generation (Figure 4.25). 
For all of the six transgenic constructs, transgenic plants with single copy of transgenic 
were isolated (Table 4.2 and 4.3) and some of them were propagated to F3 plants (Table 
4.4). Mature seeds of these homozygous lines were subjected to molecular analysis for 
the determination of the expression and accumulation of the recombinant M E A proteins. 
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4.5.3 Molecular analysis of transgenic MEA/ MEA fusion in transgenic plants 
From the western blot analysis (Figure 4.26), the recombinant LRPI-MEA fusion 
protein was detected in the transgenic plants transformed with pBI121/PP/LRPI/ 
MEATPT. However, recombinant M E A protein could not be detected in other constructs 
transgenic plants with pBI 121 /PP/LRPIIATMEA/PT or pBI121/PP/MEA/PT being 
transformed (Figure 4.27). As the M E A alone (without any fusion) could not be 
expressed in transgenic plants but the LRP-MEA fusion protein could, the LRP was 
believed to have some stabilizing effects to the recombinant M E A protein. But the 
stabilizing effect of LRP on the expression of heterologous proteins in plants maybe 
case-specific, as the expression of LRPIIA-MEA fusion proteins could not be detected in 
transgenic plants (Figure 4.27). Although the M E A is a small protein of around lOkDa, 
insertion of the M E A into the middle of the LRP might disrupt the overall conformation 
of the LRP and thus its stability lost. For further confirming the negative results, western 
blot should be performed with anti-LRP antibody in order to distinguish whether the 
LRPII/MEA was not expressed at all or it was degraded after synthesis or the M E A was 
masked by the LRP fusion, so that it could not be recognized by anti-serum against 
M E A . 
The LRPI-MEA fusion protein, with the M E A fused to the C-terminal of a full-
length of the LRP, has a calculated M W o f a r o u n d 31 kDa. From the Western blot of the 
seed proteins (soluble fraction) extracted from LRPI-MEA transformed plants (Figure 
4.26), a protein band with similar size was detected in four of the lines but not in other 
lines, this may due to the positional effect of the transgene (Mayer and Heidmann, 1994). 
As LRP is a cytosolic protein and thus recombinant LRP-fusion protein would not be 
glycosylated or fragmented in the vacuole. So, the LRPI-MEA fusion protein would be 
expected to have a single molecular form. However, there were a few bands appeared on 
the western blot just below the major band which was believed to be the putative 
LRPI/MEA fusion protein (Figure 4.26), they might be the degradation products of the 
LRPI/MEA fusion protein formed during purification steps. 
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Besides fusing with the LRP, other plant expression cassettes were constructed 
for targeting the recombinant M E A fusion proteins to the PSV where stable 
accumulation of the recombinant protein can occur. However, recombinant M E A 
proteins could be not be detected (or the expression level was too low to be detected) by 
western blot in either the C M or CS fraction of seeds proteins extracted from transgenic 
. plants carrying pBI 121 /PP/SP/MEA(J)/491/NOS and pBI 12 l/PP/SP/MEA(J)/526/NOS 
(Figure 4.28 and 4.29) in which recombinant proteins were expected to be 
compartmentalized into different sub-compartments of PSV in mature seeds of 
transgenic plants. 
The no-to-low level of recombinant proteins produced in the transgenic plants 
may be due to several reasons, including factors affecting the transcription, post-
transcriptional processing, translation, post-translational processing and protein 
degradation. As there is an assumption that increasing levels of transcription will results 
in increased protein synthesis, R N A level of the transgene is somehow co-related to the 
expression level of the recombinant proteins although this may not be the truth. 
However, as the transcriptional level of the transgenes had not been studied in this 
research, no conclusion could be drawn. For factors affecting post-transcriptional 
processing and the translational efficiency, such as codon usuage, as the M E A fusion 
protein could be detected in transgenic A. thaliana carrying pBI121/PP/LRPI/ MEA/PT 
(Figure 4.26) and the possibility of using the unique T M D and CT sequences (as 
included in construct 491 and construct 526) for delivering recombinant proteins via 
distinct vesicular transport pathways to specific vacuolar compartments under the 
control of the constitutive C a M V 35S promoter in transgenic tobacco cell lines was 
demonstrated (Jiang and Rogers 1998; Jiang and Rogers 2000), these factors seemed not 
to be the main reason for the no-to-low level of recombinant proteins detected in 
transgenic plants. Moreover, if the recombinant proteins can be successfully expressed, 
they should be targeted to the PSV of the plant cells in which they are protected from 
plant proteolytic systems in various compartments, so the high turnover rate may not 
contribute to such a low/ no accumulation of the expressed proteins. 
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The delivery systems proposed would direct recombinant proteins to defined 
vacuolar compartments and were proved by both in vitro and in vivo expression studies 
in tobacco (Jiang and Rogers 1998; Jiang and Rogers 2000). Although homologous of 
BP-80 and TIP proteins have been found among several other plant species, including A. 
thaliana used in this experiment, these delivery systems may not be applicable to other 
plant seed expression system as many of the details are still undefined. Furthermore, 
although the phaseolin promoter was reported to driven strong expression of transgenes 
in plants (Altenbach et al, 1989; Altenbach et al” 1992; Hoffman et al., 1987), in these 
two plant expression constructs, the recombinant proteins would be driven to be 
expressed only as membrane proteins in the embryo of the seeds which contributed to a 
very limited proportion in total seed proteins and thus the overall expression level of the 
recombinant proteins would be limited. All of these factors may contribute to the low/ 
no level of recombinant proteins detected in transgeninc A. thaliana carrying 
pBI121/PP/ SP/MEA(J)/491/NOS and pBI121/PP/ SP/MEA(J)/526/NOS. For 
improvement, for expression cassettes transformed into A. thaliana, a constitutively 
C a M V 35S promoter may be an alternative to the seed specific phaseolin promoter. On 
the other hand, making transgenic tobacco plant may be a better choice than making 
transgenic A. thaliana for expression constructs driven by phaseolin promoter. 
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Chapter 5 General Discussion 
5.1 Development of a vaccine for toxoplasmosis: current status 
Toxoplasmosis is a widespread parasitic infection throughout the world and is 
caused by an intracellular protozoan parasite, T. gondii (Jackson et al., 1989; Bhopale 
et al,, 1997). Human and most of the agricultural animals are the intermediate hosts of 
T. gondii and thus this disease is of major medical and veterinary importance as it will 
lead to congenital disease and abortion. It has gained importance in 
immuno-compromised patients due to the reactivation of the bradyzoites leading to 
toxoplasma encephalitis (Luft and Remington, 1992). Treatment is difficult because of 
the toxic effects of drugs and the limited protection of currently available vaccines. 
Under the present scenario, development of a successful vaccine against 
toxoplasmosis becomes a hot topic. 
5.1.1 Current status 
a. Vaccine for agricultural animals 
In the past few years, there has been considerable progress towards the 
development of vaccines against toxoplasmosis. T. gondii mutant strains, for example, 
S48, TS-4 and T-203, have been identified as vaccine candidate (Buxton and Innes, 
1995； Araujp 1994) and the live attenuated vaccine of S48 strain T. gondii has been 
approval for veterinary uses (Buxton and Innes, 1995). Although it can elicit both 
humoral and cellular immunity in immunized animals, this vaccine is not suitable for 
human being, as it may expose human to the risk of revertion to a pathogenic 
organisms. 
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b. Other vaccine candidates and the protective response induced 
Many vaccine candidates which can induce protective immune responses against 
toxoplasmosis have been identified in the recent years. Most of the works focused on 
the surface antigens of tachyzoites, including SAGl/ P30, SAG2 and SAG3 
(Couvreur et al,, 1988). They could induce effective protection in immunized hosts 
and prolonged the survival time after lethal challenge and the development of a 
subunit vaccine has mainly focused on SAGl (Petersen et al., 1998; Letscher Bru et 
al., 1998; Haumont et al, 2000; Chen et aL, 1999; Nielsen et al, 1999). However, 
as S A G antigens are stage-specific, protection elicits by vaccinating with these 
antigens may lead to stage-limited protection. 
Non-stage specific vaccine candidates have also been identified, secretory 
antigens of T. gondii, including the family of G R A proteins, which are conserved in 
both the bradyzoite and tachyzoite stages also play an important role in the 
stimulation of a protective immune response (Cesbron Delauw 1994). Recently, R0P2 
antigen which is constitutively expressed in all stages of T, gondii (tachyzoites, 
bradyzoites and sporozoites) has also been reported to be a vaccine candidate against 
T. gondii infection (Saavedra et al., 1996). But the immunogenicity of subunit may 
be limited by MHC-restricted T-cell immunity. 
5.1.2 Appropriate vaccine design - the multi-epitopic antigen (MEA) 
The M E A vaccine construct carried epitopes from different Toxoplasma antigens 
of different life stages for overcoming the problem of stage-specific protection can be 
overcome. In addition, a promiscuous helper T-cell epitope was also included for 
broadening the immunogenicity of the M E A (Herrington et aL, 1987; Herrington et 
aL, 1992; Lairmore et al., 1995; Del Guercio et al, 1997; Franke et al, 1999). The 
use of defined epitopes in M E A allows the stimulation of an appropriate immune 
response that leads to resistance, on the other hand, to minimize other non-specific 
and undesirable stimulation. 
The multip- epitopic antigen (MEA) contained 5 linear epitopes, 4 of them were 
selected from three T-cell targeted Toxoplasma antigens; 2 epitopes from P30 antigen, 
194 
named as P30I (Velge-Roussel et al,, 1994) and P30II (Gordard et al., 1994), one 
epitope from R0P2 (Saavedra et al., 1996) and one from G R A 2 (Duquesne et al, 
1991) while the last epitope was a promiscuous T-cell epitope (TTP30) selected from 
tetanus toxin (Demotz et al, 1989a; Demotz et al, 1989b) and they were linked with 
linker sequences. Based on secondary structure prediction by G O R IV (http:// 
pbiLibcp.fr/) (Gamier et al,, 1996) and the hydrophobicity plot (http://tw.expasy.org/ 
cgi-bin/protscale.pl) using the scale of Kyte and Doolittle (Kyte and Doolittle, 1982) 
(Figure 2.1), .linker sequences between epitopes was designed as Pro-Gly-Gly-Gly 
-Pro (PGGGP). The amino acid sequences of the M E A were then converted back to 
the nucleotide sequences following the codon usuage of mouse (Figure 2.2). 
5.2 Expression, Characterization and Immunological studies of the MEA 
expressed in prokaryotic system 
5.2.1 Expression and characterization ofE, coli- expressed his-tag MEA 
His-tag M E A was expressed in E. coli with the pET expression system (Novagen) 
and was identified to be a soluble protein (Figure 2.6) of 21kDa in total bacterial 
lysate upon IPTG induction (Figure 2.4). It was produced over 20% of the total 
protein of the transformed expression host. It could be purified by single-step 
TALON-resin purification (Figure 2.7). Antigenicity of this protein was demonstrated 
as it could be recognized by the seropositive serum of human (Figure 2.1 OB) and mice 
(Figure 2.1 OA), but not the sero-negative serum. Moreover, the mice immunized with 
his-tag M E A developed IgG antibodies against the corresponding Toxoplasma 
antigens - P30 (30.5kDa), G R A 2 (37.2kDa) and R0P2 (54.9kDa) and these antigens 
could be recognized by the anti-serum in immunoblots with the total T. gondii lysate 
(Figure 2.15). The cross-reactivity of anti-serum against M E A to the other three 
Toxoplasma antigens (Figure 2.11) was further confirmed by its ability to recognize 
the E. co/z-produced P30, G R A 2 and R0P2 (Figure 3.10) which antigenic and 
immunogenic properties were proved (Figure 3.12 and 3.13). These properties of 
his-tag M E A could be used as diagnostic agent or subunit. 
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5.2.2 Immunological studies on the E, coli- expressed his-tag MEA 
Humoral immunity is known to be involved in resistance against toxoplasmosis 
in mice (Frenkel and Taylor 1982) and guinea-pigs (Pavia 1986). The induction of 
specific IgM, IgG, IgA and IgE during toxoplasma infected had been demonstrated by 
Godard et al. (1990) in Fischer rats. In present study, a high level of specific IgG 
antibody against P30, G R A 2 and R0P2 antigens were detected by western blot. 
The immunological properties of the M E A antigen were further compared to the 
well-documented predominant subunit vaccine candidate, P30, in term of T-cell 
responses and cytokine expression profile. E. co/z-expressed M E A and P30 antigens 
were used for immunization of BALB/c mice. Spleenocytes were then isolated from 
vaccinated and control mice and T-cell proliferation assay and the cytokines 
expression profile in in vitro stimulated cells were performed. 
In addition to the humoral response, the cellular immune response also plays a 
key role in the control of the immunity against toxoplasmosis. Results from the T-cell 
proliferation assay showed that antigen-reactive cells were present in the spleen of the 
vaccinated mice (Figure 3.21). In naturally occurring T. gondii infection, the Thl 
immune response is predominant (Denker et al., 1998). Therefore, a vaccination 
protocol that directs immune response to appropriate T helper response, Thl rather 
than a Th2 response is desirable. However, based on the cytokine expression profile 
of in vitro stimulated spleenocytes isolated from both M E A - and P30-vaccinated mice, 
these immunizations would drive the cellular immune response to the Th2 subset but 
not the Thl subset (Figure 3.22), although the cytokine expression profile of 
M E A - v a c c i n a t e d m i c e w a s m o r e s i m i l a r t o t h e n a t u r a l l y i n f e c t e d c e l l s a s r e p o r t e d , 
than the P30-vaccinated mice (Kelly et al, 1989; Bala et al., 1994; Pelloux et al., 
1994； Gazzinelli et al., 1993; Khan et aL, 1994). These results were consistent with 
those of Petersen et al., who found that vaccination with recombinant SAGl 
expressed in E. coli yield a primarily Th2-type response (Petersen et al., 1998). 
Challenge of BALB/c mice with a lethal dose of tachyzoite of a very virulent R H 
strain gave a conclusive indication that immunization with M E A antigen could afford a 
partially protection against toxoplasmosis, even better than the P30 antigens, because of 
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the prolonged survival of the MEA-vaccinated mice when compared to the control mice 
or the P30-vaccinated mice (Figure 3.23). 
Although this vaccine could prolong the survival of the vaccinated mice, it could 
not completely protect the mice from lethal challenge. It may be necessary to alter the 
dose, timing, the route of administration and even the nature of the vaccine. As 
protein immunization will bias the T-cell response to the Th2 subtype, this bias can be 
eliminated by using lL-12 as Th-1 inducing immunoadjuvant for vaccination. 
Moreover, DNA-based immunization may be an alternative approach as it has been 
demonstrated to be a powerful method for the induction of specific humoral and 
cellular immune response. After injecting the naked D N A into the host, D N A will be 
uptake by host cells and the cells will then expressed the encoded proteins. These 
immunizations will somehow influence the immune response towards a Thl subtype, 
although the molecular basis of the D N A vaccination in the against of T. gondii 
infection remains to be determined. 
5.3 Expression of MEA in transgenic plants 
Although the E. co//-expression system had been demonstrated to be an 
inexpensive and convenient production system for high-yield production of his-tag 
M E A and the E. coz7-expressed antigen was proved to have the immunological 
properties to be a subunit vaccine candidate, for large scale production of this antigen, 
a significant investment in recombinant proteins purification was required as bacteria 
would produce contaminating endotoxins that were difficult and costly to be removed. 
Transgenic plants can be an alternative expression system as the more eukaryotic-like 
recombinant proteins can be produced at a high level with the problem of bacterial 
contamination avoided; moreover, transgenic plants expressing the recombinant 
antigen can be directly used as edible vaccine eliminating any purification steps of the 
expressed proteins (as reviewed by Fischer and Emans 2000). Therefore, in this 
research, the possibility of using plant as bio-reactor for large scale production of this 
recombinant antigen was investigated. 
Because of the short life cycle of A. thaliana, the time for screening to the 
homozygous generation can be minimized; therefore it was used as a model plant to 
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see whether the synthetic gene M E A could be expressed in plant. M E A gene was 
introduced into plant genome by Agrobacterium-mQ&i?i\.Q^ transformation via vacuum 
infiltration. Some of the plant cells and also the reproductive cells were infected with 
the transgene stably integrated into plant genome. Transgenic plant carrying the 
transgene was selected by the kanamycin resistance phenotype (Figure 4.24). By 
several generations of self crossing, homozygous F3 plants carrying a single insertion 
of transgene were obtained (Table 4.4). As the transgene integration was a random 
process, different transgenic plants were expected to carry the transgene in their 
genome at different locations and this positional effect might contribute to the 
difference in expression levels. 
Expression of the transgene was determined at translational (protein) level by 
western blotting using anti-serum against his-tag M E A . Recombinant M E A fusion 
protein could only be detected in transgenic plants transformed with 
pBI 1212/LRPI/MEA/PT (Figure 4.26) but not in transgenic plants carrying other 
plant expression constructs (Figure 4.27 to Figure 4.29) (as discussed in Chapter 4). 
Although the possibility of using plant as bioreactor to produce the recombinant M E A 
was demonstrated, more work have to be done before it can be used as an edible 
vaccine. Besides confirming its antigenicity and immunogenicity, the immunological 
properties of the plant-produced antigen have to be studied in detail. Although 
immunization with M E A antigen could only give a partially protection against the 
lethal challenge, the protection efficacy was limited by protein immunization. So, for 
recombinant protein expressed in transgenic plants, it is better to be used as an edible 
vaccine instead of as a source of antigen for purification, as edible vaccine is targeted 
to the mucosal immunity which is not as well-studied as the T-cell and B-cell 
immunity and the immune responses elicited should be distinct from that elicited by 
protein immunization. 
5.4 Preclinical Safety Assessment: Considerations in Vaccine Development 
No vaccine is totally safe and totally effective, but for every approved vaccine, 
the benefits to the public of preventing the target disease must far outweigh the risk 
and costs of that vaccination. Generally, the potential adverse effects associated with 
vaccines, including the general toxicity of vaccines, the enhancement of disease/ 
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infection after immunizations, antigenic competition, the elicitation of unwant 
immune responses, the generation of cross-reactive antibodies and the teratogenic and 
reproductive effects of the vaccines. 
As the M E A antigen is a genetically engineered vaccine which is relatively new， 
a long history of their safe use in humans does not yet exist. Therefore, extensive 
safety test is required for future development of this vaccine. Strict quality control 
guidelines have been recommended by the Biologies Division of the F D A for 
monitoring the safety, purity and potency of recombinant D N A products, including 
characterization of the expression system, production and purification procedures and 
the quality of the final product (Liu et al, 1985). 
For preclinical safety assessment, guidelines have been established in the 
European community that suggest measuring certain safety parameters in preclinical 
studies for vaccines (Committee for Proprietary Medicinal Products, 1989), including 
the local tolerance and assessment of hypersensitivity; immune function (including 
both specific and non-specific antibodies production and cell-mediated immune 
responses); local deposition of the antigen and its distribution from the injection site; 
studies to evulate adjuvant-associated toxicity, with and without the intended antigen; 
multiple-dose toxicity studies; reproductive/ developmental toxicity testing (if vaccine 
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